<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        94-276-12
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2012
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        PRIORIX-TETRA VACCINE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MEASLES VIRUS (SCHWARZ) LIVE ATTENUATED,MUMPS VIRUS (JERYL LYNN, STRAIN RIT 4385) LIVE ATTENUATED,RUBELLA VIRUS (WISTAR RA 27/3) LIVE ATTENUATED,VARICELLA ZOSTER VIRUS (OKA STRAIN) LIVE ATTENUATED
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1000,25119,1000,1995.26
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Parenteral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        3
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        18
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        212.10
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="GLAXOSMITHKLINE (GSK)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            GLAXOSMITHKLINE (GSK)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            GLAXO SAUDI ARABIA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Priorix-Tetra is a vaccine for use in children from 9 months up to and including 12 years of age<br />to protect them against illnesses caused by measles, mumps, rubella and chickenpox (varicella)<br />viruses.<br />When a person is vaccinated with Priorix-Tetra, the immune system (the body&#39;s natural defence<br />system) will make antibodies to protect the person from being infected by measles, mumps,<br />rubella and chickenpox (varicella) viruses.<br /><strong>&bull; </strong>Measles: Measles is an infectious illness caused by a virus. It is passed on by breathing in<br />droplets in the air from infected people. The main signs of the illness include a rash, runny<br />nose and a fever. Some people can get other symptoms that include ear infections, chest<br />infections such as bronchitis and pneumonia, and fits. Measles can be fatal. These effects<br />are more common in underfed or ill children.<br />&bull; Mumps: Mumps is an infectious illness also caused by a virus. It is passed on by breathing<br />in droplets in the air from infected people. The main sign of the illness is swelling of the<br />glands near the ears, on one or both sides of the face in the cheek area. Some people also<br />have inflammation of the pancreas, inflammation of the ovaries or testicles that sometimes<br />cause fertility problems in later life, meningitis, and deafness that continues after<br />recovering from the illness itself.<br /><strong>&bull; </strong>Rubella: Rubella is an infectious illness also caused by a virus. The main signs of rubella<br />are a rash and swollen glands. If pregnant women get rubella infection in the first 12 weeks<br />of pregnancy it can cause damage to the unborn child in about nine out of 10 cases. This<br />damage can include mental handicap, blindness, deafness and heart problems.</p><p><strong>&bull; </strong>Varicella: Chickenpox (varicella) is an infectious illness caused by a virus called varicella<br />zoster. It is passed on by close contact with infected people and by breathing in droplets in<br />the air from infected people. It is most common in children under the age of 10 in whom it<br />is usually mild. The main sign of the illness is a rash with raised red spots on the face and<br />head which may spread to other parts of the body. Chickenpox can be more serious in<br />adults, in pregnant women and patients who have a poor immune system.<br />As with all vaccines, Priorix-Tetra may not completely protect all people who are cinated.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Priorix-Tetra should not be given<br />If your child:<br />&bull; has previously had any allergic reaction to Priorix-Tetra, neomycin (an antibiotic) or any<br />component contained in this vaccine. The active substances and other ingredients in<br />Priorix-Tetra are listed under section 6 of the leaflet. However, if you had a skin rash<br />(dermatitis) after treatment with neomycin, you can still be vaccinated with Priorix-Tetra.<br />&bull; has previously had an allergic reaction to any vaccine against measles, mumps, rubella and<br />varicella.<br />&bull; has any severe illness or takes any medicine that weakens the immune system (see also<br />&ldquo;Take special care with Priorix-Tetra&rdquo;).<br />Priorix-Tetra must not be given during pregnancy. Pregnancy should be avoided for one month<br />following vaccination.<br />Check with your doctor if you think any of these apply to your child.<br />Take special care with Priorix-Tetra<br />Your doctor needs to know before your child starts taking Priorix-Tetra if he/she:<br />&bull; has a severe infection with a high temperature. In these cases, the vaccination will be<br />postponed until recovery. A minor infection such as a cold should not be a problem, but<br />talk to your doctor first.<br />&bull; has a history of febrile convulsions (fits) or a family history of convulsions. In this<br />your child has weakened immune system (e.g. such as HIV infection). Your child<br />should be closely monitored as the responses to the vaccines may not be sufficient to<br />ensure a protection against the illness (see section 2 &ldquo;Priorix-Tetra should not be<br />given&rdquo;).<br />&bull; case your child should be closely monitored after vaccination as fever may occur 5 to 12<br />days after vaccination.<br />&bull; has a history or family history of allergies.<br />&bull; has ever had a severe allergic reaction to eggs or anything that contained egg.<br />&bull; has had a side effect after vaccination against measles, mumps or rubella that involved<br />easy bruising or bleeding for longer than usual.<br />&bull; has had a blood or plasma transfusion, or human immunoglobulin within the last three<br />months. If so, the antibody response to Priorix-Tetra may be low so it is usual to wait<br />for three months before giving Priorix-Tetra.<br />&bull; is due to have a skin test for possible tuberculosis. If this test is done within 6 weeks after<br />receiving Priorix-Tetra, the result may not be reliable.<br />&bull; is under 12 months old. Children under 12 months may not develop a good immune<br />response to the measles virus. Your doctor will advise you if additional doses of a measles<br />containing vaccine are needed.<br />&bull; has a weakened immune system. Your child should be closely monitored as the responses<br />to the vaccines may not be sufficient to ensure a protection against the illness.<br />Fainting can occur following, or even before, any needle injection, therefore tell the doctor<br />or nurse if your child fainted with a previous injection.<br />2. What you need to know before your child receives Priorix Tetra<br />Like other vaccines, Priorix-Tetra cannot completely protect your child against catching<br />chickenpox. However, people who have been vaccinated and catch chickenpox usually have<br />a very mild disease, compared with people who have not been vaccinated.<br />The types of viruses that are in Priorix-Tetra are not usually passed on from the person<br />who has had the vaccine to other people, with the exception of the varicella virus. This<br />may happen when the healthy vaccinee has developed blisters.<br />Using other medicines or vaccines<br />Tell your doctor if your child is taking or has recently taken any other medicines, including<br />medicines obtained without a prescription or has recently received any other vaccine.<br />Aspirin or aspirin-type products (also known as salicylates) should not be taken for 6 weeks<br />after vaccination, since we now know that Reye&rsquo;s Syndrome, a rare disease of the brain and<br />liver could occur.<br />Priorix-Tetra can be given at the same time as other vaccines. A different injection site will<br />be used for each vaccine.<br />Pregnancy and breast-feeding<br />Priorix-Tetra must not be given to pregnant women.<br />If your daughter is pregnant or breast-feeding, think she may be pregnant or is planning to<br />have a baby, ask your doctor or pharmacist before the vaccine is given. It is also important<br />that your daughter does not become pregnant within one month after being vaccinated with<br />Priorix-Tetra. During this time your daughter should use an effective method of birth<br />control to avoid pregnancy.<br />Ask your doctor or pharmacist for advice before receiving Priorix-Tetra.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Priorix-Tetra will be given as an injection under the skin or into the muscle.<br />Priorix-Tetra is intended for children from 9 months up to and including 12 years of age. The<br />appropriate time and number of doses that will be given to your child will be determined by your<br />doctor on the basis of appropriate official recommendations.<br />Your doctor may wipe the skin with alcohol or other disinfecting agents and will let the skin dry<br />before the injection.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Priorix-Tetra can cause side effects, although not everybody gets them.<br />As with all injectable vaccines, there is a rare risk of allergic reactions. These may be local or<br />widespread rashes that may be itchy or blistering, swelling of the eyes and face, difficulty in<br />breathing or swallowing, a sudden drop in blood pressure and loss of consciousness. Such<br />reactions may occur before leaving the doctor&rsquo;s surgery. However, you should seek immediate<br />treatment in any event.<br />Side effects that occurred during clinical trials with Priorix-Tetra were as follows:<br /> <strong>Very common</strong> (these may occur with more than 1 in 10 doses of the vaccine):<br />&bull; local pain,<br />&bull; local redness,<br />&bull; fever greater than 37.5&deg;C*<br /><strong> Common</strong> (these may occur with up to 1 in 10 doses of the vaccine):<br />&bull; local swelling,</p><p>&bull; fever greater than 39&deg;C*,<br />&bull; irritability,<br />&bull; rash (spots and/or blisters)<br /> <strong>Uncommon </strong>(these may occur with up to 1 in 100 doses of the vaccine):<br />&bull; upper respiratory tract infection,<br />&bull; crying,<br />&bull; generally feeling unwell,<br />&bull; swollen glands in the cheek,<br />&bull; diarrhoea,<br />&bull; vomiting,<br />&bull; loss of appetite,<br />&bull; inability to sleep,<br />&bull; fatigue,<br />&bull; lack of energy,<br />&bull; nervousness,<br />&bull; runny nose,<br />&bull; swollen glands in the neck, armpit and groin<br /><strong> Rare </strong>(these may occur with up to 1 in 1,000 doses of the vaccine):<br />&bull; bronchitis,<br />&bull; infection of the middle ear,<br />&bull; coughing,<br />&bull; seizures with fever<br />* Higher rates of fever were observed after administration of the first dose of Priorix-Tetra when<br />compared to measles-mumps-rubella and varicella vaccines administered separately at the same<br />visit.<br />After commercialisation, the following additional side effects have been rarely reported in people<br />vaccinated with Priorix-Tetra :<br />&bull; infection around the brain or spinal cord (meningitis)<br />&bull; shingles (herpes zoster)<br />&bull; measles-like symptoms<br />&bull; mumps like symptoms (including transient, painful swelling of the testicles and swollen<br />glands in the neck)<br />&bull; infection or inflammation of the brain, spinal cord and peripheral nerves<br />resulting in temporary difficulty when walking (unsteadiness) and/or temporary<br />loss of control of bodily movements), stroke, inflammation of some nerves,<br />possibly with pins and needles or loss of feeling or normal movement (Guillain-<br />Barr&eacute; syndrome),<br />&bull; narrowing or blockage of blood vessels. This may include unusual bleeding or<br />bruising under the skin (Henoch Schonlein purpura) or fever which lasts for<br />more than five days, associated with a rash on the trunk sometimes followed by<br />a peeling of the skin on the hands and fingers, red eyes, lips, throat and tongue<br />(Kawasaki disease)<br />&bull; bleeding or bruising more easily than normal due to a drop in a type of blood cell<br />called platelets, unusual bleeding or bruising under the skin<br />&bull; severe condition of the skin that may affect the mouth and other parts of the<br />body.<br />&bull; chickenpox-like rash<br />&bull; joint and muscle pains<br />&bull;<br />If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, tell<br />your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.<br />Do not use Priorix-Tetra after the expiry date which is stated on the carton. The expiry date<br />refers to the last day of that month.<br />Store in a refrigerator (2C &ndash; 8C).<br />Do not freeze.<br />Store in the original package in order to protect from light.<br />Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist<br />how to dispose of medicines no longer required. These measures will help to protect the<br />environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- The active substances are:<br />After reconstitution, 1 dose (0.5 ml) contains:<br />Live attenuated measles virus1 (Schwarz strain) not less than 103.0 CCID50<br />3<br />Live attenuated mumps virus1 (RIT 4385 strain, derived from Jeryl Lynn strain)<br />not less than104.4 CCID50<br />3<br />Live attenuated rubella virus2 (Wistar RA 27/3 strain) not less than 103.0 CCID50<br />3<br />Live attenuated varicella virus2 (Oka strain) not less than 103.3 PFU<br />1 produced in chick embryo cells<br />2 produced in human diploid (MRC-5) cells<br />3 Cell Culture Infective Dose 50%<br />- The other ingredients are:<br />o Powder: amino acids, lactose, mannitol, sorbitol<br />o Solvent: water for injections<br />o Neomycin sulphate is present as traces</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Priorix-Tetra is presented as a powder and a solvent for solution for injection. The powder
and the solvent have to be mixed together before vaccination.
The powder is contained in a vial for 1 dose and the solvent is contained in either an ampoule
or a pre-filled syringe (0.5 ml) in the following pack sizes:
- vial + ampoule: pack sizes of 1, 10 or 100
- vial + pre-filled syringe: pack sizes of 1 or 10 with 2 separate needles. Pack sizes of
1, 10, 20 or 50 without needles.
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Instructions for use<br />The following information is intended for medical or healthcare professionals only:<br />The reconstituted vaccine should be inspected visually for any foreign particulate matter and/or<br />abnormal physical appearance. In the event of either being observed, the vaccine should be<br />discarded.<br />The colour of the reconstituted vaccine may vary from clear peach to fuchsia pink due to minor<br />variations of its pH. This is normal and does not impair the performance of the vaccine. In the<br />event of other variation being observed, discard the vaccine.<br />Instructions for reconstitution of the vaccine with solvent presented in ampoules<br />Priorix-Tetra is reconstituted by adding the entire content of the supplied ampoule of solvent to</p><p>the vial containing the powder. After the addition of the solvent to the powder, the mixture<br />should be well shaken until the powder is completely dissolved in the solvent.<br />After reconstitution, the vaccine should be used promptly.<br />A new needle should be used to administer the vaccine.<br />Withdraw the entire contents of the vial.<br />Instructions for reconstitution of the vaccine with solvent presented in pre-filled syringe<br />Priorix-Tetra must be reconstituted by adding the entire content of the pre-filled syringe of<br />solvent to the vial containing the powder.<br />To attach the needle to the syringe, refer to the below drawing. However, the syringe provided<br />with Priorix-Tetra might be slightly different than the syringe described in the drawing.</p><p><img width="611" height="236" alt="" src="data:image/jpeg;base64,/9j/4AAQSkZJRgABAQEAYABgAAD/4RDyRXhpZgAATU0AKgAAAAgABAE7AAIAAAANAAAISodpAAQAAAABAAAIWJydAAEAAAAaAAAQ0OocAAcAAAgMAAAAPgAAAAAc6gAAAAgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAEZlZGhhIEFsZW56aQAAAAWQAwACAAAAFAAAEKaQBAACAAAAFAAAELqSkQACAAAAAzExAACSkgACAAAAAzExAADqHAAHAAAIDAAACJoAAAAAHOoAAAAIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAyMDIwOjA2OjA4IDExOjA1OjI1ADIwMjA6MDY6MDggMTE6MDU6MjUAAABGAGUAZABoAGEAIABBAGwAZQBuAHoAaQAAAP/hCx9odHRwOi8vbnMuYWRvYmUuY29tL3hhcC8xLjAvADw/eHBhY2tldCBiZWdpbj0n77u/JyBpZD0nVzVNME1wQ2VoaUh6cmVTek5UY3prYzlkJz8+DQo8eDp4bXBtZXRhIHhtbG5zOng9ImFkb2JlOm5zOm1ldGEvIj48cmRmOlJERiB4bWxuczpyZGY9Imh0dHA6Ly93d3cudzMub3JnLzE5OTkvMDIvMjItcmRmLXN5bnRheC1ucyMiPjxyZGY6RGVzY3JpcHRpb24gcmRmOmFib3V0PSJ1dWlkOmZhZjViZGQ1LWJhM2QtMTFkYS1hZDMxLWQzM2Q3NTE4MmYxYiIgeG1sbnM6ZGM9Imh0dHA6Ly9wdXJsLm9yZy9kYy9lbGVtZW50cy8xLjEvIi8+PHJkZjpEZXNjcmlwdGlvbiByZGY6YWJvdXQ9InV1aWQ6ZmFmNWJkZDUtYmEzZC0xMWRhLWFkMzEtZDMzZDc1MTgyZjFiIiB4bWxuczp4bXA9Imh0dHA6Ly9ucy5hZG9iZS5jb20veGFwLzEuMC8iPjx4bXA6Q3JlYXRlRGF0ZT4yMDIwLTA2LTA4VDExOjA1OjI1LjEwNzwveG1wOkNyZWF0ZURhdGU+PC9yZGY6RGVzY3JpcHRpb24+PHJkZjpEZXNjcmlwdGlvbiByZGY6YWJvdXQ9InV1aWQ6ZmFmNWJkZDUtYmEzZC0xMWRhLWFkMzEtZDMzZDc1MTgyZjFiIiB4bWxuczpkYz0iaHR0cDovL3B1cmwub3JnL2RjL2VsZW1lbnRzLzEuMS8iPjxkYzpjcmVhdG9yPjxyZGY6U2VxIHhtbG5zOnJkZj0iaHR0cDovL3d3dy53My5vcmcvMTk5OS8wMi8yMi1yZGYtc3ludGF4LW5zIyI+PHJkZjpsaT5GZWRoYSBBbGVuemk8L3JkZjpsaT48L3JkZjpTZXE+DQoJCQk8L2RjOmNyZWF0b3I+PC9yZGY6RGVzY3JpcHRpb24+PC9yZGY6UkRGPjwveDp4bXBtZXRhPg0KICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICA8P3hwYWNrZXQgZW5kPSd3Jz8+/9sAQwAHBQUGBQQHBgUGCAcHCAoRCwoJCQoVDxAMERgVGhkYFRgXGx4nIRsdJR0XGCIuIiUoKSssKxogLzMvKjInKisq/9sAQwEHCAgKCQoUCwsUKhwYHCoqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioq/8AAEQgA7AJjAwEiAAIRAQMRAf/EAB8AAAEFAQEBAQEBAAAAAAAAAAABAgMEBQYHCAkKC//EALUQAAIBAwMCBAMFBQQEAAABfQECAwAEEQUSITFBBhNRYQcicRQygZGhCCNCscEVUtHwJDNicoIJChYXGBkaJSYnKCkqNDU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6g4SFhoeIiYqSk5SVlpeYmZqio6Slpqeoqaqys7S1tre4ubrCw8TFxsfIycrS09TV1tfY2drh4uPk5ebn6Onq8fLz9PX29/j5+v/EAB8BAAMBAQEBAQEBAQEAAAAAAAABAgMEBQYHCAkKC//EALURAAIBAgQEAwQHBQQEAAECdwABAgMRBAUhMQYSQVEHYXETIjKBCBRCkaGxwQkjM1LwFWJy0QoWJDThJfEXGBkaJicoKSo1Njc4OTpDREVGR0hJSlNUVVZXWFlaY2RlZmdoaWpzdHV2d3h5eoKDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uLj5OXm5+jp6vLz9PX29/j5+v/aAAwDAQACEQMRAD8A+kaKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAK2oX8Ol6fNe3QmMMK7n8iB5nx7IgLH8AawbD4i+F9V8KT+JNL1F73Srdyk0tvaTSNERyd0aoXAAOclcY56c1v6j/yC7r/AK4v/wCgmvCPFfh3Ufh5jxb4Ph8zQ9fsktNcsEOFR5E2rcqOnVufcns52gHvVpcpeWcVzCsqxyqHUTQtE4B9UcBlPsQDUteO+MPHXjFfiTq+heFoX3aPYwXsMANqkV0pZTK07zsGEYUlcxYIJyT0qOLx94y1T4jatBpdu/2PRtTtraeyL2iQfZnBDySPIwlMhJBTZ8vygEHJyAemeIvF2i+FBZtr91JapfTi3gcW0sitIeilkUhSe27GcH0NO0rxXo+ta5qmj6ddPJf6SyrewPbyRmItnbyygMDgkFSQRg9CK8B8YeItX8WeFbfVtW1QhIvHCWMWlCGNUtljB2/MBvL4ySSxHzcAYrT1rxTqHgvxh8Ytc0eJJLy3XS1jMi7lQumzeR3xuz9cZ4oA+g6K4v4e6p4ivW1KDxGszQRmGfTri7ktTcTwSKeXW2YoBuVtpwMj1INdpQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRVbUNSsdJsnvNVvLeytkIDT3MqxopJwMsxAGSQPxpkusaZDq8OlTajaR6jOhkis3nUTSKM5ZUzuI+U8gdj6UAXKKKoSa7pEV8bKXVbJLtZUhNu1wgkEjqWRNuc7mVWIHUgEjpQBfooooAKKKKACiiigAooooAKKKKACiiigAopGZUUs5CqoySTgAVwt/8AF7w7DfSWOiQ6h4iu4ztePSLYzhT7vwv5E0Ad3RXn/wDws3Uv+ie+KP8AwGT/AOKo/wCFm6l/0T3xR/4DJ/8AFUAegUV5/wD8LN1L/onvij/wGT/4qj/hZupf9E98Uf8AgMn/AMVQB6BRXn//AAs3Uv8Aonvij/wGT/4qj/hZupf9E98Uf+Ayf/FUAegUV5//AMLN1L/onvij/wABk/8AiqP+Fm6l/wBE98Uf+Ayf/FUAegUV5/8A8LN1L/onvij/AMBk/wDiqP8AhZupf9E98Uf+Ayf/ABVAHoFFef8A/CzdS/6J74o/8Bk/+Ko/4WbqX/RPfFH/AIDJ/wDFUAegUV5//wALN1L/AKJ74o/8Bk/+Ko/4WbqX/RPfFH/gMn/xVAHoFFef/wDCzdS/6J74o/8AAZP/AIqj/hZupf8ARPfFH/gMn/xVAHoFFef/APCzdS/6J74o/wDAZP8A4qj/AIWbqX/RPfFH/gMn/wAVQB6BRXn/APws3Uv+ie+KP/AZP/iqP+Fm6l/0T3xR/wCAyf8AxVAHoFFef/8ACzdS/wCie+KP/AZP/iqR/inc26+Ze+AvFUMIPzSLZh9vvgN0oA9BornfDHjvw74vVxomoLJcR/6y1lBjmj+qNz+NdFQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBXvrCz1Sxks9TtILy1lGJILiMSI4znlTkHkUy10nTrHSxpllYWtvYBWQWkMKpEFbORsAxg5ORjnJq3RQBnaj4d0XV7y3u9W0ewvrm2OYJrm1SR4uc/KzAleeeKJ/Dui3Osxavc6PYTalCAI72S1Rpkx0w5G4dT371o0UAYl74J8K6ldzXWo+GdHu7icgyzT2ETvIR0LMVyfxqWHwp4etri7uLfQdMimvo2jupEs41a4RvvK5AywPcHOa1qKAKOlaLpWg2rWuh6ZZ6bbu5kaKzt1hRmIALEKAM4AGfYVeoooAKKKKACiiigAooooAKKKOlAHO6jqph8T28JuzbwR4EhJ+U8FjnPttGf9qugWVHj3o6smM7lORXCxS/bNTuLs8gn5T/ALxz/wCg7KLkGC3f7I728khEYaFtvLHGcDg+vPpTA6+LUS0aySWk6RsMqygOCPXA5/SlfV9OiVWmvYYgzbf3jhSD6EHp+NYttrF7aoqERXEajABGxgPqOP0rB8W6supXVrGIHh8mNnPmAdWOOCPYfrQB6FHIkq7onV19VORTq47wxaCxjtpktWYmAyyPBKWyZD8oKcDIAPTPSuqhvbedtsco3/3G+Vh/wE80gJ6KKKAMfxe23wXrA8macvZSxrFBA8zuWUqAEQEnkjoP0rk75fEGkafOPD9tcXEEOmyyaZO8TCSGN3hJhZGRm8yNQxQFGJAVSrMrBvRKKAPIIPEPxF+1aONskkbkZZ7K4UXBM7qyTD7CpQiPysOfs6ZJb5lyFhs7rU59eF3qdtr13LcTaQWln0SaPy2SWdpV+SIDYhf7x7EfM33j7LRQB554K1TxfqOl66PE8s1pcJbqYj9ndWtZir7xG0ltHG6KQu3Bmxjl3BBODouv+LtXXQmGsa8bS/e1FxdroIj2M8MpmA3QECJXFvtkIx+8f5mA+X125toLy1ltbyGOe3mQxyxSoGSRSMFWB4IIOCDWHo8403xNeeHY7e3tbKG1hudOit4hGqRnKOgA4+VlB/7aCgDz7UrnxfqulSNPd+IIBDdWk9/DHpah7OVL6PclsRAftEQj8x8jzCfKjySGZWsQa/44N7fpqkmpW1l9qVZZbPTZJ7i0j3SYaBTaBJA37oEAzkAs3Hb1migDyVLnxHYapdTy6n4kngvHtDc3ltoeGih+ztmSKFoGIPnBVaMh2VWY7f4hv+C7vxLe+JbpPEN7qQit7O3ZIH05YYJJGDbz5hjBLYEbFVf5WdweAFXu6KACiiigAooooAKKKzvEN+dK8M6pqAODaWcs4I/2UJ/pQB5/qrXnxU8XXugWlzLa+FNIkEWpTQMVa/nHWEMP4B3/AP1V6JpWj6doenx2Oj2UNlbRjCxQoFH19z7muY+Eemrpvwt0b+KW7h+2TP3d5TvJP5gfhXaUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQByHjP4e6f4oUX1k39la/b/PaapbDbIjDoGI+8vqDR8PfFl34h0+70/Xolt9f0eX7NqES8KzfwyL/ssOfzrr688u4v7J/aC06a3wqa5pEsdwo/ieEgqx/A4oA9DooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKz9cn+z6PNtOGkAjU+7HH9a0Koavpf9rW8cRnaIK+44XO7ggj8iaAOQs5EitwZcxNKTJiRSnB6de2MU+Q+bfQoOVRTKfr0X+Z/Ku5MaNGEZFZfQjIrDGmaVJe3jzRJbuGABRjFhQPvHGM8k9famIy65XWZjPqMoUO3zLAojXcfcgd8ZP5V3l3oaW9rJcw3zrHGhc+aodcAZ6jB/WuEsbaa4aS4Ay0CGQkSBD5jZC4z1Oc8UAXdH1JFleWyuIS7OcIrmB9q8DKng9M+ldTot9JqF7JZanGZQse9DPGuRzggEcH+fFYM2kyw2yQ3luXSNQuLu33DgdnXj+daeg6Fcf2ZMbcjT/OmDxyZaRgF4G0HGAfm/BjxQM6Y2ZVAttcTQ4yR828f+PZ/Ksy48RNp148F7bO6IcCeNCFbjPTnp6/ypGk8Q6ejNItvqESgk7TsfH+frXInVY2up3ubae1nyXmaLKlcn+LocexGKQHd2mvadeAeVcoGP8LHH69D+FaAYMoKkEHkEd684Elrdp5iT284PO512N9cjBB/2iDU8b3dmyfZp7mAycooPmK/vkYLD6An3oA9BorjrfxRqECuZkhuo422uyttZT6EHBU+x/Ota28V2MrrHcrLayMpYLIh5A6n3Hv096ANuuZ8Vf8AEu1fQdeXhba7+xXLf9MLjCfpKID9Aa6CC9trpEe2uI5VkG5Cjg7h6j1rmfiXLfReA9SFjpL6rE9u6XEMEuyeNSv+sjGCGZTzt4PHByMEA6yivPvg54x1Tx74Uu/EGrosPm3hht4E+6kaRoCfcly5P4DtXoNABRRRQAUUUUAFFFFABWB48/5J14j/AOwXc/8Aopq36wPHn/JOvEf/AGC7n/0U1AEPw4/5Jj4b/wCwbB/6AK6WvH/Bdv4rvPA+iLZPrMduLKIIftNpbx7doxj927ke5wa3j4Z8WyAFrqUnPIfX5h/6BCKAPQqK87Hg7WXXF9o+j357PeatdzMPxdTU8PhPWYSTZaR4d018YEkE9wWH/fIQ/rQB3tFcva6H4rEQS68WRqB/zw05cj/gTs2fxFTSaJ4iT5rTxXIXBzturGJ0Pt8oU/rQB0VFc5pfiC/i1RdI8UWcdpeSZ+zXVuxNvd46hSeVcDnYfwJwa6OgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvP8AxF/yXTwd/wBeN9/6Ctd9JIkMTSSuscaAszMcBR6k15hd69Y678cvCkmltJNBFZ3oFx5TLHL8o+4xGHAx1GR70Aeo0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABSMoZcMAR6EUtFAGbf6Ha3tlNboXtfNGGaA7c8916HPTkVmaV4ZuNNmMUk1vc2jyiV90RDkqPlHUjGea6WigCr/Ztuv+oDW5/6YuUH5Dj9KPJvIv8AVXSyD+7Mn9Vx/I1aooAydUfUn02WKKxWWRgB8kvBGeeuD0zXKy3bW/y31rcW2P8Anou4D6H+H8cV6BSMoYYYAj0IoA86Nrpt7u2CJj1byztI9yOp+tRf2S8HFneSQg9I25U/h0/MGu3u/DelXnMtmisOjR/KR9MdPrWZN4PaPJ0/UZowf4JPmB+v/wCrPvQBzbPqcP8Ar4I7tF4JU4YD6/4Cok1G0GIpVmsy38DKSh/4CM/ngVuyaJrduoPlW92A2B5b7Co9cHp+tULqXyPMTULKZFHQyRZWT6//AF8UAV0ginzJatHL3LQvhvqcZU/iAauQarqtjjy7t3QHG2ddwP0YZx+IyfUVnnTtLu5F8l/LYDLPGxBjP0PI/LHvSfZNVgUm1vFucdIrgZLr/vc8fj+FAG3o+v22k27wx6QlvC0rzSfYgCu9zuYlR0JJJ9Peuhs/EWl3uPKu0VsZ2v8AKR+fb36VxkbedNGl3atE5489PmjU+x+8v406bT/M3ZwzKcqrjJb39QffcDQB6ICCAQcg9CKK85iW9sGJtbqWCMLkMHLIx9MH+eR9a0bXxZqdvgX8MUq4JZvuMvoD/CSfbgdzQB2tFc9b+NNOcILqOe1Zlyd6ZUf8CHBHuOPet23uIbu3jntpFlikUMjochge9AElFFFABWB48/5J14j/AOwXc/8Aopq36wPHn/JOvEf/AGC7n/0U1AEPw4/5Jj4b/wCwbB/6AK6Wua+HH/JMfDf/AGDYP/QBXS0AFFFFABRRRQBXv7C31Oze1vI98b++Cp7MCOQR1BHIrnINeu/DV5Hpvixi1rIwjtNZxiOT0SbtG/bP3W9jxXV1Hc20F5bSW93DHPBKpWSORQysD1BB6igCSiuVNnqXhAb9KWbVNFXlrAktPaj/AKYk/fUf3DyP4T2rf0zU7PWNPjvdNuEuLeT7rr6jqCOoIPBB5FAFmV/Lidz0VSahsbtb2381OmSKi1qbyNCvZf7kDt+lYngC9+2+H5HJyVnYfoKAOoooooAKKKKACiiigAooooAKKKKACoLy8ttPspbu+mSC3hUtJI5wFFZ2t+JrPRZIrbZLeajcD/R7C1XdLL746Ko7s2APWqllod7qd1FqXixo3ljYPb6dC26C2PZiT/rHH948DsB1oApWdle+Mrkahr8D22iqQ1lpcgw0/pLOP1WPoOpyemd4gUJ8cvBqqAqixvQABwPlWvQa8/8AEX/JdPB3/Xjff+grQB6BRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRWd4g1b+wfDWpav9ne6+w2slx5EZw0mxS20fXFcb4X8d6hq2nabq82paBqOjXCs+oXdkHg/svELSbJQ7t3wC7bMY+78wIAPQ6Kx4vGHhqaC3mh8Q6VJFdSNFbyJexlZnXGVU7vmIyMgetVrjxx4bbTWnsfE2hM8kUrW7yahH5bsgySSG+6vG7HQUAdDRXM6Z4y0uHRtPPiXxH4dj1K4tftD/AGS/UQyqAS0kW87jH8rc+x9K0p/E+gWujw6tda5psOmzkLDeyXcawyE5wFcnaeh6HsaANSisaPxh4Zl0mXVIvEWkvp0MgikvFvozCjnGFL7sA8jjPcVrQzRXNvHPbyJLDKoeOSNgyupGQQR1BHegB9FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFIQGGCAR70tFAGbdeHtKvMedZxgjoUG0r9MdKyZ/BoXJ0+/lj5zslAdc/5/H3rqKKAOIn0fXLQ5MMd2oH3omw2PTnJ/n9apNemBvKureW3Ofuuh2/kM/oTXolNkjSVCkqK6nqrDINAHBRXkUuHilDE8BlYBj7ZHyn6dqkIRl3YXGeG5AH/Al5B9zXSXfhjSbxmZ7YRuwwXjO0//AF/oaz38G+U6PY6hKhXgrKNwI7c9R9M49qAMV7ONy2EYE/Mdq7vxIXB+netzwtEIG2xjajozcfxHK/MfU89fes8+HtdSQRj7LLGG3GQtg7fy5b8hXT6ZYfY4cyACRgBgdFAycfmST9fQCgC9RRRQAVgePP8AknXiP/sF3P8A6Kat+sDx5/yTrxH/ANgu5/8ARTUAQ/Dj/kmPhv8A7BsH/oArpa5r4cf8kx8N/wDYNg/9AFTXfib7H4gu7A2N1cx29vDIWtIGlYM5kyCB7IMfU0Ab9Fc7/wAJnbHPlaRrsjD+EaXKv6sAKjHiXW7zH9m+Eb5QTjfqE8Vuq+5AZmx+FAHTVinxDHe6s+m6GFvJoHAu5gf3Nt/slh1fH8I59cVSn8Paxrts8fiLWGt4pFINppOYl/4FIfnb8NoPpVHT/EFl4M8jQvENlDo0O7Za30Eeyzn9Of8Alm57q3foTQB2tFIrK6BkYMrDIIOQRS0AFcprek3eiX0viPwvCXmY7tR05Thb1B1ZR0EwHQ/xdD2I6uigDzf4gfEG2svDJjjsp5rTV7Q/ZL6MjyyWXoe4I9K534U+OhGToUGnXF7dXE5kDREBY1wASxPQDFdkuiafd6hrfgzV4BJp92v9oWS/3FckSBT2KyfMPTzBV7wJ4A03wJpb29m7XV1MxM13KoDuM8Lx0A9PxoA6qiiigAooooAKKKaxIGRQA6imJIG470+gArntS1e9v7+XR/DJjFzHgXd9Iu6Ozz2x/HJjkL0HU9gbniLU5dO00LYhXv7uQW9mjdDI38R9lALH2U1NoukQaHpMNjbZYJkySt96Vycs7HuSck0AQ6J4dsdCSVrYPNd3B3XN5O2+advVm/kBgDsBWrRRQAV51r0sjfH3wpG8LIiWN4UkzkOCo/Igj+Vei15/4i/5Lp4O/wCvG+/9BWgD0CiiigAooooAKKKKACiiigAooooAKKKKAM/Xzqg8P3p8PiNtTEJ+yiUgIZO27Pb1rzOx8DDT/ibZeKNL8Pv4Qt7eKc65IbyH7HeJ5eAI0Rj8u4b9zrEMLuK7unrlMlijnheGeNZIpFKujrlWB4IIPUUAeefDnw/Jo99rMdjcwX3hi1uzc6DHburBBPGsjqpzt2rvIQ55EjZPNYXgnwHqGlfDHxHBqnhRY9fuJr17Qs1s8r+dGUXbIHIXhiDlhxnrnn1uw0+y0qxjstLs4LK0iyI4LaJY40ycnCqABySfxqxQB4LZ+CfFUEnw0e58J3U6+GrS5S+QXNocSOu2PbmbBIKhs9sjvkDGt9F1rwT4Q+H8OpaHqq+ItGvL+SG3sreLUQY3ILOYI5lZ1+dBuDrtOc9Vz9J1n6toGj6/DHFruk2OpxxNujS8tkmCHpkBgcGgDwjRfC19f+E/B7eCY9eB8KapPHqVpeQwWl6JJVV2kSObdCNofKqxPD9c817L4C0BfC/giw0iOO8ijtw+yK9mjlmjVpGYKzRgJkBui5A6AsBk7On6bY6RYR2OlWdvY2kWfLt7aJY40ySThVAAyST9TVmgAooooAKKKKACisXWdbks5ks9PiE95IdqrjPPXH5cnsBSWt3rFlcW8euC1ljuW2LLbKV8p+oVgScg4xuGOe3NAG3RRRQAUUUUAFFFNllSGJpJWCogyxPYUAOorLttZaZWllspYrfzNiy7ge+Mkdhng9cHPpWpQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWB48/5J14j/AOwXc/8Aopq36wPHn/JOvEf/AGC7n/0U1AGN4U1y20L4R+G5p1eaaTToEtrWIZluJPLGEQdz79AOTxW54W0q70+xnu9YZW1XUZftF3sOVjOAFjU/3UUBffk96w/hZoNlZ+BdD1ILJPe3GnQ5uJ3LsilQdiZ+6o9Bj3zXcUAFFFc94ovLvztN0vTbh7ae+nw00e3cka8tjORnHPToDQB0NQ3dnbX9pJa30EdxbyrteKVAysPQg1T0xp4by7sbi4e4EOx4pJMb9rA8EgAHlWrSoA5O08DvoJI8Iaxc6Xbk5+wzD7TbL/uqx3J/wFgPapoE8WzXslrcatpMQjIYtFYSb2Q9CN0uOxHQ9K6as3WIrhFiv7BDJcWpJMQ6zRn7yfXgEe4HrQBctYZILZY57h7mQfelcAFvwAAFTVBZXtvqNlFd2cglhlXcjD/PB7Y7VPQBz3iqxmH2LXbBGe80h2l8tRzNCwxLH9SACP8AaVa27O7g1Cyhu7OVZredBJHIp4ZSMg1NXM+D1/s+51vQ1/1Wn3xe3GOFimUShR7BmcfQUAdNRRRQAUUUUAFFFFAGfcSG2ueOnUVfVgyhh0IyKy9c/dxxS++01Vu9aOneDb3UEw0trE/lqf4n/gH4kgUAVdLY6/42vtTbmy0jdYWfo0xwZ3H0+VM+z11NZvh/SU0Pw/Z6cnLQxjzH/vyHl2PuWJP41pUANd9kbPtZtoJwoyT9KwW8c+HIneO61NLWVDhoblGicf8AAWAJ/CugrJvpW1LUP7LtmwkYDXkqn7qnpGPdu/ov1FAFKLxS+ryiLw1p9xcqeTe3MLw26D1BYBnPsox7iuX1OxNp8c/CLyzyXNxLZXvmSueuFGAF6KBk8D8cnmvSlUKoVQAAMAAdK4DxF/yXTwd/1433/oK0AegUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABUV1OLa1kmIzsUkD1PYVLWR4nuGt9FdkBLZJH/AVLf+y0AUNDQCG91y4O9zvSJiP4VPzN/wJgfwCjtWlLZ6jLZorXEUrbo3ZZY8HcrBiNy8Y4/u/jWdJpE0NrYW1reOA6JGYzymETO7A9wM5z1q79o1m0/19tHcqMfMh5/MDJ/75/GgC59tmj/4+bOVR/ejw4+vHP6VJDf2tw2yKZS+MmMnaw+qnkVSTxBbbtt1HLbPzw6/4Vb32OorsPk3G05KMAxU+4PSgC1RVP8As1Y/+PWeeA9gH3D8mzRjUIjwYLlffMbY+vIJ/AUAOv7s2cAZQpZmwN5wqjGST7AAmsm7uptRVLYSxAGRchQyyHOcEow4AIJzk/dpmr3xlkSKS2kRwREImIJd5D90EHH3A2fQMDTdKuPteq3F9dS7o4ASHxhQB8o2+q/6zk8nINAGtqEMaaWtoi4SRkhCjsCQP0GT+FX6xJ9Zt5L6xV0mt9s7MxuIWQbfLcZyRgDJHfvW0jrIoZGDKeQQcg0ALRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFYHjz/knXiP8A7Bdz/wCimrfrA8ef8k68R/8AYLuf/RTUAQ/Dj/kmPhv/ALBsH/oArfur21sYfOvrmG2iHV5pAi/mawPhx/yTHw3/ANg2D/0AVl+IoodY8ZWtnfhTaQOS6yEBWCRiQjnruZ4s+yY7mgDp9SvUl8N3V3p1yrqYGaKeFww6dQRxXI6PcRz+MtPQJDI6I7vLtcujbXATezMW4OT05IqrHBb2IlhtryQRahawXRiWf5fN8wLL8o4+ZSvHqDWP4dSaVp7oS+Q/9khg5OXjklUnr04ab+nagDvLfxFpL+Krlor1ZEktEQsqtsVo3fPOMEnzP/Ha1v7d0z/n8T8jWfDo0NvBHDD4iv0jjUIiieLCgDAH3Kf/AGWv/Qy6h/3/AIv/AIigC7/bumf8/ifkaP7d0z/n8T8jVL+y1/6GXUP+/wDF/wDEUf2Wv/Qy6h/3/i/+IoAzru5j029l1Hw5dwMZm33OnysUjnbu6Nj5H/Ru+DzU9l8QdBuCI76d9Kn6GLUE8r8n+434Matf2Wv/AEMuof8Af+L/AOIpr6RFKhSTxFfOjDBVpoiD+GygC/P4g0e2tDdT6rZRwKNxla4Xbj65rmfDHibR7vUta1Z76GH7XNGI4ZG2usKptR2Xqu87mGexFeS69ounQ+Kr8JbwyGBZmjlMag7hc43fKAM446VJplrD/bd85Ulo44WUlicEouadgPf4tZ06eZIo7yIyOcIpbBY+gz1qtN4r8O287w3GvaZFLGxV43vI1ZSOoIJ4NWNQsm1DR2t4pFilKq0UjLuCOMFWxxnBAr5w1Kee38ZGWe8lhcXk8cwgmTaN00vC5Q8bsdc96QH0Va+JdCvrhYLLWtOuJm+7HFdo7H8Ac1p18vxylZJgbu4Y211KVaWaN9qsu8HG0Hr1weOoHFfSOk6i9/AwuIhDcRFRIgbcpyoYMDxkEH+Y7UAX6K8/udQmsvi5dPEc7rJYijE7SMBs4/z1q8L+K71a8e80+CdgIwC7Hjg9OKANnxFe2cemSxyXcCSoQQjSANn6fSuV1G5J8H3zcmO2urW4mAGcRLMjOfwVSfwrndbWzHiWbzbOFYWlz5YxgZgPcjrXb6VfaLaX3kbjF9sBixNIHVzjO3kdxmmB1qsrqGQhlYZBByCKUnAyeBXnHiWwfwtZQN4Z8RX2nwzTeX9mVftcUI2sfkj2syjjGAcDPSubW+lmbOsavc6v/wBM7zTr3yvxjQBT+INID02bXJNUuGsfDRWZlbbPf4zDb+oB6O/+yOB3I6HU0/T4NMtBBb7jyWeRzl5GPVmPcmvPLfx3eWkKQ25tEhRdqRpot4iqPQACrsfjy+aMFrixBPY6fdgj8NtAHoFef+Iv+S6eDv8Arxvv/QVpf+E8vQcCSwf6Wd2P/ZKxF1i51f43eFWukjUx2d5t8uGWPOVH/PRRnp2zQB61RRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFYni1WOgybV3feBA90ZR+pFbdRzwR3Nu8M6B43GGU9xQBTEb3EVpeWc8eFh+XeuVIbBzwR6V5x4r+PWj+G5/7OtrKTVdVkl8mGK1f9yWzgbpCOM+ihj9K7SfRrLRdKml1DWLxNItY2klhlkURhRydzBdxHtnn3rFTwbH4yWHXPEts0FwLm3uNNtXUZsYIpVkVCOzybfn9Mhf4MkA7E3tjcAxTPHk/KY5l29e2GqGbQbGXBWMxFTkeWeB9AcgfgK0HjSRcSIrj0YZqr/ZkCf8erSWp7eS+AP+AnK/pQBT/s3UrYf6HqBcAcJNk/qc0NqWpWak3lh5irn54j1A57Z/XbVzy9Qi+5NFOueki7Tj0yOP0qtqV5MNLuUns5kd4iqmM71LEYAyORz3IAoA524mlnmecZEgVUQHtLNyx4/uphfbJrWsNPjltrezIPlSL9omGcHZ0jU4xjPX6qaypF+0yjqVury5cYxxgrED/3yTW4+lpqN/c3XnSRSIfJjZeCAAO/XGSTwRQBeNg6/wDHvdzKP7kn7xcfjz+tVGsZY2Lm0iZjli9nIYXY/To34mgWusWp/cXSXCZ+7KOcfX/Emk/tm5tl/wCJjYSRgDLOnQfj90f99Z9qAD7VLAQpu5IzkKFvIeCe/wAy4Bq1HfzbN723mx8nzLWQSD8uD+ABoh1ixuPlE4Un+GQFc/n1p7afZTHzUjVWIAEkLFGx9VwaAFTUrR22mYRv02yDYfyNWqovY3AXCXQmUZIS5jDjPbkYP86q/ZJbcYS1kh7BrGbge+xvl/QmgDYorj9W8WXOi3UIPl3Fu8qxMZ42hdCeueOgBUk471dtPG2mXH2wyh447NlWWdcSRHcSAVK8kZBGcCgDo6KrWupWV6qm0uoZdw3LtcEkeuKs0AFFFFABRRWbr3iHSvDGlvqOu3sdnaocb36sfQAck+woA0qKx/DPivRvF+lnUPD94t1ArlH+UqyN6FTyK2KACiiigArA8ef8k68R/wDYLuf/AEU1b9YHjz/knXiP/sF3P/opqAIfhx/yTHw3/wBg2D/0AVj+ILS0Pji2TV4Ip7a4kKqJV+VTJGFT/wAfhx7F19as/CbV7bVPhro8UG5ZrK0ignicYZGCDBx6MMMD3BrpNX0LTddtxBq1otxGOgJII/EEHsPyFAHmqxeHxqKNZ2Pl3FjbQQuy2kgZZ3kG8E7eCFAJz2YVU0Mwz2N5aX9utzFJoy+Yu3csrRqA67e/MLDH1Fel3um2uk+Fbu302ARRpG0m0ZYsRySSeWJx1OTXMaFYxx+KrK4jCmORHR/3kbgttkOVKsTtPXkdSfWgBy6B8MnUMvhnTirDII0ZuR/37pf+Ee+Gf/Qsaf8A+CZv/jdbNnonka9LawajqS2kFqhEJuSVUszYC9xtCY/GtX+yF/5/b7/wIagDkf8AhHvhn/0LGn/+CZv/AI3R/wAI98M/+hY0/wD8Ezf/ABuuu/shf+f2+/8AAhqiubK2srWS4u9Tu4YY13PJJdEKo9zQBy3/AAj3wz/6FjT/APwTN/8AG6D4e+GYGT4Y04D1OjN/8bq59i1jX2B0y9v9I07P/H1O5a4nH+xG3CD/AGmyf9kda0V8D6GyD7fDNqcmMGW/uHmY/wDfRwPwAoA8V1ZLC2129h0yKO2sxDMtvCkflqo+09AuBj6Yp2lyxnWNQAkXLRQgDcOcIua9Qn8F+CYvFFtp48OwyXV1BJMxUtsijUqMlc4GWYAYHrVC9+HvhzSfGekDTbBba31Hzop4I2OAyoXV1z908EHHBzz0p3A727vV0/SXu3jeURRg+XHjc57AZ4yTxXz1q+q67HNqbrqFpZi0keZYDKztFsunfHEeNwOT1/HtXv66Lb+ZG00tzOImDqks7FQw5Bx0OOvNYsvw50KW+nuv9LR5yxdUuCF+Zix4+rGkB4ze63rEfiOV5dZtTJfQiXzYnZiWEbR9DGuSVbb6DOa9+0azuII5Li+2CecINiHIjVVwFzgZPUk47+1ZMXw68PpfQ3csVxcSQAiMS3DFQDjIwMZHA4PFdTQB51fWklz8W7iOFd7i0WXGQMLtC5/M1qWuj3rapfAJGCPLzuf/AGfYGuisG0rUJW1bTfs88kgMBuogCWCsQV3egYHipLjS7G6mMtxaxSSEAFmXkigDyfxVpiN4hmt9SSF40xK+8blAWFjk8dsV0ukeBPD9yLXUobO1NpLGXUW9t5fnIy9G4BKkHp34rR8WeGNAHh7UbybTITIlu5DcjnaVHQ+9UfhZ4iGo+H/7GuZM3mlqsa5PMkHRH/ADafce9MBPE3gXR5bW3OleHYy0c26QW0aRuV2sOCwweSOK4+HRNGkvxZTaLfWVyxwiXzQQeYf9ksmG+gzXtlQ3Vpb31s9vewR3EMgw0cqhlb8DSA8zHw4jz82gzEf9fcA/9p0h+GcGfl8PtjtnUl/+N12BivPCx325mv8ARv4oCS81mPVD1dB3U5YdsjiuggniuYEmt5FlikUMjochgehBoA8tb4ZIfu6AAPfUgD+kdUdP0OXQvjR4WgkgkgR7S8ZUe9Nx/AM4yo29q9jrz/xF/wAl08Hf9eN9/wCgrQB6BRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFc34l1G6uryHw1oczQ6heJ5lxdJ1sbbOGk/325VB65PIQ0AVm/4rPxF5Y+bQNHn+f8Au3t2h6e8cRHPrIMfwHPW1W07T7XSdNt7DT4VgtbaMRxRr0UD+f171ZoAKKKKACs7WZxFbxhugbzXx12xjf8AzC1o1XurRboKd7RyJnY6YyMjB4PBHsaAOcismTWLS0PIjHm7lbIJchm5/wB6N/wIq5LMNOvp/tEl9bCafckyRmWJsgADGDt/IfWpNKiDapL+7hUWwZQY49m7LYBxnqNjf99VekH2nVUjPMdsokI9XOQv5AE/iD2oAihvLl0zBLaXwHBMb7GJ78cj9am/tFEOLmGa3/2nTK/XcMgD64qWeytrnmeFHbGN2PmA+vWqOova6Jp0+oXWqNYWluu+WSdwY0Ueu7oPoc0AWDa6dqC7wkEwbnchHPvkVVbQFjbdY3U1ueONxI49wQT+Jx7VFasuqWFvqUNtb3sF1FHPFPDmF3VhlTg+xB5NSed9n6XVza4zxdx70+pb0/4EKAD/AIndqOsV4oB64DH05GP5fjThrwhbbf2stuc4DEcdPfGfoM1Yju7oqGEMVzGeklvL29cH+hNRXuqRfYZUKvFM67USaMjJbgDPTqfWgDzjxXqC3euRuCdkUbXDZGCM8jI/3fLFc55f+jIh/wBZM5zj2+Xj8TVvUrkT3V5cKCVeXZGO+xeePwwPwqL/AFVyM/MLaPJ/2iBk/iWYflVAdL4It21TxfO9wxngtbQxEyfNwSFVcnkfcY8V6E8QsLq28mV1imkKNG7kqPkZsjPT7vbjk1zPwwsTDot3evy9xOUDEdVQbc/i24/jXReI136DcKo/fMAkB5ysjHap456t+VSBj2/jZnfdLZxtAVaQOk4VlQHGSH2j34JFa0fibTDhbqZrFyM7LxDF7dTwfwNeN+NtROmWeo26QQt5lv5BKL5bFR8g+XhsZ8zrnNUjrskF5qNrBc3cFuLKNBbyN5iuSWBBDYKrjt+tAHu+s61aaFol1qt6zG1tY/MlMS7yF9cDr614Hba3Y/GP4328OpXIGgWAZrOzkyPtRH+z6seT/sjFdWsRvPhzdPkwy31+9uTGpQuNpUjbk4BOBjoO1c14EsE+F8S3N1Aja3dxsZVuYyPKjzwinIIJ7nn6UDOn8BWcXhf48eLfD+noIdPuLaK7ihQYVDgHgdgN5Fev1434Ju7jXPjxquvSW/kW1zpkccXzhgWVY9ygj0OfSvZKBBRRRQAVgePP+SdeI/8AsF3P/opq36wPHn/JOvEf/YLuf/RTUAch4esrjTPAXhfxVo8RkuLfSbeK/tkHN3bBATj1dMll9eV716VbXEN5axXNtIssMyB43U8MpGQR+Fc18Plkf4V+Hlhk8pzpkG19u7B2Dt3ptlNqvhdZLe60lrzTjIzxy6Z8xhDckGEncBnJwpbGcUAdXXLeJ4BpuraVrsFuzLbSmK48iIu2x+CdqjJA5/HFamm+J9F1aUw2GowPOv3rdm2Sr9UbDD8RWrQBl6VKb2/vb5EdYJBHHCzoVLhQSTggHGXI/CtSsbU/F2h6VcfZbm/R7voLS3BmmJ/65oC36VT/ALS8S6vxpelx6Rbt0utTO6THqIUP/oTD6UAbt5ew2MHmTk8naiKMs7f3VHc1mwaZPqd1Hf66ijym3W1ju3JCezt2Z/0Xt6mCy8M3sN99sv8AxJqF5PjGPLhjRR6ABMgfjXQ0AFFFFAFCLS4o9fudVLu800EduFbG2NVLNx9S3P0FYthL/wAJF43k1GE7tO0aN7WCQdJrhyPNI9QgUJn1LelMuP7Q1zUdU0rTbk2lotyEvbxW/eAeVH+7i9GI6semeAT06LTbaystMgttLSNLSFAkSxHKgDjr3oAtUUUUAFeY/G74g/8ACH+FTp2nS7dW1NWjiKnmGPo0n17D3+lenV4F8XPhHqd9HrfjO4143s0MfmpZi22hIV/hDbj91cnpzz60Ac98A/iD/YGvHw3qk2NP1KTMDOeIZzx+TdPrivp6vi34b+C18eeKjpP9pnTXWBp0lEe8kqRwBkeuc+1fYmjWl5YaLaWmpXov7qGMJJc+Xs80jjcRk4Prz1oGzA+J18LLwDe56zMkQ/Fh/QGuL+H2lXbeGbjxDpcZfUbS6JhQHH2iJVHmRf8AAs8ejKppvx58QJDHpmixv87E3UoHYDKr/Nvyrv8A4f6S2jeBNMtpV2zNEJpR/tP8x/LOPwoEbGmara6taxXNk++KWFZVJGCA2RgjsQVII7EVcrldMli0r4hanpcjrGNRt0vbOPoG2lhMB77mDEf7ZNdVQAVitbSaFcSXFkrSWEzF5rVRkwserxj0PUr+I5yDtVDc2lveRhLqFJlByA65xQBJFKk8SywuHRxlWU5BFcD4i/5Lp4O/68b7/wBBWty78ImHEvhjU7jRZ1yRGh823fP96Fjj8V2n3rjZJtdf44eFIfEdpaRSxWd6I7izlLRzgqOdrDKEehz160AerUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRWTfeKNI03V4tMvbox3UpjVR5LsgaRtkas4XarM3CgkE4OKANaiio4p0llmjUSBoWCsXjZQSVDfKSMMMEcjIzkdQRQBJRRRQBmeINbj0HSWujC9zO7LDbWsf37iZuEjHpk9T0ABJ4BqDwzocukWc0+oyrc6tfv59/cKOGfGAi56Igwqj0GTySTel1Szh1i30yV2F3cRPNCnlMVZUKhjuxtBG9eM55q5QAUUUUAFFFFABRRRQBjxrNp2rXchtZZLeYAq8WG+bJJG3r1Y89OKvWMMiRyS3A2zTvvZc529gv4DFWqKACvLPiz4Hj8farpWgvq1/HJceZP5KOvkW0Ua/NKUAy7F2jQbj0ZsYwa9TrlvCH/E4vNS8VSfMuouILEntaREhCP99i8me4dfSgDR8Iafc6T4I0PTdQAF1ZafBbzhTkb0jVWwfTINbFFFAFaTTrWRy5hCOTkvGSjH6kdao6jo91dWZhttSkiPJXzUEgzggE9DxnPXqBWvRQB5nP8ADu9hmsUjbfAhJuZY33HOQQyocY6Yxk1zd1peo2No813B5ck04iEcgKOxySDgjABPHX/GvcKRlV1w4DD0IzTuBneHdO/snw5YWJ+9DCofBzl8Zb9SawvEusSu1qlvHbbFaS5XzrnyzII+AR7EnI55wK6NtJs2ztiMYOcrE7Rq2fUKQDWRr/hiTVZQ9vJAE8tYjBKh2lAclQQeAfoaQHjfjJtURJ/7Us7hVO0gzJvU5ZVBz6ZJI57msi8vIV1LVJjtWJVgLruxuAUnG1vUkV6prHhK7eAbbWa2lV43E9qfNUkMDyuRkcDgjHtXNWHhybU/GU6X6WsqXtwheQRNC3lQgbzswBhj1P8A9amBvRaaLPTfDGgPhDDb+fO2/wAvY7fMcnBAwxH1xisvxrNeSao9tcSmaMKIl89A2T977y57fSteLWbO88Ralqs91cxW4UpDLANy7Vx1HcegwevPauMnuTc30s9vcQzSAmYEKUYMcjoP4sE9qEB1/wAN7YNrizJCsIWOWQorA7QxUdR16V6lXG/DvTfs9jcXZBwxEMZPPC/eOf8AeOP+A12VDAKKKKQBWB48/wCSdeI/+wXc/wDopq36wPHn/JOvEf8A2C7n/wBFNQBD8OP+SY+G/wDsGwf+gCulrmvhx/yTHw3/ANg2D/0AV0tAGfqmgaTrcYTV9NtrwL90zRBiv0PUfhWba+B9LsZlaxuNUt4lOfIj1OcRn8N/6V0VFAFPT9I0/SlcabZQWvmMWkMUYUuT3Y9Sfc1coooAKKKKACsnxLq8mjaK01pGs17M629nCx4kmc4UH2HU+wNaN1dQWVrLc3kyQQRKXkkkbCqB1JNc1pKz+KdZt/EF3A9vp1oG/syCVcPKWGDcMO2VyFB5wST1GADjvHNzr3hfwhLovh+C8nuJw9xqmtCIqNz8uVI6E9P9kACuf+C+ua/ozHTpLK81DQnk2+ZGhf7I55yP9k55H4+tezeKYPtPhPVIf+elrIv/AI6a5z4U2f2PwxcLjG66Y9P9laAO4ooooAKZPDHc28kE6B4pUKOp6MCMEU+igD5B1Oy1P4MfFqOeGJpIraUy2xbhbm3bIK59cEg+hFe3r+0D4GOj/azdXQuNmfsRtn8zdj7ucbfxziu08U+ENE8ZaX9h8QWS3EanMbg7XiPqrDkV5p/wzR4Z+2iT+19U+z7smHKZx6btuaBnD+DoNR+MPxXm1fUIWXToJVmuB1VEX/Vwg9ycflk19PDjpWX4e8OaV4W0iPTNCs0tbZOcLyXPdmPUk+prUoEcj4/0i5uLKx13SUZtT0K4F3EqdZYuk0XvuTPHqBXUWd5BqFjBeWciywTxiSN16MpGQamrlJXPgi6lnYM3hydzI+0Z/s+Rj8zY/wCeRPJ/ukk9DwAdXRTIpY54UlgkWSN1DI6HIYHoQR1FPoAK8/8AEP8AyXTwd/1433/oK16BXn/iH/kung7/AK8b7/0FaAPQKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArhfE2j6tceLor3SdMuRIzWy/bILmIQSIkhZluYpG5C7so8amQHOCv8XdUUAeaan4Z16HR7y2spNdvXs9RjSyeDWJUmktnnSeUu0kqh9qM0Kkljhfc1Q1bQvFR1a9gsbHxSdPW7na2kh11Rvh+xxIikvc7+Z0ZxnBG48jcwPrVFAHkTaZ40vdcnuvL8QWUzWhjtne7Bt47o2gVTIq3W3YJc5AgbLc7yp40oNM8T2/wl8QQXj60NS3PJYoshFzHhUKiN1up2YbwThpOclSNuAfS6KAPI77w94tvIblLOw1uDzLXUV0+W51WMz2LvDD5QeVZi3M0UjDaXADqDhchYdU0vxrqN/qTwaR4rtIJ3u5bdI9chQLvgj8pDtusqFmR2wuAAQM7Sy17FRQB5G2meMr7Xb++SLxBZS3FrMlmst1m3jnMQA3qt3twNrhcQqNzKfMbCub/AIP0LxNF4l099fXX/scFtMd01/siWQyho1eMXkzSYBl5YtkMoP3F2+m0UAFFFFABRRRQAUUUUAc342uZn0uDRLCRo73W5vscbofmijIJmkHptjDYP94qO9b9rbQ2VnDa2saxQQRrHHGo4RQMAD6AVz2lQS6r411LWrqJ0gsV/s2wWRSMjIaeUA/3nCpn0iz3rpqACiiigAooooAKKKKACiiigArm/HT2y+G3Se6ureedhDbLZRxPcTSN0jjEisMnHJxwASSACRraxrFpoWmSX1+zCNSFVI13PK5OFRFHLMxwAB1NZeh6Pdz6gfEHiNVGpyIUt7VW3Jp8R/gU9C5wN79yMD5QMgHmPwr+E2o6Pq/ib/hJbyZ3/c2tvIrBxsKLM6gsvIBZFyAuSh4HSotR0F4fixpvhfQ5o7uUqbu+naHAs48YAGD1PXB7kV6R4qm8c2l2T4QtdNv7e4j27byQxtav/e4++p6465pvgHwQfCltdXmp3X9o67qcnm396R95uyr6KKAOnsLKLTrCG0txiOFAo9/erFFFABRRRQAVgePP+SdeI/8AsF3P/opq36wPHn/JOvEf/YLuf/RTUAQ/Dj/kmPhv/sGwf+gCulrmvhx/yTHw3/2DYP8A0AV0tABRRRQAUVnatr+maHGh1K6WN5DiKFQXklPoqLlmP0FZQ1DxPrX/ACDdPi0S1bpcaj+8mI9RCpwP+BN+FAHSkhVJYgAckntWBeeM9Njme10kS61fLx9m08eZtP8Atv8AcT/gRFRr4Ks7r5/EV5ea5JnO28kxCD7QphPzBrftrWCzt1gtII4IUGFjiQKo+gFAHOweH77W7qO+8YPE6RuJLfSYDughYdGcn/WuPcBR2HeunoooAgvY/OsJ4/78bD9KzvDFl9g0kxYxmUt+g/wrYpAoUYUYFAC0UUUAFFFFABRRRQAUUUUAFIwDKVYAgjBB70tFAHKHwvf6DO0/gu6jggYlpNIusm2Y9zGRzEfplf8AZq0vi6Cz2p4ktZtFlPG+f5oCfaZfl/762n2roaR0WRCjqGVhgqRkEUAJHIk0ayQusiMMqynII9Qa4HxD/wAl08Hf9eN9/wCgrW3L4PjspGuPCt5Jok5O4wxjfayH/ahPA+q7T71yNxd6rcfHDwpFrmnpaXENlegSQS74ZwVHzJ/EOnIYce/WgD1OiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAry/xo9hb/EW1upZ7WW7D2SR2lwxiueJi260cZ8zkr5kOPmG0ll4z6hRQB5tqvjLxLo+i3M+oXmiWlxp+oR2Nw9zZSpDMZbhRG6Ez/KBA6yMMtgk8/KaydR+I17o+t6nYQ6t4SivIr2aK5mkgaMy+VYwyiQr5+SQ2+Ign+EDIKkH1TTdMttJtPs9n5xUsXZ57iSeRie7PIzM3YDJ4AAHAAq3QB5M3xT1W41yePS59DuoIrE3cdijo1xcH7IJhHGftAdmZjxiErt53E5FWJNeuvG3wZ8Sz38Gn3kkAkSJrV4ZI5CiJIrFYppxGysem8kbQ3GQB3UXhfTYdabVU+2m4aQyFH1C4aDcRjcIS/lg/ReOta9AHkeofFq6037I0ur6FPG+oiITQwFYb21zCJJopXuAqiMyOh2+aSYy20ANtn0j4ha9qM2kbNa8M3f9oPebbe1tnMkotmxiM/aDlpFBI4+XcPv7fm9VooA8e0Pxv/wk/iLwtPrj6XFeR6tLHbtDPBvKPZS7kKpPKVIcqDlgTlPlB4r2GiigAooooAKKKKACqup6naaPps1/qUywW0C7nc8+wAA5JJwABySQBVqsa40FtQ8SRajqdwJ7azw1jZhcJHLjmV+fnfsvQKM9zkAFLR9Mu9X1OPxD4ihMMqA/2dp74P2JCMF27GZh1P8ACDtH8RbpqKKACiiigAooooAKKKKACsDx5/yTrxH/ANgu5/8ARTVv1gePP+SdeI/+wXc/+imoAh+HH/JMfDf/AGDYP/QBXSEhVJYgAdSe1ec+CNd1K6+HegWHhWwW4mj0+FJr66yltAwQZHrIw9F49SK2YPAUd7L9p8X6pda/OefJlbyrVPZYFOCP97caANG48X6Ws7W+nGXVrpTgwaenmlT6Mw+Rf+BMKqyQeK9b4luIfDtoeq2+Li6Yf75GxPwDfWuitraCzt0gtIY4IUGFjiQKqj2AqWgDJ0bwxpehu81nA0l3KP3t5cOZZ5f9525/Dp7VrUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFef+If+S6eDv+vG+/8AQVr0CvP/ABD/AMl08Hf9eN9/6CtAHoFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAUNdvLzT/D9/d6ZaG8vILd5IbcAkyOASFwOT9Byelc34e8eW9zCkesXtvNLPdy21rNY2c6pIY4RI6yIQxt5RiT91I27CcZrqdT0+LVtMnsblpEinTY7ROUYD2Ycg+4rmp/Bsp2QSTyaqLq8jur7UL6dYp08sKEWNIYlRgVBQ8pwx5bOKAJW+IGi3BMNndXUEyXFvBIbnR7sLG0rxhEbKLtZxIoGSMFgSCARTrb4jeGLu0muLa9uJEhCbgun3G9i0nlhVTy9ztv+UqoJU8ECi98DRXr6kza3qkX9oahbai4jEH7uSAoYwuYj8uYo8g5J2Dnls4GrfDC5XRng0nWby/laIQNDqMttHG8Zn85slbVwSWyMMjKQSCO9AHS2vj3w9ePaJDc3IN24SPzbC4j2sXMah9yDy9zqyrv27ipC5Iq1e+K9H0/WF0u5uJftbKSEjtZZFzsZ9m5VK+YVRiEzuIHAORXMaX8L7Vm0bUNaMI1PTFRFENrZyp5ccrPHGGa2XYF3H5okiPPOSoNb9/4UN3qV7dWmuarpi38Xl3MNk8QWRthQShmjZ0cLtwVZR8i8dcgFWT4k+GIVUzXN7GzeZ+6fS7oSDy9pcFDHuBUOrEEZ2nd05rqI5EmiWSJ1eN1DK6nIYHoQe4rzWP4VXWm6tZw6NrN1DpTC5a9m328c+6VI1IRFttmG8pdxyrZJIOc59IggjtreOCBdkUSBEUdgBgCgCSiiigAooooAKKKKACsvxPYtqfhLV7FM7rqxmhXHXLIR/WtSigDj/hPfx6h8KtAeLgxWi28i91eP5CD75FdhXlYuT8I/GF2L1GHg/XLkzpcqMrp1y33lYDojdc9vzr1GCeK5gSa3kSWKRQyOjAqwPcEdaAH0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXnupyf2h+0DodvAN39l6RcTzkfw+YQig/lmui8X+M9K8G6X9q1OQvPJ8ttZxcy3L9lVevXv0FZHw68N6lZLqPiPxQoXXtckEs8YORbRAYjhH0HX3+lAHb0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAEN3Z29/Zy2t9BHcW8y7ZIpVDKw9CDXAt8KpdImeTwH4p1Lw7GxLfYwBc2wPtG/T869EooA4NfDXxGVQD4/tWwOp0WPJ/wDHqX/hG/iL/wBD7af+CVP/AIqu7ooA4T/hG/iL/wBD7af+CVP/AIqj/hG/iL/0Ptp/4JU/+Kru6KAOE/4Rv4i/9D7af+CVP/iqP+Eb+Iv/AEPtp/4JU/8Aiq7uigDhP+Eb+Iv/AEPtp/4JU/8AiqP+Eb+Iv/Q+2n/glT/4qu7ooA4T/hG/iL/0Ptp/4JU/+Ko/4Rv4i/8AQ+2n/glT/wCKru6KAOE/4Rv4i/8AQ+2n/glT/wCKo/4Rv4i/9D7af+CVP/iq7uigDhP+Eb+Iv/Q+2n/glT/4qj/hG/iL/wBD7af+CVP/AIqu7ooA4T/hG/iL/wBD7af+CVP/AIqj/hG/iL/0Ptp/4JU/+Kru6KAOE/4Rv4i/9D7af+CVP/iqP+Eb+Iv/AEPtp/4JU/8Aiq7uigDhP+Eb+Iv/AEPtp/4JU/8AiqP+Eb+Iv/Q+2n/glT/4qu7ooA4T/hG/iL/0Ptp/4JU/+KqKXwj8Qboqlx8RRDF/H9l0iNHI9iScV6BRQByHhv4a6L4f1L+1rh7nWNZI51HUZfNkH+72X8K6+iigAooooAKKKKACiiigAooooAKKKKAP/9k=" /></p><p>1. Holding the syringe barrel in one hand (avoid holding the syringe plunger),<br />unscrew the syringe cap by twisting it anticlockwise.<br />2. To attach the needle to the syringe, twist the needle clockwise into the syringe<br />until you feel it lock. (see picture)<br />3. Remove the needle protector, which on occasion can be a little stiff.<br />Add the solvent to the powder. After the addition of the solvent to the powder, the<br />mixture should be well shaken until the powder is completely dissolved in the solvent.<br />After reconstitution, the vaccine should be used promptly.<br />A new needle should be used to administer the vaccine.<br />Withdraw the entire contents of the vial.<br />Any unused product or waste material should be disposed of in accordance with local<br />requirements.</p><p><strong>Manufacturer:</strong><br />GlaxoSmithKline Biologicals s.a. 89, rue de l&rsquo;Institut - 1330 Rixensart Belgium<br />Tel: (32) 2 656 81 11 Fax: (32) 2 656 80 00<br /><strong>Marketing Authorization holder:</strong><br />Glaxo Saudi Arabia Ltd.* Jeddah, KSA<br />Address: P.O. Box 22617 Jeddah 21416 &ndash; Kingdom of Saudi Arabia<br />*member of the GlaxoSmithKline group of companies</p><p><br /><strong>For any information about this medicinal product, please contact:</strong><br />GlaxoSmithKline - Head Office, Jeddah<br />Tel: +966-12-6536666<br />Mobile: +966-56-904-9882<br />Email: gcc.medinfo@gsk.com<br />website: https://healthksa.gsk.com/<br />P.O. Box 55850, Jeddah 21544, Saudi Arabia<br />Priorix-Tetra is a trademark owned by or licensed to GSK group of companies.<br />&copy;2017 GSK, all rights reserved.</p><table border="1" cellspacing="1" cellpadding="1" style="width:100%"><tbody><tr><td><strong>To report any side effect(s):</strong><br />Kingdom of Saudi Arabia<br />-National Pharmacovigilance centre (NPC)<br />&bull; Fax: +966-11-205-7662<br />Call NPC at +966-11-2038222, Ext: 2353-2356-2317-2354-2334-2340<br />Toll-free: 8002490000<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc<br /><strong>-GlaxoSmithKline - Head Office, Jeddah</strong><br />&bull; Tel: 00966(012)6536666<br />&bull; Fax: 00966(012)6536660<br />&bull; P.O Box 55850, Jeddah 21544, Saudi Arabia</td></tr></tbody></table><table border="1" cellspacing="1" cellpadding="1" style="width:100%"><tbody><tr><td><p><strong>THIS IS A MEDICAMENT</strong><br />- Medicament is a product which affects your health, and its consumption contrary to<br />instructions is dangerous for you.<br />- Follow strictly the doctor&rsquo;s prescription, the method of use and the instructions of the<br />pharmacist who sold the medicament.<br />- The doctor and the pharmacist are experts in medicine, its benefits and risks.<br />- Do not by yourself interrupt the period of treatment prescribed for you.<br />- Do not repeat the same prescription without consulting your doctor.<br />- Keep all medicine out of reach of children</p><p><br />Council of Arab Health Ministers<br />Union of Arab Pharmacists</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                GDS Version Number: GDS12
Date of issue: 12 October 2015
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>بريوركس تترا هو لقاح خاص بالأطفال من سن 9 شهرًا حتى 12 عامًا لحمايتهم من الامراض التى تسببها الحصبة<br />والنكاف والحصبة الالمانية )فيروسات الجدرى القرمزية والجديرى(.<br />عندما يتم تطعيم شخص ببريوركس تترا, الجهاز المناعي )نظام المناعة فى الجسم نظام الدفاع الطبيعية ( سيحمي<br />الشخص من الاصابة بالعدوى من الحصبة والنكاف والحصبة الالمانية )فيروسات الجدرى القرمزية والجديرى(.</p><p><br />&bull; الحصبة: مرض الحصبة مرض معد سببه فيروس. انه ينتقل من شخص الى اخر عن طريق التنفس فى قطرات<br />الماء فى الهواء من المصابين. العلامات الرئيسية للمرض تشمل سلسلة والرشح وحمى. يمكن البعض اعراض<br />اخرى تشمل اصابات الاذن والصدر الاصابة بامراض مثل الالتهاب الشعبى والالتهاب الرئوى, والافراد.<br />الحصبة قد يكون مهلكا. هذه الاثار هى اكثر شيوعا فى الاطفال المرضى أو ناقصين التغذية.</p><p><br />&bull; الغدة النكفية: الغدة النكفية هو مرض سببه فيروس ايضا. انه ينتقل من شخص الى اخر عن طريق التنفس فى<br />قطرات الماء فى الهواء من المصابين. العلامة الرئيسية للمرض هي تورم في الغدد القريبة من الأذنين، على واحد<br />أو كلا الجانبين من الوجه في منطقة الخد. بعض الناس لديهم أيضا التهاب البنكرياس، التهاب المبيضات أو<br />الخصيتين التي تسبب في بعض الأحيان مشاكل الخصوبة في الحياة في وقت لاحق، والتهاب السحايا، والصمم الذي<br />يستمر بعد التعافي من المرض نفسه.</p><p>&bull; الحصبة الألمانية: الحصبة الألمانية مرض معد أيضا بسبب فيروس. العلامات الرئيسية للحصبة الألمانية هي<br />طفح جلدي وتورم. إذا أصيبت النساء الحوامل بالعدوى بالحصبة الألمانية في الأسابيع الاثنى عشر الاولى من<br />الحمل، فإنها قد تسبب ضررا للطفل الذي لم يولد بعد في حوالي تسع حالات من أصل 10 حالات. ويمكن أن<br />يشمل هذا الضرر العقلية الذهنية، والعمى، والصمم، ومشاكل القلب.</p><p><br />&bull; الحماق )فاريسيلا(: جدري الماء )فاريسيلا( هو مرض معد تسببه فيروس يسمى الحماق النطاقي. يتم تمريرها<br />عن طريق الاتصال الوثيق مع المصابين و تنفس في قطرات في الهواء من الناس المصابين. هو الأكثر شيوعا<br />في الأطفال الذين تقل أعمارهم عن 10 الذين عادة ما تكون خفيفة. العلامة الرئيسية للمرض هي طفح جلدي<br />مع بقع حمراء مرتفعة على الوجه والرأس والتي قد تنتشر إلى أجزاء أخرى من الجسم. جدري الماء يمكن أن<br />يكون أكثر خطورة في البالغين، في النساء الحوامل والمرضى الذين يعانون من ضعف الجهاز المناعي</p><p><br />وكما هو الحال في جميع اللقاحات، قد لا يحمي بريوركس تترا جميع الأشخاص الذين يتم تطعيمهم به بشكل كامل.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>يجب عدم تعاطي بريوركس تترا في الحالات التالية</strong><br />لا ينبغي إعطاء بريوريكس-تيترا</p><p>إذا كان طفلك:<br />&bull; كان لديه في السابق أي رد فعل تحسسي على بريوريكس-تيترا، نيوميسين )مضاد حيوي( أو أي مكون يحتوي على هذا<br />اللقاح. وترد المواد الفعالة وغيرها من المكونات في بريوريكس-تيترا تحت القسم 6 من النشرة. ومع ذلك، إذا كان لديك<br />طفح جلدي )التهاب الجلد( بعد العلاج مع النيومايسين، لا يزال بإمكانك تطعيم مع بريوريكس-تيترا.<br />&bull; كان لديه سابقا رد فعل تحسسي على أي لقاح ضد الحصبة والنكاف والحصبة الألمانية وفاريسيلا.<br />&bull; يعاني من أي مرض خطير أو يأخذ أي دواء يضعف نظام المناعة )انظر أيضا &quot;توخ الحذر الخاص مع بريوريكس-<br />تيترا&quot;(.<br />يجب عدم إعطاء بريوريكس-تيترا خلال فترة الحمل. وينبغي تجنب الحمل لمدة شهر واحد بعد التلقيح.<br />تحقق مع طبيبك إذا كنت تعتقد أن أي من هذه تنطبق على طفلك.<br /><strong>رعاية خاصة مع بريوريكس-تيترا</strong><br />يجب أن يعرف طبيبك قبل أن يبدأ طفلك في أخذ بريوريكس-تيترا إذا كان / هي:<br />&bull; لديه عدوى شديدة مع ارتفاع في درجة الحرارة. في هذه الحالات، سيتم تأجيل التطعيم حتى الانتعاش. عدوى بسيطة<br />مثل البرد لا ينبغي أن يكون مشكلة، ولكن التحدث مع طبيبك أولا.<br />&bull; له تاريخ من التشنجات الحموية )يناسب( أو تاريخ عائلي من التشنجات. في هذا طفلك ضعفت جهاز المناعة )على<br />سبيل المثال مثل عدوى فيروس العوز المناعي البشري(. يجب مراقبة الطفل عن كثب حيث قد لا تكون الاستجابات<br />للّقاحات كافية لضمان الحماية من المرض )انظر القسم 2 &quot;يجب عدم تعاطي بريوركس تترا في الحالات التالية&quot;(.<br />&bull; يجب مراقبة حالة طفلك عن كثب بعد التطعيم حيث قد تحدث الحمى من 5 إلى 12 يوما بعد التلقيح.<br />&bull; لديه تاريخ أو تاريخ عائلي من الحساسية.<br />&bull; كان لديه أي وقت مضى رد فعل تحسسي شديد للبيض أو أي شيء يحتوي على البيض.<br />&bull; كان له أثر جانبي بعد التلقيح ضد الحصبة والنكاف أو الحصبة الألمانية التي تنطوي على كدمات سهلة أو نزيف لفترة<br />أطول من المعتاد.<br />&bull; نقل الدم أو البلازما، أو الغلوبولين المناعي البشري خلال الأشهر الثلاثة الماضية. إذا كان الأمر كذلك، قد تكون<br />استجابة الأجسام المضادة ل بريوريكس-تيترا منخفضة لذلك فمن المعتاد أن ننتظر لمدة ثلاثة أشهر قبل إعطاء<br />بريوريكس-تيترا.</p><p>&bull; ومن المقرر أن يكون اختبار الجلد للسل ممكن. إذا تم إجراء هذا الاختبار في غضون 6 أسابيع بعد تلقي بريوريكس-<br />تيترا، فإن النتيجة قد لا تكون موثوقة.<br />&bull; أقل من 12 شهرا. الأطفال الذين تقل أعمارهم عن 12 شهرا قد لا يطورون استجابة مناعية جيدة لفيروس الحصبة.<br />سوف ينصحك الطبيب إذا كانت هناك حاجة إلى جرعات إضافية من الحصبة التي تحتوي على لقاح.<br />&bull; لديه جهاز المناعة ضعيفة. يجب مراقبة طفلك عن كثب ألن االستجابات لللقاحات قد ال تكون كافية لضمان الحماية من<br />المرض.<br />يمكن أن يحدث الإغماء بعد أو حتى قبل أي حقن الإبرة، لذلك أخبر الطبيب أو الممرضة إذا كان طفلك أغمي عليه حقن<br />سابق.<br />مثل اللقاحات الأخرى، بريوريكس-تيترا لا يمكن أن تحمي تماما طفلك ضد اصطياد جدري الماء. ومع ذلك، فإن<br />الأشخاص الذين تم تطعيمهم والقبض على جدري الماء عادة ما يكون لديهم مرض معتدل جدا، مقارنة مع الناس الذين لم<br />يتم تطعيمهم.<br />لا يتم عادة نقل أنواع الفيروسات الموجودة في بريوريكس-تيترا من الشخص الذي كان لديه اللقاح إلى أشخاص آخرين،<br />باستثناء فيروس الحماق. وقد يحدث هذا عندما يطور اللقاح الصحي بثور.<br /><strong>الأدوية الأخرى وبريوركس تترا</strong><br />أبلغ الطبيب أو الصيدلاني إذا كان الطفل يتناول أدوية أخرى، أو تناول أيّ أدوية أخرى مؤخرًا، أو تناول أيّ لقاح<br />آخر مؤخرًا.<br />قد يؤجل الطبيب التطعيم باللقاح لمدة 3 أشهر على الأقل إذا كان الطفل قد تم نقل دم أو مضادات حيوية بشرية<br />)غلوبولين مناعي( له.<br />وإذا لزم إجراء فحص التوبركولين، فيجب القيام بذلك إما في أي وقت قبل التطعيم بلقاح بريوركس تترا، أو بشكل متزامن<br />مع التطعيم به، أو بعد التطعيم به بمدة 6 أسابيع.<br />يجب الامتناع عن استخدام الساليسيلات )مادة موجودة في العديد من الأدوية المستخدمة في خفض الحمى وتخفيف الألم(<br />لمدة 6 أسابيع بعد التطعيم بلقاح بريوركس تترا. لأننا نعرف الآن أن متلازمة راي، وهو مرض نادر في الدماغ والكبد<br />يمكن أن يحدث.<br />يمكن إعطاء بريوركس تترا في نفس وقت تناول الأدوية الأخرى. لكن يلزم حقن كل لقاح في موضع حقن مختلف.<br /><strong>الحمل والرضاعة الطبيعية</strong><br />يجب عدم إعطاء بريوركس تترا للنساء الحوامل.<br />إذا كانت ابنتك حاملاً أو ترضع رضاعة طبيعية، أو إذا كنتِ تظنين أنها حامل أو تخطط الحمل، فيجب استشارة الطبيب<br />أو الصيدلاني قبل التطعيم بهذا اللقاح. من المهم أيضًا ألا تكون البنت حاملاً خلال شهر بعد تعاطي اللقاح. وخلال تلك<br />الفترة، يجب على البنت استخدام طريقة فعالة لتنظيم النسل لتجنب حدوث الحمل.<br />اسأل طبيبك أو الصيدلي عن المشورة قبل تلقي بريوريكس-تيترا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يتم حقن بريوركس تترا أسفل الجلد في أعلى الذراع أو في الجانب الخارجي للفخذ.<br />بريوركس تترا مخصص للأطفال من سن 11 شهرًا حتى 12 عامًا. وسيتم تحديد الوقت المناسب وعدد مرات حقن الطفل<br />بواسطة الطبيب بناءً على التوصيات الرسمية الملائمة.<br />ويجب عدم إعطاء اللقاح عن طريق الوريد أبدًا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، بريوريكس-تيترا يمكن أن يسبب آثار جانبية، وإن لم يكن الجميع يحصل عليها. كما هو الحال مع<br />جميع اللقاحات عن طريق الحقن، وهناك خطر نادر من الحساسية. قد تكون هذه الطفح الجلدي محلية أو واسعة الانتشار<br />التي قد تكون حكة أو بثورية، وتورم في العيون والوجه، وصعوبة في التنفس أو البلع، وانخفاض مفاجئ في ضغط الدم<br />وفقدان الوعي. هذه<br />قد تحدث ردود الفعل قبل مغادرة جراحة الطبيب. ومع ذلك، يجب أن تسعى العلاج الفوري في أي حال.<br />الآثار الجانبية التي وقعت خلال التجارب السريرية مع بريوريكس-تيترا كانت على النحو التالي:<br />قد تحدث الآثار الجانبية التالية عند تناول هذا اللقاح:<br />شائعة جدًا )قد تصيب هذه الأعراض أكثر من شخص في كل 10 جرعات لقاح(: <br />&bull; الألم المحلي،<br />&bull; احمرار محلي،<br />&bull; حمى أكبر من 37.5 درجة مئوية *<br />شائعة )قد تصيب هذه الأعراض شخصًا في كل 10 جرعات لقاح(: <br />&bull; تورم في موقع الحقن<br />&bull; حمى عندما تزيد الحرارة عن 39،5 درجة مئوية*<br />&bull; سرعة الانفعال<br />&bull; طفح جلدي )بقع و/أو بثور(<br />غير شائعة )قد تصيب هذه الأعراض شخصًا في كل 100 جرعة لقاح(: <br />&bull; عدوى الجهاز التنفسي العلوي<br />&bull; بكاء غير عادي، توتر، عدم القدرة على النوم<br />&bull; الشعور بسوء الحالة الصحية بشكل عام، النُوام، التعب<br />&bull; تورم الغدد النكفية )الغدد الموجودة في الوجنة(<br />&bull; إسهال<br />&bull; قيء<br />&bull; فقدان الشهية<br />&bull; عدم القدرة على النوم<br />&bull; إعياء<br />&bull; نقص الطاقة<br />&bull; العصبية<br />&bull; التهاب الأنف<br />&bull; تورم الغدد اللمفاوية<br />نادرة )قد تصيب هذه الأعراض شخصًا في كل 1000 جرعة لقاح(: <br />&bull; عدوى الأذن الوسطى<br />&bull; تشنجات مرتبطة بالحمى<br />&bull; السعال<br />&bull; التهاب الشعب الهوائية<br />* تمت ملاحظة وجود معدلات أعلى من الحمى بعد إعطاء أول جرعة من بريوركس تترا عند المقارنة باللقاحات الخاصة<br />بعلاج الحصبة والنكاف والحصبة الألمانية والحماق التي يتم إعطاؤها بشكل منفصل في نفس الزيارة.<br />بعد التسويق، نادرا ما يتم الإبلاغ عن الآثار الجانبية الإضافية التالية في الأشخاص الذين تم تطعيمهم باستخدام<br />بريوريكس-تيترا:<br />&bull; عدوى حول الدماغ أو الحبل الشوكي )التهاب السحايا(<br />&bull; القوباء المنطقية )الهربس النطاقي(<br />&bull; أعراض تشبه الحصبة<br />&bull; النكاف مثل الأعراض )بما في ذلك عابرة، تورم مؤلم في الخصيتين وتورم الغدد في الرقبة(<br />&bull; العدوى أو التهاب الدماغ والحبل الشوكي والأعصاب الطرفية مما يؤدي إلى صعوبة مؤقتة عند المشي )عدم الثبات( و<br />/ أو فقدان مؤقت للسيطرة على الحركات الجسدية(، والسكتة الدماغية، والتهاب بعض الأعصاب، وربما مع دبابيس<br />والإبر أو فقدان الشعور أو حركة طبيعية )متلازمة غيلان باريه(،<br />&bull; تضييق أو انسداد الأوعية الدموية. وهذا قد يشمل نزيف غير عادي أو كدمات تحت الجلد )هينوش شونلين فرفرية( أو<br />الحمى التي تستمر لأكثر من خمسة أيام، ويرتبط مع طفح جلدي على الجذع في بعض الأحيان تليها تقشير الجلد على<br />اليدين والأصابع والعيون الحمراء والشفتين ، الحلق واللسان )مرض كاواساكي(<br />&bull; نزيف أو كدمات بسهولة أكبر من المعتاد بسبب انخفاض في نوع من خلايا الدم تسمى الصفائح الدموية، نزيف غير<br />عادي أو كدمات تحت الجلد<br />&bull; حالة شديدة من الجلد التي قد تؤثر على الفم وأجزاء أخرى من الجسم.<br />&bull; الطفح الجلدي مثل الطفح الجلدي<br />&bull; آلام المفاصل والعضلات<br />&bull;<br />إذا كان أي من الأثار الجانبية خطير، أو إذا لاحظت أي آثار جانبية غير مدرجة في هذه النشرة، أخبر طبيبك أو الصيدلي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يجب حفظ اللقاح بعيدًا عن متناول ومرأى الأطفال.<br />لا تستخدم هذا اللقاح بعد تاريخ انتهاء الصلاحية الموضح على العلبة الكرتونية. يشير تاريخ انتهاء الصلاحية إلى اليوم<br />الأخير من الشهر المذكور.<br />8 درجات مئوية(. - يجب حفظه ونقله في ثلاجة ) 2<br />يجب عدم تجميده.<br />يُحفظ في العبوة الأصلية للحماية من الضوء.<br />8 درجات مئوية(. وفي حالة عدم تناوله خلال - وبعد الاستنشاء، يجب تناول اللقاح على الفور أو حفظه في الثلاجة ) 2<br />24 ساعة، يجب التخلص منه.<br />لا تتخلص من الأدوية في الفضلات السائلة ولا المخلفات المنزلية. استشر الصيدلاني حول كيفية التخلص من الأدوية التي<br />لم يعد الطفل يستخدمها. فهذا من شأنه أن يحافظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>- المواد الفعَّالة هي: فيروسات الحصبة والنكاف والحصبة الألمانية والحماق الحية المُوَهّنة.<br />- المكونات الأخرى هي:<br />. المسحوق: أحماض أمينية، ولاكتوز لا مائي، ومانيتول وسوربيتول ومستنبت 199<br />المذيب: ماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>يتم تقديم بريوركس تترا في صورة مسحوق ومذيب لمحلول الحقن )المسحوق في فيال لجرعة واحدة والمذيب في محقنة<br />معبأة مسبقًا ) 0،5 مل(( مع إبر منفصلة أو بدونها بأحجام العبوات التالية:<br />. - مع إبرتين منفصلتين: بأحجام عبوات 1 أو 10<br />. - بدون إبر: بأحجام عبوة 1 أو 10 أو 20 أو 50<br />يتم تقديم بريوركس تترا في صورة مسحوق أبيض اللون إلى وردي قليلاً ومذيب صافي عديم اللون )ماء للحقن( لاستنشاء<br />اللقاح.<br />لا تتوفر جميع أحجام العبوات في السوق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>تعليمات الاستخدام<br />المعلومات التالية مخصصة للمهنيين الطبيين أو المتخصصين في الرعاية الصحية فقط:<br />وينبغي فحص اللقاح المعاد تشكيله بصريا لأي جسيمات أجنبية و / أو مظهر طبيعي غير طبيعي. في حالة وجود أي<br />ملاحظة، يجب التخلص من اللقاح.<br />لون اللقاح المعاد قد تختلف من الخوخ واضحة إلى الوردي الفوشيه بسبب الاختلافات الطفيفة من الرقم الهيدروجيني. هذا<br />أمر طبيعي ولا يضعف أداء اللقاح. في حالة وجود اختلاف آخر لوحظ، تجاهل اللقاح.<br />تعليمات لإعادة تشكيل اللقاح مع المذيب المقدمة في أمبولات<br />يتم إعادة تشكيل بريوريكس-تيترا عن طريق إضافة المحتوى الكامل للأمبولة الموردة من المذيبات القارورة التي تحتوي<br />على مسحوق. بعد إضافة المذيب إلى المسحوق، يجب أن يهتز الخليط جيدا حتى يذوب المسحوق تماما في المذيب.<br />بعد إعادة التشكيل، يجب استخدام اللقاح على وجه السرعة.<br />وينبغي استخدام إبرة جديدة لإدارة اللقاح.<br />سحب محتويات القارورة بأكملها.<br />تعليمات لإعادة تشكيل اللقاح مع المذيبات المعروضة في حقنة مملوءة مسبقا<br />يجب إعادة تشكيل بريوريكس-تيترا عن طريق إضافة محتوى كامل حقنة مملوءة مسبقا من المذيبات إلى قارورة تحتوي<br />على مسحوق.<br />لإرفاق الإبرة إلى حقنة، الرجوع إلى الرسم أدناه. ومع ذلك، فإن حقنة المقدمة مع بريوريكس-تيترا قد تكون مختلفة قليلا<br />من حقنة وصفها في الرسم</p><p><img width="500" height="253" alt="" src="data:image/jpeg;base64,/9j/4AAQSkZJRgABAQEAYABgAAD/4RDyRXhpZgAATU0AKgAAAAgABAE7AAIAAAANAAAISodpAAQAAAABAAAIWJydAAEAAAAaAAAQ0OocAAcAAAgMAAAAPgAAAAAc6gAAAAgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAEZlZGhhIEFsZW56aQAAAAWQAwACAAAAFAAAEKaQBAACAAAAFAAAELqSkQACAAAAAzExAACSkgACAAAAAzExAADqHAAHAAAIDAAACJoAAAAAHOoAAAAIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAyMDIwOjA2OjA4IDExOjA1OjI1ADIwMjA6MDY6MDggMTE6MDU6MjUAAABGAGUAZABoAGEAIABBAGwAZQBuAHoAaQAAAP/hCx9odHRwOi8vbnMuYWRvYmUuY29tL3hhcC8xLjAvADw/eHBhY2tldCBiZWdpbj0n77u/JyBpZD0nVzVNME1wQ2VoaUh6cmVTek5UY3prYzlkJz8+DQo8eDp4bXBtZXRhIHhtbG5zOng9ImFkb2JlOm5zOm1ldGEvIj48cmRmOlJERiB4bWxuczpyZGY9Imh0dHA6Ly93d3cudzMub3JnLzE5OTkvMDIvMjItcmRmLXN5bnRheC1ucyMiPjxyZGY6RGVzY3JpcHRpb24gcmRmOmFib3V0PSJ1dWlkOmZhZjViZGQ1LWJhM2QtMTFkYS1hZDMxLWQzM2Q3NTE4MmYxYiIgeG1sbnM6ZGM9Imh0dHA6Ly9wdXJsLm9yZy9kYy9lbGVtZW50cy8xLjEvIi8+PHJkZjpEZXNjcmlwdGlvbiByZGY6YWJvdXQ9InV1aWQ6ZmFmNWJkZDUtYmEzZC0xMWRhLWFkMzEtZDMzZDc1MTgyZjFiIiB4bWxuczp4bXA9Imh0dHA6Ly9ucy5hZG9iZS5jb20veGFwLzEuMC8iPjx4bXA6Q3JlYXRlRGF0ZT4yMDIwLTA2LTA4VDExOjA1OjI1LjEwNzwveG1wOkNyZWF0ZURhdGU+PC9yZGY6RGVzY3JpcHRpb24+PHJkZjpEZXNjcmlwdGlvbiByZGY6YWJvdXQ9InV1aWQ6ZmFmNWJkZDUtYmEzZC0xMWRhLWFkMzEtZDMzZDc1MTgyZjFiIiB4bWxuczpkYz0iaHR0cDovL3B1cmwub3JnL2RjL2VsZW1lbnRzLzEuMS8iPjxkYzpjcmVhdG9yPjxyZGY6U2VxIHhtbG5zOnJkZj0iaHR0cDovL3d3dy53My5vcmcvMTk5OS8wMi8yMi1yZGYtc3ludGF4LW5zIyI+PHJkZjpsaT5GZWRoYSBBbGVuemk8L3JkZjpsaT48L3JkZjpTZXE+DQoJCQk8L2RjOmNyZWF0b3I+PC9yZGY6RGVzY3JpcHRpb24+PC9yZGY6UkRGPjwveDp4bXBtZXRhPg0KICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICA8P3hwYWNrZXQgZW5kPSd3Jz8+/9sAQwAHBQUGBQQHBgUGCAcHCAoRCwoJCQoVDxAMERgVGhkYFRgXGx4nIRsdJR0XGCIuIiUoKSssKxogLzMvKjInKisq/9sAQwEHCAgKCQoUCwsUKhwYHCoqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioq/8AAEQgA7AJjAwEiAAIRAQMRAf/EAB8AAAEFAQEBAQEBAAAAAAAAAAABAgMEBQYHCAkKC//EALUQAAIBAwMCBAMFBQQEAAABfQECAwAEEQUSITFBBhNRYQcicRQygZGhCCNCscEVUtHwJDNicoIJChYXGBkaJSYnKCkqNDU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6g4SFhoeIiYqSk5SVlpeYmZqio6Slpqeoqaqys7S1tre4ubrCw8TFxsfIycrS09TV1tfY2drh4uPk5ebn6Onq8fLz9PX29/j5+v/EAB8BAAMBAQEBAQEBAQEAAAAAAAABAgMEBQYHCAkKC//EALURAAIBAgQEAwQHBQQEAAECdwABAgMRBAUhMQYSQVEHYXETIjKBCBRCkaGxwQkjM1LwFWJy0QoWJDThJfEXGBkaJicoKSo1Njc4OTpDREVGR0hJSlNUVVZXWFlaY2RlZmdoaWpzdHV2d3h5eoKDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uLj5OXm5+jp6vLz9PX29/j5+v/aAAwDAQACEQMRAD8A+kaKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAK2oX8Ol6fNe3QmMMK7n8iB5nx7IgLH8AawbD4i+F9V8KT+JNL1F73Srdyk0tvaTSNERyd0aoXAAOclcY56c1v6j/yC7r/AK4v/wCgmvCPFfh3Ufh5jxb4Ph8zQ9fsktNcsEOFR5E2rcqOnVufcns52gHvVpcpeWcVzCsqxyqHUTQtE4B9UcBlPsQDUteO+MPHXjFfiTq+heFoX3aPYwXsMANqkV0pZTK07zsGEYUlcxYIJyT0qOLx94y1T4jatBpdu/2PRtTtraeyL2iQfZnBDySPIwlMhJBTZ8vygEHJyAemeIvF2i+FBZtr91JapfTi3gcW0sitIeilkUhSe27GcH0NO0rxXo+ta5qmj6ddPJf6SyrewPbyRmItnbyygMDgkFSQRg9CK8B8YeItX8WeFbfVtW1QhIvHCWMWlCGNUtljB2/MBvL4ySSxHzcAYrT1rxTqHgvxh8Ytc0eJJLy3XS1jMi7lQumzeR3xuz9cZ4oA+g6K4v4e6p4ivW1KDxGszQRmGfTri7ktTcTwSKeXW2YoBuVtpwMj1INdpQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRVbUNSsdJsnvNVvLeytkIDT3MqxopJwMsxAGSQPxpkusaZDq8OlTajaR6jOhkis3nUTSKM5ZUzuI+U8gdj6UAXKKKoSa7pEV8bKXVbJLtZUhNu1wgkEjqWRNuc7mVWIHUgEjpQBfooooAKKKKACiiigAooooAKKKKACiiigAopGZUUs5CqoySTgAVwt/8AF7w7DfSWOiQ6h4iu4ztePSLYzhT7vwv5E0Ad3RXn/wDws3Uv+ie+KP8AwGT/AOKo/wCFm6l/0T3xR/4DJ/8AFUAegUV5/wD8LN1L/onvij/wGT/4qj/hZupf9E98Uf8AgMn/AMVQB6BRXn//AAs3Uv8Aonvij/wGT/4qj/hZupf9E98Uf+Ayf/FUAegUV5//AMLN1L/onvij/wABk/8AiqP+Fm6l/wBE98Uf+Ayf/FUAegUV5/8A8LN1L/onvij/AMBk/wDiqP8AhZupf9E98Uf+Ayf/ABVAHoFFef8A/CzdS/6J74o/8Bk/+Ko/4WbqX/RPfFH/AIDJ/wDFUAegUV5//wALN1L/AKJ74o/8Bk/+Ko/4WbqX/RPfFH/gMn/xVAHoFFef/wDCzdS/6J74o/8AAZP/AIqj/hZupf8ARPfFH/gMn/xVAHoFFef/APCzdS/6J74o/wDAZP8A4qj/AIWbqX/RPfFH/gMn/wAVQB6BRXn/APws3Uv+ie+KP/AZP/iqP+Fm6l/0T3xR/wCAyf8AxVAHoFFef/8ACzdS/wCie+KP/AZP/iqR/inc26+Ze+AvFUMIPzSLZh9vvgN0oA9BornfDHjvw74vVxomoLJcR/6y1lBjmj+qNz+NdFQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBXvrCz1Sxks9TtILy1lGJILiMSI4znlTkHkUy10nTrHSxpllYWtvYBWQWkMKpEFbORsAxg5ORjnJq3RQBnaj4d0XV7y3u9W0ewvrm2OYJrm1SR4uc/KzAleeeKJ/Dui3Osxavc6PYTalCAI72S1Rpkx0w5G4dT371o0UAYl74J8K6ldzXWo+GdHu7icgyzT2ETvIR0LMVyfxqWHwp4etri7uLfQdMimvo2jupEs41a4RvvK5AywPcHOa1qKAKOlaLpWg2rWuh6ZZ6bbu5kaKzt1hRmIALEKAM4AGfYVeoooAKKKKACiiigAooooAKKKOlAHO6jqph8T28JuzbwR4EhJ+U8FjnPttGf9qugWVHj3o6smM7lORXCxS/bNTuLs8gn5T/ALxz/wCg7KLkGC3f7I728khEYaFtvLHGcDg+vPpTA6+LUS0aySWk6RsMqygOCPXA5/SlfV9OiVWmvYYgzbf3jhSD6EHp+NYttrF7aoqERXEajABGxgPqOP0rB8W6supXVrGIHh8mNnPmAdWOOCPYfrQB6FHIkq7onV19VORTq47wxaCxjtpktWYmAyyPBKWyZD8oKcDIAPTPSuqhvbedtsco3/3G+Vh/wE80gJ6KKKAMfxe23wXrA8macvZSxrFBA8zuWUqAEQEnkjoP0rk75fEGkafOPD9tcXEEOmyyaZO8TCSGN3hJhZGRm8yNQxQFGJAVSrMrBvRKKAPIIPEPxF+1aONskkbkZZ7K4UXBM7qyTD7CpQiPysOfs6ZJb5lyFhs7rU59eF3qdtr13LcTaQWln0SaPy2SWdpV+SIDYhf7x7EfM33j7LRQB554K1TxfqOl66PE8s1pcJbqYj9ndWtZir7xG0ltHG6KQu3Bmxjl3BBODouv+LtXXQmGsa8bS/e1FxdroIj2M8MpmA3QECJXFvtkIx+8f5mA+X125toLy1ltbyGOe3mQxyxSoGSRSMFWB4IIOCDWHo8403xNeeHY7e3tbKG1hudOit4hGqRnKOgA4+VlB/7aCgDz7UrnxfqulSNPd+IIBDdWk9/DHpah7OVL6PclsRAftEQj8x8jzCfKjySGZWsQa/44N7fpqkmpW1l9qVZZbPTZJ7i0j3SYaBTaBJA37oEAzkAs3Hb1migDyVLnxHYapdTy6n4kngvHtDc3ltoeGih+ztmSKFoGIPnBVaMh2VWY7f4hv+C7vxLe+JbpPEN7qQit7O3ZIH05YYJJGDbz5hjBLYEbFVf5WdweAFXu6KACiiigAooooAKKKzvEN+dK8M6pqAODaWcs4I/2UJ/pQB5/qrXnxU8XXugWlzLa+FNIkEWpTQMVa/nHWEMP4B3/AP1V6JpWj6doenx2Oj2UNlbRjCxQoFH19z7muY+Eemrpvwt0b+KW7h+2TP3d5TvJP5gfhXaUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQByHjP4e6f4oUX1k39la/b/PaapbDbIjDoGI+8vqDR8PfFl34h0+70/Xolt9f0eX7NqES8KzfwyL/ssOfzrr688u4v7J/aC06a3wqa5pEsdwo/ieEgqx/A4oA9DooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKz9cn+z6PNtOGkAjU+7HH9a0Koavpf9rW8cRnaIK+44XO7ggj8iaAOQs5EitwZcxNKTJiRSnB6de2MU+Q+bfQoOVRTKfr0X+Z/Ku5MaNGEZFZfQjIrDGmaVJe3jzRJbuGABRjFhQPvHGM8k9famIy65XWZjPqMoUO3zLAojXcfcgd8ZP5V3l3oaW9rJcw3zrHGhc+aodcAZ6jB/WuEsbaa4aS4Ay0CGQkSBD5jZC4z1Oc8UAXdH1JFleWyuIS7OcIrmB9q8DKng9M+ldTot9JqF7JZanGZQse9DPGuRzggEcH+fFYM2kyw2yQ3luXSNQuLu33DgdnXj+daeg6Fcf2ZMbcjT/OmDxyZaRgF4G0HGAfm/BjxQM6Y2ZVAttcTQ4yR828f+PZ/Ksy48RNp148F7bO6IcCeNCFbjPTnp6/ypGk8Q6ejNItvqESgk7TsfH+frXInVY2up3ubae1nyXmaLKlcn+LocexGKQHd2mvadeAeVcoGP8LHH69D+FaAYMoKkEHkEd684Elrdp5iT284PO512N9cjBB/2iDU8b3dmyfZp7mAycooPmK/vkYLD6An3oA9BorjrfxRqECuZkhuo422uyttZT6EHBU+x/Ota28V2MrrHcrLayMpYLIh5A6n3Hv096ANuuZ8Vf8AEu1fQdeXhba7+xXLf9MLjCfpKID9Aa6CC9trpEe2uI5VkG5Cjg7h6j1rmfiXLfReA9SFjpL6rE9u6XEMEuyeNSv+sjGCGZTzt4PHByMEA6yivPvg54x1Tx74Uu/EGrosPm3hht4E+6kaRoCfcly5P4DtXoNABRRRQAUUUUAFFFFABWB48/5J14j/AOwXc/8Aopq36wPHn/JOvEf/AGC7n/0U1AEPw4/5Jj4b/wCwbB/6AK6WvH/Bdv4rvPA+iLZPrMduLKIIftNpbx7doxj927ke5wa3j4Z8WyAFrqUnPIfX5h/6BCKAPQqK87Hg7WXXF9o+j357PeatdzMPxdTU8PhPWYSTZaR4d018YEkE9wWH/fIQ/rQB3tFcva6H4rEQS68WRqB/zw05cj/gTs2fxFTSaJ4iT5rTxXIXBzturGJ0Pt8oU/rQB0VFc5pfiC/i1RdI8UWcdpeSZ+zXVuxNvd46hSeVcDnYfwJwa6OgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvP8AxF/yXTwd/wBeN9/6Ctd9JIkMTSSuscaAszMcBR6k15hd69Y678cvCkmltJNBFZ3oFx5TLHL8o+4xGHAx1GR70Aeo0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABSMoZcMAR6EUtFAGbf6Ha3tlNboXtfNGGaA7c8916HPTkVmaV4ZuNNmMUk1vc2jyiV90RDkqPlHUjGea6WigCr/Ztuv+oDW5/6YuUH5Dj9KPJvIv8AVXSyD+7Mn9Vx/I1aooAydUfUn02WKKxWWRgB8kvBGeeuD0zXKy3bW/y31rcW2P8Anou4D6H+H8cV6BSMoYYYAj0IoA86Nrpt7u2CJj1byztI9yOp+tRf2S8HFneSQg9I25U/h0/MGu3u/DelXnMtmisOjR/KR9MdPrWZN4PaPJ0/UZowf4JPmB+v/wCrPvQBzbPqcP8Ar4I7tF4JU4YD6/4Cok1G0GIpVmsy38DKSh/4CM/ngVuyaJrduoPlW92A2B5b7Co9cHp+tULqXyPMTULKZFHQyRZWT6//AF8UAV0ginzJatHL3LQvhvqcZU/iAauQarqtjjy7t3QHG2ddwP0YZx+IyfUVnnTtLu5F8l/LYDLPGxBjP0PI/LHvSfZNVgUm1vFucdIrgZLr/vc8fj+FAG3o+v22k27wx6QlvC0rzSfYgCu9zuYlR0JJJ9Peuhs/EWl3uPKu0VsZ2v8AKR+fb36VxkbedNGl3atE5489PmjU+x+8v406bT/M3ZwzKcqrjJb39QffcDQB6ICCAQcg9CKK85iW9sGJtbqWCMLkMHLIx9MH+eR9a0bXxZqdvgX8MUq4JZvuMvoD/CSfbgdzQB2tFc9b+NNOcILqOe1Zlyd6ZUf8CHBHuOPet23uIbu3jntpFlikUMjochge9AElFFFABWB48/5J14j/AOwXc/8Aopq36wPHn/JOvEf/AGC7n/0U1AEPw4/5Jj4b/wCwbB/6AK6Wua+HH/JMfDf/AGDYP/QBXS0AFFFFABRRRQBXv7C31Oze1vI98b++Cp7MCOQR1BHIrnINeu/DV5Hpvixi1rIwjtNZxiOT0SbtG/bP3W9jxXV1Hc20F5bSW93DHPBKpWSORQysD1BB6igCSiuVNnqXhAb9KWbVNFXlrAktPaj/AKYk/fUf3DyP4T2rf0zU7PWNPjvdNuEuLeT7rr6jqCOoIPBB5FAFmV/Lidz0VSahsbtb2381OmSKi1qbyNCvZf7kDt+lYngC9+2+H5HJyVnYfoKAOoooooAKKKKACiiigAooooAKKKKACoLy8ttPspbu+mSC3hUtJI5wFFZ2t+JrPRZIrbZLeajcD/R7C1XdLL746Ko7s2APWqllod7qd1FqXixo3ljYPb6dC26C2PZiT/rHH948DsB1oApWdle+Mrkahr8D22iqQ1lpcgw0/pLOP1WPoOpyemd4gUJ8cvBqqAqixvQABwPlWvQa8/8AEX/JdPB3/Xjff+grQB6BRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRWd4g1b+wfDWpav9ne6+w2slx5EZw0mxS20fXFcb4X8d6hq2nabq82paBqOjXCs+oXdkHg/svELSbJQ7t3wC7bMY+78wIAPQ6Kx4vGHhqaC3mh8Q6VJFdSNFbyJexlZnXGVU7vmIyMgetVrjxx4bbTWnsfE2hM8kUrW7yahH5bsgySSG+6vG7HQUAdDRXM6Z4y0uHRtPPiXxH4dj1K4tftD/AGS/UQyqAS0kW87jH8rc+x9K0p/E+gWujw6tda5psOmzkLDeyXcawyE5wFcnaeh6HsaANSisaPxh4Zl0mXVIvEWkvp0MgikvFvozCjnGFL7sA8jjPcVrQzRXNvHPbyJLDKoeOSNgyupGQQR1BHegB9FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFIQGGCAR70tFAGbdeHtKvMedZxgjoUG0r9MdKyZ/BoXJ0+/lj5zslAdc/5/H3rqKKAOIn0fXLQ5MMd2oH3omw2PTnJ/n9apNemBvKureW3Ofuuh2/kM/oTXolNkjSVCkqK6nqrDINAHBRXkUuHilDE8BlYBj7ZHyn6dqkIRl3YXGeG5AH/Al5B9zXSXfhjSbxmZ7YRuwwXjO0//AF/oaz38G+U6PY6hKhXgrKNwI7c9R9M49qAMV7ONy2EYE/Mdq7vxIXB+netzwtEIG2xjajozcfxHK/MfU89fes8+HtdSQRj7LLGG3GQtg7fy5b8hXT6ZYfY4cyACRgBgdFAycfmST9fQCgC9RRRQAVgePP8AknXiP/sF3P8A6Kat+sDx5/yTrxH/ANgu5/8ARTUAQ/Dj/kmPhv8A7BsH/oArpa5r4cf8kx8N/wDYNg/9AFTXfib7H4gu7A2N1cx29vDIWtIGlYM5kyCB7IMfU0Ab9Fc7/wAJnbHPlaRrsjD+EaXKv6sAKjHiXW7zH9m+Eb5QTjfqE8Vuq+5AZmx+FAHTVinxDHe6s+m6GFvJoHAu5gf3Nt/slh1fH8I59cVSn8Paxrts8fiLWGt4pFINppOYl/4FIfnb8NoPpVHT/EFl4M8jQvENlDo0O7Za30Eeyzn9Of8Alm57q3foTQB2tFIrK6BkYMrDIIOQRS0AFcprek3eiX0viPwvCXmY7tR05Thb1B1ZR0EwHQ/xdD2I6uigDzf4gfEG2svDJjjsp5rTV7Q/ZL6MjyyWXoe4I9K534U+OhGToUGnXF7dXE5kDREBY1wASxPQDFdkuiafd6hrfgzV4BJp92v9oWS/3FckSBT2KyfMPTzBV7wJ4A03wJpb29m7XV1MxM13KoDuM8Lx0A9PxoA6qiiigAooooAKKKaxIGRQA6imJIG470+gArntS1e9v7+XR/DJjFzHgXd9Iu6Ozz2x/HJjkL0HU9gbniLU5dO00LYhXv7uQW9mjdDI38R9lALH2U1NoukQaHpMNjbZYJkySt96Vycs7HuSck0AQ6J4dsdCSVrYPNd3B3XN5O2+advVm/kBgDsBWrRRQAV51r0sjfH3wpG8LIiWN4UkzkOCo/Igj+Vei15/4i/5Lp4O/wCvG+/9BWgD0CiiigAooooAKKKKACiiigAooooAKKKKAM/Xzqg8P3p8PiNtTEJ+yiUgIZO27Pb1rzOx8DDT/ibZeKNL8Pv4Qt7eKc65IbyH7HeJ5eAI0Rj8u4b9zrEMLuK7unrlMlijnheGeNZIpFKujrlWB4IIPUUAeefDnw/Jo99rMdjcwX3hi1uzc6DHburBBPGsjqpzt2rvIQ55EjZPNYXgnwHqGlfDHxHBqnhRY9fuJr17Qs1s8r+dGUXbIHIXhiDlhxnrnn1uw0+y0qxjstLs4LK0iyI4LaJY40ycnCqABySfxqxQB4LZ+CfFUEnw0e58J3U6+GrS5S+QXNocSOu2PbmbBIKhs9sjvkDGt9F1rwT4Q+H8OpaHqq+ItGvL+SG3sreLUQY3ILOYI5lZ1+dBuDrtOc9Vz9J1n6toGj6/DHFruk2OpxxNujS8tkmCHpkBgcGgDwjRfC19f+E/B7eCY9eB8KapPHqVpeQwWl6JJVV2kSObdCNofKqxPD9c817L4C0BfC/giw0iOO8ijtw+yK9mjlmjVpGYKzRgJkBui5A6AsBk7On6bY6RYR2OlWdvY2kWfLt7aJY40ySThVAAyST9TVmgAooooAKKKKACisXWdbks5ks9PiE95IdqrjPPXH5cnsBSWt3rFlcW8euC1ljuW2LLbKV8p+oVgScg4xuGOe3NAG3RRRQAUUUUAFFFNllSGJpJWCogyxPYUAOorLttZaZWllspYrfzNiy7ge+Mkdhng9cHPpWpQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWB48/5J14j/AOwXc/8Aopq36wPHn/JOvEf/AGC7n/0U1AGN4U1y20L4R+G5p1eaaTToEtrWIZluJPLGEQdz79AOTxW54W0q70+xnu9YZW1XUZftF3sOVjOAFjU/3UUBffk96w/hZoNlZ+BdD1ILJPe3GnQ5uJ3LsilQdiZ+6o9Bj3zXcUAFFFc94ovLvztN0vTbh7ae+nw00e3cka8tjORnHPToDQB0NQ3dnbX9pJa30EdxbyrteKVAysPQg1T0xp4by7sbi4e4EOx4pJMb9rA8EgAHlWrSoA5O08DvoJI8Iaxc6Xbk5+wzD7TbL/uqx3J/wFgPapoE8WzXslrcatpMQjIYtFYSb2Q9CN0uOxHQ9K6as3WIrhFiv7BDJcWpJMQ6zRn7yfXgEe4HrQBctYZILZY57h7mQfelcAFvwAAFTVBZXtvqNlFd2cglhlXcjD/PB7Y7VPQBz3iqxmH2LXbBGe80h2l8tRzNCwxLH9SACP8AaVa27O7g1Cyhu7OVZredBJHIp4ZSMg1NXM+D1/s+51vQ1/1Wn3xe3GOFimUShR7BmcfQUAdNRRRQAUUUUAFFFFAGfcSG2ueOnUVfVgyhh0IyKy9c/dxxS++01Vu9aOneDb3UEw0trE/lqf4n/gH4kgUAVdLY6/42vtTbmy0jdYWfo0xwZ3H0+VM+z11NZvh/SU0Pw/Z6cnLQxjzH/vyHl2PuWJP41pUANd9kbPtZtoJwoyT9KwW8c+HIneO61NLWVDhoblGicf8AAWAJ/CugrJvpW1LUP7LtmwkYDXkqn7qnpGPdu/ov1FAFKLxS+ryiLw1p9xcqeTe3MLw26D1BYBnPsox7iuX1OxNp8c/CLyzyXNxLZXvmSueuFGAF6KBk8D8cnmvSlUKoVQAAMAAdK4DxF/yXTwd/1433/oK0AegUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABUV1OLa1kmIzsUkD1PYVLWR4nuGt9FdkBLZJH/AVLf+y0AUNDQCG91y4O9zvSJiP4VPzN/wJgfwCjtWlLZ6jLZorXEUrbo3ZZY8HcrBiNy8Y4/u/jWdJpE0NrYW1reOA6JGYzymETO7A9wM5z1q79o1m0/19tHcqMfMh5/MDJ/75/GgC59tmj/4+bOVR/ejw4+vHP6VJDf2tw2yKZS+MmMnaw+qnkVSTxBbbtt1HLbPzw6/4Vb32OorsPk3G05KMAxU+4PSgC1RVP8As1Y/+PWeeA9gH3D8mzRjUIjwYLlffMbY+vIJ/AUAOv7s2cAZQpZmwN5wqjGST7AAmsm7uptRVLYSxAGRchQyyHOcEow4AIJzk/dpmr3xlkSKS2kRwREImIJd5D90EHH3A2fQMDTdKuPteq3F9dS7o4ASHxhQB8o2+q/6zk8nINAGtqEMaaWtoi4SRkhCjsCQP0GT+FX6xJ9Zt5L6xV0mt9s7MxuIWQbfLcZyRgDJHfvW0jrIoZGDKeQQcg0ALRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFYHjz/knXiP8A7Bdz/wCimrfrA8ef8k68R/8AYLuf/RTUAQ/Dj/kmPhv/ALBsH/oArfur21sYfOvrmG2iHV5pAi/mawPhx/yTHw3/ANg2D/0AVl+IoodY8ZWtnfhTaQOS6yEBWCRiQjnruZ4s+yY7mgDp9SvUl8N3V3p1yrqYGaKeFww6dQRxXI6PcRz+MtPQJDI6I7vLtcujbXATezMW4OT05IqrHBb2IlhtryQRahawXRiWf5fN8wLL8o4+ZSvHqDWP4dSaVp7oS+Q/9khg5OXjklUnr04ab+nagDvLfxFpL+Krlor1ZEktEQsqtsVo3fPOMEnzP/Ha1v7d0z/n8T8jWfDo0NvBHDD4iv0jjUIiieLCgDAH3Kf/AGWv/Qy6h/3/AIv/AIigC7/bumf8/ifkaP7d0z/n8T8jVL+y1/6GXUP+/wDF/wDEUf2Wv/Qy6h/3/i/+IoAzru5j029l1Hw5dwMZm33OnysUjnbu6Nj5H/Ru+DzU9l8QdBuCI76d9Kn6GLUE8r8n+434Matf2Wv/AEMuof8Af+L/AOIpr6RFKhSTxFfOjDBVpoiD+GygC/P4g0e2tDdT6rZRwKNxla4Xbj65rmfDHibR7vUta1Z76GH7XNGI4ZG2usKptR2Xqu87mGexFeS69ounQ+Kr8JbwyGBZmjlMag7hc43fKAM446VJplrD/bd85Ulo44WUlicEouadgPf4tZ06eZIo7yIyOcIpbBY+gz1qtN4r8O287w3GvaZFLGxV43vI1ZSOoIJ4NWNQsm1DR2t4pFilKq0UjLuCOMFWxxnBAr5w1Kee38ZGWe8lhcXk8cwgmTaN00vC5Q8bsdc96QH0Va+JdCvrhYLLWtOuJm+7HFdo7H8Ac1p18vxylZJgbu4Y211KVaWaN9qsu8HG0Hr1weOoHFfSOk6i9/AwuIhDcRFRIgbcpyoYMDxkEH+Y7UAX6K8/udQmsvi5dPEc7rJYijE7SMBs4/z1q8L+K71a8e80+CdgIwC7Hjg9OKANnxFe2cemSxyXcCSoQQjSANn6fSuV1G5J8H3zcmO2urW4mAGcRLMjOfwVSfwrndbWzHiWbzbOFYWlz5YxgZgPcjrXb6VfaLaX3kbjF9sBixNIHVzjO3kdxmmB1qsrqGQhlYZBByCKUnAyeBXnHiWwfwtZQN4Z8RX2nwzTeX9mVftcUI2sfkj2syjjGAcDPSubW+lmbOsavc6v/wBM7zTr3yvxjQBT+INID02bXJNUuGsfDRWZlbbPf4zDb+oB6O/+yOB3I6HU0/T4NMtBBb7jyWeRzl5GPVmPcmvPLfx3eWkKQ25tEhRdqRpot4iqPQACrsfjy+aMFrixBPY6fdgj8NtAHoFef+Iv+S6eDv8Arxvv/QVpf+E8vQcCSwf6Wd2P/ZKxF1i51f43eFWukjUx2d5t8uGWPOVH/PRRnp2zQB61RRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFYni1WOgybV3feBA90ZR+pFbdRzwR3Nu8M6B43GGU9xQBTEb3EVpeWc8eFh+XeuVIbBzwR6V5x4r+PWj+G5/7OtrKTVdVkl8mGK1f9yWzgbpCOM+ihj9K7SfRrLRdKml1DWLxNItY2klhlkURhRydzBdxHtnn3rFTwbH4yWHXPEts0FwLm3uNNtXUZsYIpVkVCOzybfn9Mhf4MkA7E3tjcAxTPHk/KY5l29e2GqGbQbGXBWMxFTkeWeB9AcgfgK0HjSRcSIrj0YZqr/ZkCf8erSWp7eS+AP+AnK/pQBT/s3UrYf6HqBcAcJNk/qc0NqWpWak3lh5irn54j1A57Z/XbVzy9Qi+5NFOueki7Tj0yOP0qtqV5MNLuUns5kd4iqmM71LEYAyORz3IAoA524mlnmecZEgVUQHtLNyx4/uphfbJrWsNPjltrezIPlSL9omGcHZ0jU4xjPX6qaypF+0yjqVury5cYxxgrED/3yTW4+lpqN/c3XnSRSIfJjZeCAAO/XGSTwRQBeNg6/wDHvdzKP7kn7xcfjz+tVGsZY2Lm0iZjli9nIYXY/To34mgWusWp/cXSXCZ+7KOcfX/Emk/tm5tl/wCJjYSRgDLOnQfj90f99Z9qAD7VLAQpu5IzkKFvIeCe/wAy4Bq1HfzbN723mx8nzLWQSD8uD+ABoh1ixuPlE4Un+GQFc/n1p7afZTHzUjVWIAEkLFGx9VwaAFTUrR22mYRv02yDYfyNWqovY3AXCXQmUZIS5jDjPbkYP86q/ZJbcYS1kh7BrGbge+xvl/QmgDYorj9W8WXOi3UIPl3Fu8qxMZ42hdCeueOgBUk471dtPG2mXH2wyh447NlWWdcSRHcSAVK8kZBGcCgDo6KrWupWV6qm0uoZdw3LtcEkeuKs0AFFFFABRRWbr3iHSvDGlvqOu3sdnaocb36sfQAck+woA0qKx/DPivRvF+lnUPD94t1ArlH+UqyN6FTyK2KACiiigArA8ef8k68R/wDYLuf/AEU1b9YHjz/knXiP/sF3P/opqAIfhx/yTHw3/wBg2D/0AVj+ILS0Pji2TV4Ip7a4kKqJV+VTJGFT/wAfhx7F19as/CbV7bVPhro8UG5ZrK0ignicYZGCDBx6MMMD3BrpNX0LTddtxBq1otxGOgJII/EEHsPyFAHmqxeHxqKNZ2Pl3FjbQQuy2kgZZ3kG8E7eCFAJz2YVU0Mwz2N5aX9utzFJoy+Yu3csrRqA67e/MLDH1Fel3um2uk+Fbu302ARRpG0m0ZYsRySSeWJx1OTXMaFYxx+KrK4jCmORHR/3kbgttkOVKsTtPXkdSfWgBy6B8MnUMvhnTirDII0ZuR/37pf+Ee+Gf/Qsaf8A+CZv/jdbNnonka9LawajqS2kFqhEJuSVUszYC9xtCY/GtX+yF/5/b7/wIagDkf8AhHvhn/0LGn/+CZv/AI3R/wAI98M/+hY0/wD8Ezf/ABuuu/shf+f2+/8AAhqiubK2srWS4u9Tu4YY13PJJdEKo9zQBy3/AAj3wz/6FjT/APwTN/8AG6D4e+GYGT4Y04D1OjN/8bq59i1jX2B0y9v9I07P/H1O5a4nH+xG3CD/AGmyf9kda0V8D6GyD7fDNqcmMGW/uHmY/wDfRwPwAoA8V1ZLC2129h0yKO2sxDMtvCkflqo+09AuBj6Yp2lyxnWNQAkXLRQgDcOcIua9Qn8F+CYvFFtp48OwyXV1BJMxUtsijUqMlc4GWYAYHrVC9+HvhzSfGekDTbBba31Hzop4I2OAyoXV1z908EHHBzz0p3A727vV0/SXu3jeURRg+XHjc57AZ4yTxXz1q+q67HNqbrqFpZi0keZYDKztFsunfHEeNwOT1/HtXv66Lb+ZG00tzOImDqks7FQw5Bx0OOvNYsvw50KW+nuv9LR5yxdUuCF+Zix4+rGkB4ze63rEfiOV5dZtTJfQiXzYnZiWEbR9DGuSVbb6DOa9+0azuII5Li+2CecINiHIjVVwFzgZPUk47+1ZMXw68PpfQ3csVxcSQAiMS3DFQDjIwMZHA4PFdTQB51fWklz8W7iOFd7i0WXGQMLtC5/M1qWuj3rapfAJGCPLzuf/AGfYGuisG0rUJW1bTfs88kgMBuogCWCsQV3egYHipLjS7G6mMtxaxSSEAFmXkigDyfxVpiN4hmt9SSF40xK+8blAWFjk8dsV0ukeBPD9yLXUobO1NpLGXUW9t5fnIy9G4BKkHp34rR8WeGNAHh7UbybTITIlu5DcjnaVHQ+9UfhZ4iGo+H/7GuZM3mlqsa5PMkHRH/ADafce9MBPE3gXR5bW3OleHYy0c26QW0aRuV2sOCwweSOK4+HRNGkvxZTaLfWVyxwiXzQQeYf9ksmG+gzXtlQ3Vpb31s9vewR3EMgw0cqhlb8DSA8zHw4jz82gzEf9fcA/9p0h+GcGfl8PtjtnUl/+N12BivPCx325mv8ARv4oCS81mPVD1dB3U5YdsjiuggniuYEmt5FlikUMjochgehBoA8tb4ZIfu6AAPfUgD+kdUdP0OXQvjR4WgkgkgR7S8ZUe9Nx/AM4yo29q9jrz/xF/wAl08Hf9eN9/wCgrQB6BRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFc34l1G6uryHw1oczQ6heJ5lxdJ1sbbOGk/325VB65PIQ0AVm/4rPxF5Y+bQNHn+f8Au3t2h6e8cRHPrIMfwHPW1W07T7XSdNt7DT4VgtbaMRxRr0UD+f171ZoAKKKKACs7WZxFbxhugbzXx12xjf8AzC1o1XurRboKd7RyJnY6YyMjB4PBHsaAOcismTWLS0PIjHm7lbIJchm5/wB6N/wIq5LMNOvp/tEl9bCafckyRmWJsgADGDt/IfWpNKiDapL+7hUWwZQY49m7LYBxnqNjf99VekH2nVUjPMdsokI9XOQv5AE/iD2oAihvLl0zBLaXwHBMb7GJ78cj9am/tFEOLmGa3/2nTK/XcMgD64qWeytrnmeFHbGN2PmA+vWqOova6Jp0+oXWqNYWluu+WSdwY0Ueu7oPoc0AWDa6dqC7wkEwbnchHPvkVVbQFjbdY3U1ueONxI49wQT+Jx7VFasuqWFvqUNtb3sF1FHPFPDmF3VhlTg+xB5NSed9n6XVza4zxdx70+pb0/4EKAD/AIndqOsV4oB64DH05GP5fjThrwhbbf2stuc4DEcdPfGfoM1Yju7oqGEMVzGeklvL29cH+hNRXuqRfYZUKvFM67USaMjJbgDPTqfWgDzjxXqC3euRuCdkUbXDZGCM8jI/3fLFc55f+jIh/wBZM5zj2+Xj8TVvUrkT3V5cKCVeXZGO+xeePwwPwqL/AFVyM/MLaPJ/2iBk/iWYflVAdL4It21TxfO9wxngtbQxEyfNwSFVcnkfcY8V6E8QsLq28mV1imkKNG7kqPkZsjPT7vbjk1zPwwsTDot3evy9xOUDEdVQbc/i24/jXReI136DcKo/fMAkB5ysjHap456t+VSBj2/jZnfdLZxtAVaQOk4VlQHGSH2j34JFa0fibTDhbqZrFyM7LxDF7dTwfwNeN+NtROmWeo26QQt5lv5BKL5bFR8g+XhsZ8zrnNUjrskF5qNrBc3cFuLKNBbyN5iuSWBBDYKrjt+tAHu+s61aaFol1qt6zG1tY/MlMS7yF9cDr614Hba3Y/GP4328OpXIGgWAZrOzkyPtRH+z6seT/sjFdWsRvPhzdPkwy31+9uTGpQuNpUjbk4BOBjoO1c14EsE+F8S3N1Aja3dxsZVuYyPKjzwinIIJ7nn6UDOn8BWcXhf48eLfD+noIdPuLaK7ihQYVDgHgdgN5Fev1434Ju7jXPjxquvSW/kW1zpkccXzhgWVY9ygj0OfSvZKBBRRRQAVgePP+SdeI/8AsF3P/opq36wPHn/JOvEf/YLuf/RTUAch4esrjTPAXhfxVo8RkuLfSbeK/tkHN3bBATj1dMll9eV716VbXEN5axXNtIssMyB43U8MpGQR+Fc18Plkf4V+Hlhk8pzpkG19u7B2Dt3ptlNqvhdZLe60lrzTjIzxy6Z8xhDckGEncBnJwpbGcUAdXXLeJ4BpuraVrsFuzLbSmK48iIu2x+CdqjJA5/HFamm+J9F1aUw2GowPOv3rdm2Sr9UbDD8RWrQBl6VKb2/vb5EdYJBHHCzoVLhQSTggHGXI/CtSsbU/F2h6VcfZbm/R7voLS3BmmJ/65oC36VT/ALS8S6vxpelx6Rbt0utTO6THqIUP/oTD6UAbt5ew2MHmTk8naiKMs7f3VHc1mwaZPqd1Hf66ijym3W1ju3JCezt2Z/0Xt6mCy8M3sN99sv8AxJqF5PjGPLhjRR6ABMgfjXQ0AFFFFAFCLS4o9fudVLu800EduFbG2NVLNx9S3P0FYthL/wAJF43k1GE7tO0aN7WCQdJrhyPNI9QgUJn1LelMuP7Q1zUdU0rTbk2lotyEvbxW/eAeVH+7i9GI6semeAT06LTbaystMgttLSNLSFAkSxHKgDjr3oAtUUUUAFeY/G74g/8ACH+FTp2nS7dW1NWjiKnmGPo0n17D3+lenV4F8XPhHqd9HrfjO4143s0MfmpZi22hIV/hDbj91cnpzz60Ac98A/iD/YGvHw3qk2NP1KTMDOeIZzx+TdPrivp6vi34b+C18eeKjpP9pnTXWBp0lEe8kqRwBkeuc+1fYmjWl5YaLaWmpXov7qGMJJc+Xs80jjcRk4Prz1oGzA+J18LLwDe56zMkQ/Fh/QGuL+H2lXbeGbjxDpcZfUbS6JhQHH2iJVHmRf8AAs8ejKppvx58QJDHpmixv87E3UoHYDKr/Nvyrv8A4f6S2jeBNMtpV2zNEJpR/tP8x/LOPwoEbGmara6taxXNk++KWFZVJGCA2RgjsQVII7EVcrldMli0r4hanpcjrGNRt0vbOPoG2lhMB77mDEf7ZNdVQAVitbSaFcSXFkrSWEzF5rVRkwserxj0PUr+I5yDtVDc2lveRhLqFJlByA65xQBJFKk8SywuHRxlWU5BFcD4i/5Lp4O/68b7/wBBWty78ImHEvhjU7jRZ1yRGh823fP96Fjj8V2n3rjZJtdf44eFIfEdpaRSxWd6I7izlLRzgqOdrDKEehz160AerUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRWTfeKNI03V4tMvbox3UpjVR5LsgaRtkas4XarM3CgkE4OKANaiio4p0llmjUSBoWCsXjZQSVDfKSMMMEcjIzkdQRQBJRRRQBmeINbj0HSWujC9zO7LDbWsf37iZuEjHpk9T0ABJ4BqDwzocukWc0+oyrc6tfv59/cKOGfGAi56Igwqj0GTySTel1Szh1i30yV2F3cRPNCnlMVZUKhjuxtBG9eM55q5QAUUUUAFFFFABRRRQBjxrNp2rXchtZZLeYAq8WG+bJJG3r1Y89OKvWMMiRyS3A2zTvvZc529gv4DFWqKACvLPiz4Hj8farpWgvq1/HJceZP5KOvkW0Ua/NKUAy7F2jQbj0ZsYwa9TrlvCH/E4vNS8VSfMuouILEntaREhCP99i8me4dfSgDR8Iafc6T4I0PTdQAF1ZafBbzhTkb0jVWwfTINbFFFAFaTTrWRy5hCOTkvGSjH6kdao6jo91dWZhttSkiPJXzUEgzggE9DxnPXqBWvRQB5nP8ADu9hmsUjbfAhJuZY33HOQQyocY6Yxk1zd1peo2No813B5ck04iEcgKOxySDgjABPHX/GvcKRlV1w4DD0IzTuBneHdO/snw5YWJ+9DCofBzl8Zb9SawvEusSu1qlvHbbFaS5XzrnyzII+AR7EnI55wK6NtJs2ztiMYOcrE7Rq2fUKQDWRr/hiTVZQ9vJAE8tYjBKh2lAclQQeAfoaQHjfjJtURJ/7Us7hVO0gzJvU5ZVBz6ZJI57msi8vIV1LVJjtWJVgLruxuAUnG1vUkV6prHhK7eAbbWa2lV43E9qfNUkMDyuRkcDgjHtXNWHhybU/GU6X6WsqXtwheQRNC3lQgbzswBhj1P8A9amBvRaaLPTfDGgPhDDb+fO2/wAvY7fMcnBAwxH1xisvxrNeSao9tcSmaMKIl89A2T977y57fSteLWbO88Ralqs91cxW4UpDLANy7Vx1HcegwevPauMnuTc30s9vcQzSAmYEKUYMcjoP4sE9qEB1/wAN7YNrizJCsIWOWQorA7QxUdR16V6lXG/DvTfs9jcXZBwxEMZPPC/eOf8AeOP+A12VDAKKKKQBWB48/wCSdeI/+wXc/wDopq36wPHn/JOvEf8A2C7n/wBFNQBD8OP+SY+G/wDsGwf+gCulrmvhx/yTHw3/ANg2D/0AV0tAGfqmgaTrcYTV9NtrwL90zRBiv0PUfhWba+B9LsZlaxuNUt4lOfIj1OcRn8N/6V0VFAFPT9I0/SlcabZQWvmMWkMUYUuT3Y9Sfc1coooAKKKKACsnxLq8mjaK01pGs17M629nCx4kmc4UH2HU+wNaN1dQWVrLc3kyQQRKXkkkbCqB1JNc1pKz+KdZt/EF3A9vp1oG/syCVcPKWGDcMO2VyFB5wST1GADjvHNzr3hfwhLovh+C8nuJw9xqmtCIqNz8uVI6E9P9kACuf+C+ua/ozHTpLK81DQnk2+ZGhf7I55yP9k55H4+tezeKYPtPhPVIf+elrIv/AI6a5z4U2f2PwxcLjG66Y9P9laAO4ooooAKZPDHc28kE6B4pUKOp6MCMEU+igD5B1Oy1P4MfFqOeGJpIraUy2xbhbm3bIK59cEg+hFe3r+0D4GOj/azdXQuNmfsRtn8zdj7ucbfxziu08U+ENE8ZaX9h8QWS3EanMbg7XiPqrDkV5p/wzR4Z+2iT+19U+z7smHKZx6btuaBnD+DoNR+MPxXm1fUIWXToJVmuB1VEX/Vwg9ycflk19PDjpWX4e8OaV4W0iPTNCs0tbZOcLyXPdmPUk+prUoEcj4/0i5uLKx13SUZtT0K4F3EqdZYuk0XvuTPHqBXUWd5BqFjBeWciywTxiSN16MpGQamrlJXPgi6lnYM3hydzI+0Z/s+Rj8zY/wCeRPJ/ukk9DwAdXRTIpY54UlgkWSN1DI6HIYHoQR1FPoAK8/8AEP8AyXTwd/1433/oK16BXn/iH/kung7/AK8b7/0FaAPQKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArhfE2j6tceLor3SdMuRIzWy/bILmIQSIkhZluYpG5C7so8amQHOCv8XdUUAeaan4Z16HR7y2spNdvXs9RjSyeDWJUmktnnSeUu0kqh9qM0Kkljhfc1Q1bQvFR1a9gsbHxSdPW7na2kh11Rvh+xxIikvc7+Z0ZxnBG48jcwPrVFAHkTaZ40vdcnuvL8QWUzWhjtne7Bt47o2gVTIq3W3YJc5AgbLc7yp40oNM8T2/wl8QQXj60NS3PJYoshFzHhUKiN1up2YbwThpOclSNuAfS6KAPI77w94tvIblLOw1uDzLXUV0+W51WMz2LvDD5QeVZi3M0UjDaXADqDhchYdU0vxrqN/qTwaR4rtIJ3u5bdI9chQLvgj8pDtusqFmR2wuAAQM7Sy17FRQB5G2meMr7Xb++SLxBZS3FrMlmst1m3jnMQA3qt3twNrhcQqNzKfMbCub/AIP0LxNF4l099fXX/scFtMd01/siWQyho1eMXkzSYBl5YtkMoP3F2+m0UAFFFFABRRRQAUUUUAc342uZn0uDRLCRo73W5vscbofmijIJmkHptjDYP94qO9b9rbQ2VnDa2saxQQRrHHGo4RQMAD6AVz2lQS6r411LWrqJ0gsV/s2wWRSMjIaeUA/3nCpn0iz3rpqACiiigAooooAKKKKACiiigArm/HT2y+G3Se6ureedhDbLZRxPcTSN0jjEisMnHJxwASSACRraxrFpoWmSX1+zCNSFVI13PK5OFRFHLMxwAB1NZeh6Pdz6gfEHiNVGpyIUt7VW3Jp8R/gU9C5wN79yMD5QMgHmPwr+E2o6Pq/ib/hJbyZ3/c2tvIrBxsKLM6gsvIBZFyAuSh4HSotR0F4fixpvhfQ5o7uUqbu+naHAs48YAGD1PXB7kV6R4qm8c2l2T4QtdNv7e4j27byQxtav/e4++p6465pvgHwQfCltdXmp3X9o67qcnm396R95uyr6KKAOnsLKLTrCG0txiOFAo9/erFFFABRRRQAVgePP+SdeI/8AsF3P/opq36wPHn/JOvEf/YLuf/RTUAQ/Dj/kmPhv/sGwf+gCulrmvhx/yTHw3/2DYP8A0AV0tABRRRQAUVnatr+maHGh1K6WN5DiKFQXklPoqLlmP0FZQ1DxPrX/ACDdPi0S1bpcaj+8mI9RCpwP+BN+FAHSkhVJYgAckntWBeeM9Njme10kS61fLx9m08eZtP8Atv8AcT/gRFRr4Ks7r5/EV5ea5JnO28kxCD7QphPzBrftrWCzt1gtII4IUGFjiQKo+gFAHOweH77W7qO+8YPE6RuJLfSYDughYdGcn/WuPcBR2HeunoooAgvY/OsJ4/78bD9KzvDFl9g0kxYxmUt+g/wrYpAoUYUYFAC0UUUAFFFFABRRRQAUUUUAFIwDKVYAgjBB70tFAHKHwvf6DO0/gu6jggYlpNIusm2Y9zGRzEfplf8AZq0vi6Cz2p4ktZtFlPG+f5oCfaZfl/762n2roaR0WRCjqGVhgqRkEUAJHIk0ayQusiMMqynII9Qa4HxD/wAl08Hf9eN9/wCgrW3L4PjspGuPCt5Jok5O4wxjfayH/ahPA+q7T71yNxd6rcfHDwpFrmnpaXENlegSQS74ZwVHzJ/EOnIYce/WgD1OiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAry/xo9hb/EW1upZ7WW7D2SR2lwxiueJi260cZ8zkr5kOPmG0ll4z6hRQB5tqvjLxLo+i3M+oXmiWlxp+oR2Nw9zZSpDMZbhRG6Ez/KBA6yMMtgk8/KaydR+I17o+t6nYQ6t4SivIr2aK5mkgaMy+VYwyiQr5+SQ2+Ign+EDIKkH1TTdMttJtPs9n5xUsXZ57iSeRie7PIzM3YDJ4AAHAAq3QB5M3xT1W41yePS59DuoIrE3cdijo1xcH7IJhHGftAdmZjxiErt53E5FWJNeuvG3wZ8Sz38Gn3kkAkSJrV4ZI5CiJIrFYppxGysem8kbQ3GQB3UXhfTYdabVU+2m4aQyFH1C4aDcRjcIS/lg/ReOta9AHkeofFq6037I0ur6FPG+oiITQwFYb21zCJJopXuAqiMyOh2+aSYy20ANtn0j4ha9qM2kbNa8M3f9oPebbe1tnMkotmxiM/aDlpFBI4+XcPv7fm9VooA8e0Pxv/wk/iLwtPrj6XFeR6tLHbtDPBvKPZS7kKpPKVIcqDlgTlPlB4r2GiigAooooAKKKKACqup6naaPps1/qUywW0C7nc8+wAA5JJwABySQBVqsa40FtQ8SRajqdwJ7azw1jZhcJHLjmV+fnfsvQKM9zkAFLR9Mu9X1OPxD4ihMMqA/2dp74P2JCMF27GZh1P8ACDtH8RbpqKKACiiigAooooAKKKKACsDx5/yTrxH/ANgu5/8ARTVv1gePP+SdeI/+wXc/+imoAh+HH/JMfDf/AGDYP/QBXSEhVJYgAdSe1ec+CNd1K6+HegWHhWwW4mj0+FJr66yltAwQZHrIw9F49SK2YPAUd7L9p8X6pda/OefJlbyrVPZYFOCP97caANG48X6Ws7W+nGXVrpTgwaenmlT6Mw+Rf+BMKqyQeK9b4luIfDtoeq2+Li6Yf75GxPwDfWuitraCzt0gtIY4IUGFjiQKqj2AqWgDJ0bwxpehu81nA0l3KP3t5cOZZ5f9525/Dp7VrUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFef+If+S6eDv+vG+/8AQVr0CvP/ABD/AMl08Hf9eN9/6CtAHoFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAUNdvLzT/D9/d6ZaG8vILd5IbcAkyOASFwOT9Byelc34e8eW9zCkesXtvNLPdy21rNY2c6pIY4RI6yIQxt5RiT91I27CcZrqdT0+LVtMnsblpEinTY7ROUYD2Ycg+4rmp/Bsp2QSTyaqLq8jur7UL6dYp08sKEWNIYlRgVBQ8pwx5bOKAJW+IGi3BMNndXUEyXFvBIbnR7sLG0rxhEbKLtZxIoGSMFgSCARTrb4jeGLu0muLa9uJEhCbgun3G9i0nlhVTy9ztv+UqoJU8ECi98DRXr6kza3qkX9oahbai4jEH7uSAoYwuYj8uYo8g5J2Dnls4GrfDC5XRng0nWby/laIQNDqMttHG8Zn85slbVwSWyMMjKQSCO9AHS2vj3w9ePaJDc3IN24SPzbC4j2sXMah9yDy9zqyrv27ipC5Iq1e+K9H0/WF0u5uJftbKSEjtZZFzsZ9m5VK+YVRiEzuIHAORXMaX8L7Vm0bUNaMI1PTFRFENrZyp5ccrPHGGa2XYF3H5okiPPOSoNb9/4UN3qV7dWmuarpi38Xl3MNk8QWRthQShmjZ0cLtwVZR8i8dcgFWT4k+GIVUzXN7GzeZ+6fS7oSDy9pcFDHuBUOrEEZ2nd05rqI5EmiWSJ1eN1DK6nIYHoQe4rzWP4VXWm6tZw6NrN1DpTC5a9m328c+6VI1IRFttmG8pdxyrZJIOc59IggjtreOCBdkUSBEUdgBgCgCSiiigAooooAKKKKACsvxPYtqfhLV7FM7rqxmhXHXLIR/WtSigDj/hPfx6h8KtAeLgxWi28i91eP5CD75FdhXlYuT8I/GF2L1GHg/XLkzpcqMrp1y33lYDojdc9vzr1GCeK5gSa3kSWKRQyOjAqwPcEdaAH0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXnupyf2h+0DodvAN39l6RcTzkfw+YQig/lmui8X+M9K8G6X9q1OQvPJ8ttZxcy3L9lVevXv0FZHw68N6lZLqPiPxQoXXtckEs8YORbRAYjhH0HX3+lAHb0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAEN3Z29/Zy2t9BHcW8y7ZIpVDKw9CDXAt8KpdImeTwH4p1Lw7GxLfYwBc2wPtG/T869EooA4NfDXxGVQD4/tWwOp0WPJ/wDHqX/hG/iL/wBD7af+CVP/AIqu7ooA4T/hG/iL/wBD7af+CVP/AIqj/hG/iL/0Ptp/4JU/+Kru6KAOE/4Rv4i/9D7af+CVP/iqP+Eb+Iv/AEPtp/4JU/8Aiq7uigDhP+Eb+Iv/AEPtp/4JU/8AiqP+Eb+Iv/Q+2n/glT/4qu7ooA4T/hG/iL/0Ptp/4JU/+Ko/4Rv4i/8AQ+2n/glT/wCKru6KAOE/4Rv4i/8AQ+2n/glT/wCKo/4Rv4i/9D7af+CVP/iq7uigDhP+Eb+Iv/Q+2n/glT/4qj/hG/iL/wBD7af+CVP/AIqu7ooA4T/hG/iL/wBD7af+CVP/AIqj/hG/iL/0Ptp/4JU/+Kru6KAOE/4Rv4i/9D7af+CVP/iqP+Eb+Iv/AEPtp/4JU/8Aiq7uigDhP+Eb+Iv/AEPtp/4JU/8AiqP+Eb+Iv/Q+2n/glT/4qu7ooA4T/hG/iL/0Ptp/4JU/+KqKXwj8Qboqlx8RRDF/H9l0iNHI9iScV6BRQByHhv4a6L4f1L+1rh7nWNZI51HUZfNkH+72X8K6+iigAooooAKKKKACiiigAooooAKKKKAP/9k=" /></p><p>1. عقد برميل حقنة في يد واحدة )تجنب عقد المكبس حقنة(، فك غطاء حقنة عن طريق التواء عكس اتجاه عقارب<br />الساعة.<br />2. لإرفاق الإبرة إلى حقنة، تويست الإبرة في اتجاه عقارب الساعة في حقنة حتى تشعر أنه قفل. )انظر الصورة(<br />3. إزالة حامي الإبرة، والتي في بعض الأحيان يمكن أن تكون قاسية قليلا.<br />إضافة المذيب إلى مسحوق. بعد إضافة المذيب إلى المسحوق، يجب أن يهتز الخليط جيدا حتى يذوب المسحوق تماما في<br />المذيب. بعد إعادة التشكيل، يجب استخدام اللقاح على وجه السرعة.<br />وينبغي استخدام إبرة جديدة لإدارة اللقاح. سحب محتويات القارورة بأكملها.<br />يجب التخلص من أي منتج أو نفايات غير مستخدمة وفقا للمتطلبات المحلية.<br />بريوريكس-تيترا علامة تجارية مملوكة أو مرخصة لمجموعة شركات جلاكسو سميث كلاين<br />2017 جلاكسو سميث كلاين، جميع الحقوق محفوظة.</p><p>&nbsp;</p><p>الصانع:<br />GlaxoSmithKline Biologicals s.a.<br />89, rue de l&rsquo;Institut - 1330 Rixensart<br />بلجيكا<br />00 80 656 2 ) 11 فاكس: ) 32 81 656 2 ) هاتف: ) 32</p><p>&nbsp;</p><p>الشركة المالكة لرخصة التسويق<br />جلاكسو العربية السعودية المحدودة*، جدة، السعودية<br />العنوان: صندوق بريد 22617 ، جدة 21416 ، المملكة العربية السعودية<br />*عضو في مجموعة شركات جلاكسو سميث كلاين</p><p>للإستفسار عن أي معلومات عن هذا المستحضر الدوائي، يرجى الإتصال بالأرقام التالية:</p><p>جلاكسو سميث كلاين &ndash; المكتب الرئيسي، جدة.<br />هاتف: 00966126536666<br />جوال: 00966569049882<br />gcc.medinfo@gsk.com : إيميل<br />https://healthksa.gsk.com/ : موقع إلكتروني<br />ص.ب. 55850 ، جدة 21544 ، المملكة العربية السعودية.</p><p>&nbsp;</p><table style="width:100%" border="1" cellspacing="1" cellpadding="1"><tbody><tr><td>للإبلاغ عن أية آثار جانبية:<br />المملكة العربية السعودية<br />)NPC( - المركز القومي للتيقظ والسلامة الدوائية<br />+ 966-11-205- &bull; فاكس: 7662<br />-2353-2356- 966 + تحويلة: 2317 -11- &bull; الاتصال بالإدارة التنفيذية للتيقظ وإدارة الأزمات. هاتف: 2038222<br />2340-2334-2354<br />npc.drug@sfda.gov.sa : &bull; البريد الإلكتروني<br />www.sfda.gov.sa/npc : &bull; الموقع الإلكتروني<br />- جلاكسو سميث كلاين &ndash; المكتب الرئيسي، جدة.<br />&bull; هاتف: 00966126536666<br />&bull; جوال: 00966569049882<br />gcc.medinfo@gsk.com : &bull; إيميل<br />https://healthksa.gsk.com/ : &bull; موقع إلكتروني<br />&bull; ص.ب. 55850 ، جدة 21544 ، المملكة العربية السعودية.</td></tr></tbody></table><table style="width:100%" border="1" cellspacing="1" cellpadding="1"><tbody><tr><td>هذا المنتج هو دواء<br />- الدواء مستحضر يؤثر على صحتك، وتناوله خلافًا للتعليمات يعرضك للخطر.<br />- اتبع بدقة وصفة الطبيب وطريقة الاستعمال المنصوص عليها وتعليمات الصيدلاني الذي صرفه لك.<br />- إن الطبيب والصيدلاني هما الخبيران بالدواء وبنفعه وضرره.<br />- لا تقطع مدة العلاج المحددة لك من تلقاء نفسك.<br />- لا تكرر صرف الدواء بدون استشارة الطبيب.<br />- يجب الاحتفاظ بجميع الأدوية بعيدًا عن متناول الأطفال.<br />مجلس وزراء الصحة العرب<br />اتحاد الصيادلة العرب</td></tr></tbody></table><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            GDS نص رقم : 12
تاريخ الإصدار: 12 أكتوبر 201
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Priorix Tetra
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                After reconstitution, 1 dose (0.5 ml) contains:

Live attenuated measles virus1 (Schwarz strain)	not less than 103.0 CCID503
Live attenuated mumps virus1 (RIT 4385 strain, derived from Jeryl Lynn strain)	
		not less than 104.4 CCID503
Live attenuated rubella virus2 (Wistar RA 27/3 strain)	not less than 103.0 CCID503
Live attenuated varicella virus2 (OKA strain)	not less than 103.3 PFU4

1 produced in chick embryo cells
2 produced in human diploid (MRC-5) cells
3 Cell Culture Infective Dose 50%
4 Plaque forming units

The powder is white to slightly pink.
The solvent is clear and colourless.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder and solvent for solution for injection.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-right:28.3pt"><strong><em>Priorix-Tetra<sup>TM</sup></em></strong> is indicated for active immunisation in subjects from the age of 9 months up to 12 years of age inclusive against measles, mumps, rubella and varicella (see also &ldquo;Warnings and Precautions&rdquo;).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Posology</strong></p><p>Subjects from the age of 9 months up to and including 12 years of age should should receive 2 doses of <strong><em>Priorix-Tetra<sup>TM</sup></em></strong> to ensure optimal protection against measles, mumps, rubella and varicella (see Pharmacodynamics). It is preferable to respect an interval of at least 6 weeks between doses. In no circumstances should this interval be less than 4 weeks.</p><p>&nbsp;</p><p>Alternatively, and in accordance with applicable official recommendations*:</p><p style="margin-left:28.35pt; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A single dose of <strong><em>Priorix-Tetra<sup>TM</sup></em></strong> may be administered to children who have already received a single dose of another measles, mumps and rubella (MMR) vaccine and/or a single dose of another varicella vaccine.</p><p style="margin-left:28.35pt; text-indent:-28.35pt">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A single dose of <strong><em>Priorix-Tetra<sup>TM</sup></em></strong> may be administered followed by a single dose of another measles, mumps and rubella (MMR) vaccine and/or a single dose of another varicella vaccine.</p><p style="margin-left:28.35pt; text-indent:-28.35pt">&nbsp;</p><p><em>* Applicable official recommendations may vary regarding the interval between doses and the need for one or two doses of measles, mumps and rubella and of varicella-containing vaccines.</em></p><p>&nbsp;</p><p>Efficacy has not been evaluated in subjects above 6 years of age.</p><p>&nbsp;</p><p><strong>Method of administration</strong></p><p>The vaccine is to be injected subcutaneously (SC) or intramuscularly (IM).</p><p>The preferred injection site is the deltoid region of the upper arm.</p><p>The vaccine should be administered subcutaneously in subjects with bleeding disorders (e.g. thrombocytopenia or any coagulation disorder).</p><p>For information on instructions for preparation or reconstitution please refer to the &ldquo;Instructions for Use/Handling&rdquo; section.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Priorix-TetraTM is contraindicated in subjects with known hypersensitivity to neomycin or to any other component of the vaccine (for egg allergy, see Warnings and Precautions). A history of contact dermatitis to neomycin is not a contraindication. 

Priorix-TetraTM is contraindicated in subjects having shown signs of hypersensitivity after previous administration of measles, mumps, rubella and/or varicella vaccines.

Priorix-TetraTM is contra-indicated in pregnant women.  Pregnancy should be avoided for one month after vaccination (see Pregnancy and Lactation).

Priorix-TetraTM is contraindicated in subjects with severe humoral or cellular (primary or acquired) immunodeficiency (see also “Warnings and Precautions”).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of a rare anaphylactic event following the administration of the vaccine.</p><p>As with other vaccines, the administration of <strong><em>Priorix-Tetra<sup>TM</sup></em></strong> should be postponed in subjects suffering from acute severe febrile illness. However, the presence of a minor infection, such as a cold, should not result in the deferral of vaccination.</p><p>Syncope (fainting) can occur following, or even before, any vaccination as a psychogenic response to the needle injection. It is important that procedures are in place to avoid injury from faints.</p><p>Alcohol and other disinfecting agents must be allowed to evaporate from the skin before injection of the vaccine since they can inactivate the attenuated viruses in the vaccine.</p><p>Limited protection against measles or varicella may be obtained by vaccination up to 72 hours after exposure to natural disease.</p><p>Infants in their first year of life may not respond sufficiently to the measles component of the vaccine, due to the possible persistence of maternal measles antibodies. Additional doses of a measles containing vaccine should be given according to official recommendations.</p><p>There is an increased risk of fever and febrile convulsions 5 to 12 days after the first dose of <strong><em>Priorix-Tetra</em></strong><strong><em><sup>TM</sup></em></strong><strong> </strong>as compared with 2 separate injections of MMR and varicella vaccines (see Adverse Reactions and Pharmacodynamics). There was no indication of an increased risk after the second dose.</p><p>Fever rates are usually high after the first dose of measles-containing vaccines.</p><p>Vaccination of subjects with a history of febrile convulsions or a family history of convulsions should be considered with caution. Alternative immunisation of these subjects with separate MMR and varicella vaccines should be considered for the first dose (see Posology). In any case, vaccinees should be monitored for fever during the risk period.</p><p>The measles and mumps components of the vaccine are produced in chick embryo cell culture and may therefore contain traces of egg protein. Persons with a history of anaphylactic, anaphylactoid, or other immediate reactions (e.g. generalised urticaria, swelling of the mouth and throat, difficulty breathing, hypotension, or shock) subsequent to egg ingestion may be at an enhanced risk of immediate-type hypersensitivity reactions after vaccination, although these types of reactions have been shown to be very rare. Individuals who have experienced anaphylaxis after egg ingestion should be vaccinated with extreme caution, with adequate treatment for anaphylaxis on hand should such a reaction occur.</p><p>Transmission of measles, mumps and rubella viruses from vaccinees to susceptible contacts has never been documented, although pharyngeal excretion of the rubella virus is known to occur about 7 to 28 days after vaccination with peak excretion around the 11<sup>th</sup> day.</p><p>Transmission of the Oka vaccine virus has been shown to occur at a very low rate in seronegative contacts of vaccinees with rash. Transmission of the Oka vaccine from a vaccinee who does not develop a rash to seronegative contacts cannot be excluded.</p><p><strong><em>Priorix-Tetra<sup>TM</sup></em></strong> must not be administered intravascularly or intradermally.</p><p>As with any vaccine, a protective immune response may not be elicited in all vaccinees.</p><p>As for other varicella vaccines, cases of varicella disease have been shown to occur in persons who have previously received <strong><em>Priorix-Tetra<sup>TM</sup></em></strong>. These breakthrough cases are usually mild, with a fewer number of lesions and less fever as compared to cases in unvaccinated individuals.</p><p>Cases of worsening of thrombocytopenia and recurrence of thrombocytopenia in subjects who suffered thrombocytopenia after the first dose have been reported following vaccination with live measles, mumps and rubella vaccines. In such cases, the risk-benefit of immunising with <strong><em>Priorix-Tetra<sup>TM</sup></em></strong> should be carefully evaluated.</p><p style="text-align:justify">There is limited data on the use of <strong><em>Priorix-Tetra<sup>TM</sup></em></strong> in immunocompromised subjects, therefore vaccination should be considered with caution and only when, in the opinion of the physician, the benefits outweigh the risks.</p><p style="text-align:justify">Immunocompromised subjects who have no contraindication for this vaccination (see &quot;Contraindications&quot;) may not respond as well as immunocompetent subjects, therefore some of these subjects may acquire measles, mumps, rubella or varicella despite appropriate vaccine administration. Immunocompromised subjects should be monitored carefully for signs of measles, mumps, rubella and varicella.</p><p>Very few reports exist on disseminated varicella with internal organ involvement following vaccination with Oka varicella vaccine strain mainly in immunocompromised subjects.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Clinical studies have demonstrated that <strong><em>Priorix-Tetra<sup>TM</sup></em> </strong>can be given simultaneously with any of the following monovalent or combination vaccines: hexavalent vaccines (DTPa-HBV-IPV/Hib), diphtheria-tetanus-acellular pertussis vaccine (DTPa), <em>Haemophilus influenzae</em> type b vaccine (Hib), inactivated polio vaccine (IPV), hepatitis B vaccine (HBV), hepatitis A vaccine (HAV), meningococcal serogroup B vaccine (MenB), meningococcal serogroup C conjugate vaccine (MenC), meningococcal serogroups A, C, W-135 and Y conjugate vaccine (MenACWY) and pneumococcal conjugate vaccine (PCV).</p><p style="text-align:justify">If <strong><em>Priorix-Tetra<sup>TM</sup></em></strong> is to be given at the same time as another injectable vaccine, the vaccines should always be administered at different injection sites.</p><p style="text-align:justify">If tuberculin testing has to be done it should be carried out before or simultaneously with vaccination since it has been reported that combined measles, mumps and rubella vaccines may cause a temporary depression of tuberculin skin sensitivity. As this anergy may last up to a maximum of 6 weeks, tuberculin testing should not be performed within that period after vaccination to avoid false negative results.</p><p style="text-align:justify">In subjects who have received human gammaglobulins or a blood transfusion, vaccination should be delayed for at least three months because of the likelihood of vaccine failure due to passively acquired antibodies.</p><p style="text-align:justify">Salicylates should be avoided for 6 weeks after each vaccination as Reye&rsquo;s Syndrome has been reported following the use of salicylates during natural varicella infection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy</p><p>Pregnant women must not be vaccinated with <strong><em>Priorix-Tetra<sup>TM</sup></em></strong>. Pregnancy should be avoided for one month after vaccination. Women who intend to become pregnant should be advised to delay pregnancy.</p><p>&nbsp;</p><p>Adequate human data on the<strong> </strong>use of <strong><em>Priorix-Tetra<sup>TM</sup></em></strong> during pregnancy are not available<strong> </strong>and animal studies on reproductive toxicity have not been conducted.</p><p><em><u>&nbsp;</u></em></p><p>Lactation</p><p>Adequate human data on the use of <strong><em>Priorix-Tetra<sup>TM</sup></em></strong> during lactation are not available.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">The safety profile presented below is based on data from more than 6,700 doses administered subcutaneously to children from 9 to 27 months of age.&nbsp; Events were recorded for up to 42 days after vaccination.</p><p style="text-align:justify"><strong>&nbsp;</strong></p><p style="text-align:justify">Frequencies are reported as:</p><p style="text-align:justify">Very common (&sup3;1/10) / Common (&sup3;1/100 to &lt;1/10) / Uncommon (&sup3;1/1,000 to &lt;1/100) / Rare (&sup3;1/10,000 to &lt;1/1,000) / Very rare (&lt;1/10,000)</p><table border="1" cellspacing="0" cellpadding="0" style="width:100.0%"><tbody><tr><td style="vertical-align:top; width:31.68%"><p>System Organ Class</p></td><td style="vertical-align:top; width:18.3%"><p style="text-align:center">Frequency</p></td><td style="vertical-align:top; width:50.02%"><p style="text-align:center">Adverse reactions</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:31.68%"><p>Infections and infestations</p></td><td style="vertical-align:top; width:18.3%"><p>Uncommon</p></td><td style="vertical-align:top; width:50.02%"><p>upper respiratory tract infection</p></td></tr><tr><td style="height:8.4pt; vertical-align:top; width:18.3%"><p>Rare</p></td><td style="height:8.4pt; vertical-align:top; width:50.02%"><p>otitis media</p></td></tr><tr><td style="height:8.4pt; vertical-align:top; width:31.68%"><p style="margin-right:-2.55pt">Blood and lymphatic system disorders</p></td><td style="height:8.4pt; vertical-align:top; width:18.3%"><p>Uncommon</p></td><td style="height:8.4pt; vertical-align:top; width:50.02%"><p>lymphadenopathy</p></td></tr><tr><td style="vertical-align:top; width:31.68%"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top; width:18.3%"><p>Uncommon:</p></td><td style="vertical-align:top; width:50.02%"><p>anorexia</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:31.68%"><p>Psychiatric disorders</p></td><td style="vertical-align:top; width:18.3%"><p>Common</p></td><td style="vertical-align:top; width:50.02%"><p>irritability</p></td></tr><tr><td style="vertical-align:top; width:18.3%"><p>Uncommon</p></td><td style="vertical-align:top; width:50.02%"><p>crying, nervousness, insomnia</p></td></tr><tr><td style="vertical-align:top; width:31.68%"><p>Nervous system disorders</p></td><td style="vertical-align:top; width:18.3%"><p>Rare</p></td><td style="vertical-align:top; width:50.02%"><p>febrile convulsions</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:31.68%"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top; width:18.3%"><p>Uncommon</p></td><td style="vertical-align:top; width:50.02%"><p>rhinitis</p></td></tr><tr><td style="height:13.8pt; vertical-align:top; width:18.3%"><p>Rare</p></td><td style="height:13.8pt; vertical-align:top; width:50.02%"><p>cough, bronchitis</p></td></tr><tr><td style="height:13.8pt; vertical-align:top; width:31.68%"><p>Gastrointestinal disorders</p></td><td style="height:13.8pt; vertical-align:top; width:18.3%"><p>Uncommon</p></td><td style="height:13.8pt; vertical-align:top; width:50.02%"><p>parotid gland enlargement, diarrhoea, vomiting</p></td></tr><tr><td style="height:3.0pt; vertical-align:top; width:31.68%"><p>Skin and subcutaneous tissue disorders</p></td><td style="height:3.0pt; vertical-align:top; width:18.3%"><p>Common</p></td><td style="height:3.0pt; vertical-align:top; width:50.02%"><p>rash</p></td></tr><tr><td rowspan="3" style="height:14.5pt; vertical-align:top; width:31.68%"><p>General disorders and administration site conditions</p></td><td style="height:14.5pt; vertical-align:top; width:18.3%"><p>Very common</p></td><td style="height:14.5pt; vertical-align:top; width:50.02%"><p>pain and redness at the injection site, fever (rectal &sup3;38&deg;C - &pound;39.5&deg;C; axillary/oral: &sup3;37.5&deg;C - &pound;39&deg;C)*</p></td></tr><tr><td style="height:14.5pt; vertical-align:top; width:18.3%"><p>Common</p></td><td style="height:14.5pt; vertical-align:top; width:50.02%"><p>swelling at the injection site, fever (rectal &gt;39.5&deg;C; axillary/oral &gt;39&deg;C)*</p></td></tr><tr><td style="height:14.5pt; vertical-align:top; width:18.3%"><p>Uncommon</p></td><td style="height:14.5pt; vertical-align:top; width:50.02%"><p>lethargy, malaise, fatigue</p></td></tr></tbody></table><p style="margin-right:-2.55pt">*Following the administration of the first dose of the combined measles-mumps-rubella-varicella vaccine, higher incidences of fever (approximately 1.5 fold) were observed when compared to the concomitant administration of measles-mumps-rubella and varicella vaccines at separate injection sites.</p><p style="margin-right:-2.55pt">&nbsp;</p><p style="margin-right:-2.55pt">&nbsp;</p><p>&nbsp;</p><p>During post-marketing surveillance, the following additional reactions have been reported after measles-mumps-rubella and varicella vaccination:</p><table border="1" cellspacing="0" cellpadding="0" style="width:100.0%"><tbody><tr><td style="vertical-align:top; width:31.68%"><p>System Organ Class</p></td><td style="vertical-align:top; width:18.3%"><p style="text-align:center">Frequency</p></td><td style="vertical-align:top; width:50.02%"><p style="text-align:center">Adverse reactions</p></td></tr><tr><td style="vertical-align:top; width:31.68%"><p>Infections and infestations</p></td><td style="vertical-align:top; width:18.3%"><p>Rare</p></td><td style="vertical-align:top; width:50.02%"><p>meningitis, herpes zoster, measles-like syndrome, mumps-like syndrome (including orchitis, epididymitis and parotitis)</p></td></tr><tr><td style="height:8.4pt; vertical-align:top; width:31.68%"><p style="margin-right:-2.55pt">Blood and lymphatic system disorders</p></td><td style="height:8.4pt; vertical-align:top; width:18.3%"><p>Rare</p></td><td style="height:8.4pt; vertical-align:top; width:50.02%"><p>thrombocytopenia, thrombocytopenic purpura</p></td></tr><tr><td style="height:8.4pt; vertical-align:top; width:31.68%"><p style="margin-right:-2.55pt">Immune system disorders</p></td><td style="height:8.4pt; vertical-align:top; width:18.3%"><p>Rare</p></td><td style="height:8.4pt; vertical-align:top; width:50.02%"><p>allergic reactions (including anaphylactic and anaphylactoid reactions)</p></td></tr><tr><td style="vertical-align:top; width:31.68%"><p>Nervous system disorders</p></td><td style="vertical-align:top; width:18.3%"><p>Rare</p></td><td style="vertical-align:top; width:50.02%"><p style="margin-right:7.0pt">encephalitis, cerebrovascular accident, cerebellitis, cerebellitis like symptoms, (including transient gait disturbance and transient ataxia), Guillain-Barr&eacute; syndrome, transverse myelitis, peripheral neuritis</p></td></tr><tr><td style="height:14.5pt; vertical-align:top; width:31.68%"><p>Vascular disorders</p></td><td style="height:14.5pt; vertical-align:top; width:18.3%"><p>Rare</p></td><td style="height:14.5pt; vertical-align:top; width:50.02%"><p>vasculitis (including Henoch Schonlein purpura and Kawasaki syndrome)</p></td></tr><tr><td style="height:14.5pt; vertical-align:top; width:31.68%"><p>Skin and subcutaneous tissue disorders</p></td><td style="height:14.5pt; vertical-align:top; width:18.3%"><p>Rare</p></td><td style="height:14.5pt; vertical-align:top; width:50.02%"><p>erythema multiforme, varicella like rash</p></td></tr><tr><td style="height:14.5pt; vertical-align:top; width:31.68%"><p>Musculoskeletal and connective tissue disorders</p></td><td style="height:14.5pt; vertical-align:top; width:18.3%"><p>Rare</p></td><td style="height:14.5pt; vertical-align:top; width:50.02%"><p>arthralgia, arthritis</p></td></tr></tbody></table><p>&nbsp;</p><p><strong><em>To report any side effect(s):</em></strong></p><p style="margin-left:5.9pt; margin-right:0in"><strong>Kingdom</strong><strong> of Saudi Arabia</strong></p><p style="margin-left:5.9pt; margin-right:0in"><strong>National</strong><strong> </strong><strong>Pharmacovigilance</strong><strong> centre (NPC)</strong></p><p>&bull; Fax: +966-11-205-7662</p><p style="margin-left:25.05pt; text-align:left; text-indent:-.25in"><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->&bull; Call NPC at +966-11-2038222, Ext: 2317-2356-2353-2354-2334-2340</p><p>&bull; Toll-free: 8002490000</p><p style="margin-left:12.55pt; text-align:left; text-indent:-6.65pt"><!--[if !supportLists]-->&bull;&nbsp; <!--[endif]-->E-mail: npc.drug@sfda.gov.sa</p><p style="margin-left:12.55pt; margin-right:0in; text-align:left; text-indent:-6.65pt"><!--[if !supportLists]-->&bull;&nbsp; <!--[endif]-->Website: www.sfda.gov.sa/npc</p><p style="margin-right:7.1pt"><strong><em>&nbsp;</em></strong></p><p style="margin-right:7.1pt"><strong><em>&nbsp;</em></strong></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Insufficient data are available.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><u>Efficacy and effectiveness</u></p><table border="1" cellspacing="0" cellpadding="0" style="width:473.2pt"><tbody><tr><td style="vertical-align:top; width:133.0pt"><p style="text-align:center">The efficacy of GlaxoSmithKline&rsquo;s Oka/RIT varicella &nbsp;vaccines in preventing confirmed varicella disease (by RPCR or exposure to varicella case) has been evaluated in a large active controlled clinical trial in which children aged 12-22 months received two doses of <strong><em>Priorix-Tetra<sup>TM</sup></em></strong> (N = 2,279)&nbsp; or one dose of monovalent Oka/RIT vaccine (N = 2,263). was &nbsp;. s The observed vaccine efficacy against confirmed varicella of any severity and against moderate or severe confirmed varicella were respectively 94.9% (97.5% CI: 92.4;96.6%) and 99.5% (97.5% CI: 97.5;99.9%) after 2 doses of <strong><em>Priorix-Tetra<sup>TM</sup></em></strong> and 65.4 % (97.5% CI: 57.2;72.1%) and 90.7% (97.5% CI: 85.9;93.9%) after one dose of monovalent Oka/RIT vaccine (mean follow-up period 35 months).<strong>Group</strong></p></td><td style="vertical-align:top; width:63.8pt"><p style="text-align:center"><strong>Timing</strong></p></td><td style="vertical-align:top; width:134.65pt"><p style="text-align:center"><strong>Efficacy against confirmed varicella of any severity</strong></p></td><td style="vertical-align:top; width:141.75pt"><p style="text-align:center"><strong>Efficacy against moderate or severe confirmed varicella</strong></p></td></tr><tr><td rowspan="2" style="height:12.75pt; vertical-align:top; width:133.0pt"><p style="text-align:center"><strong>Priorix-Tetra</strong></p><p style="text-align:center"><strong>(2 doses)</strong></p><p style="text-align:center"><strong>&nbsp;</strong></p><p style="text-align:center"><strong>N = 2,489</strong></p></td><td style="height:12.75pt; vertical-align:top; width:63.8pt"><p style="text-align:center">Year 2</p></td><td style="height:12.75pt; vertical-align:top; width:134.65pt"><p style="text-align:center">94.9%</p><p style="text-align:center">(97.5% CI: 92.4;96.6)</p></td><td style="height:12.75pt; vertical-align:top; width:141.75pt"><p style="text-align:center">99.5%</p><p style="text-align:center">(97.5% CI: 97.5;99.9)</p></td></tr><tr><td style="height:12.75pt; vertical-align:top; width:63.8pt"><p style="text-align:center">Year 6<sup>(1)</sup></p></td><td style="height:12.75pt; vertical-align:top; width:134.65pt"><p style="text-align:center">95.0%</p><p style="text-align:center">(95%&nbsp;CI: 93.6;96.2)</p></td><td style="height:12.75pt; vertical-align:top; width:141.75pt"><p style="text-align:center">99.0%</p><p style="text-align:center">(95% CI: 97.7;99.6)</p></td></tr><tr><td rowspan="2" style="height:26.65pt; vertical-align:top; width:133.0pt"><p style="text-align:center"><strong>Monovalent Oka vaccine (1 dose)</strong></p><p style="text-align:center"><strong>&nbsp;</strong></p><p style="text-align:center"><strong>N = 2,487</strong></p></td><td style="height:26.65pt; vertical-align:top; width:63.8pt"><p style="text-align:center">Year 2</p></td><td style="height:26.65pt; vertical-align:top; width:134.65pt"><p style="text-align:center">65.4 %</p><p style="text-align:center">(97.5% CI: 57.2;72.1)</p></td><td style="height:26.65pt; vertical-align:top; width:141.75pt"><p style="text-align:center">90.7%</p><p style="text-align:center">(97.5% CI: 85.9;93.9)</p></td></tr><tr><td style="height:26.6pt; vertical-align:top; width:63.8pt"><p style="text-align:center">Year 6<sup>(1)</sup></p></td><td style="height:26.6pt; vertical-align:top; width:134.65pt"><p style="text-align:center">67.0%</p><p style="text-align:center">(95% CI: 61.8;71.4)</p></td><td style="height:26.6pt; vertical-align:top; width:141.75pt"><p style="text-align:center">90.3%</p><p style="text-align:center">(95% CI: 86.9;92.8)</p></td></tr></tbody></table><p>Effectiveness data suggest a higher level of protection and a decrease in breakthrough varicella following two doses of varicella-containing vaccine than following one dose.</p><p>In an outbreak situation the effectiveness of two doses of <strong><em>Priorix-Tetra<sup>TM</sup></em></strong> was 91% (95% CI: 65;98%) against any disease and 94% (95% CI: 54;99%) against moderate disease.</p><p>&nbsp;</p><p><u>Immune response</u></p><p>Seroconversion rates after two subcutaneous doses of <strong><em>Priorix-Tetra<sup>TM</sup></em> </strong>given with an interval of 6 weeks in approximately 2,000 previously unvaccinated children from 11 to 23 months of age are summarized in the table below:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:172.0pt"><p><strong>Antibody Test (cut-off)</strong></p></td><td style="vertical-align:top; width:135.4pt"><p style="text-align:center"><strong>Post dose 1</strong></p></td><td style="vertical-align:top; width:135.4pt"><p style="text-align:center"><strong>Post dose 2</strong></p></td></tr><tr><td style="vertical-align:top; width:172.0pt"><p><strong>Measles, ELISA (150mIU/ml)</strong></p></td><td style="vertical-align:top; width:135.4pt"><p style="text-align:center">96.4%</p></td><td style="vertical-align:top; width:135.4pt"><p style="text-align:center">99.1%</p></td></tr><tr><td style="vertical-align:top; width:172.0pt"><p><strong>Mumps, ELISA (231U/ml)</strong></p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Neutralisations (1:28)</strong></p></td><td style="vertical-align:top; width:135.4pt"><p style="text-align:center">91.3%</p><p style="text-align:center">95.4%</p></td><td style="vertical-align:top; width:135.4pt"><p style="text-align:center">98.8%</p><p style="text-align:center">99.4%</p></td></tr><tr><td style="vertical-align:top; width:172.0pt"><p><strong>Rubella, ELISA (4IU/ml)</strong></p></td><td style="vertical-align:top; width:135.4pt"><p style="text-align:center">99.7%</p></td><td style="vertical-align:top; width:135.4pt"><p style="text-align:center">99.9%</p></td></tr><tr><td style="vertical-align:top; width:172.0pt"><p><strong>Varicella, IFA (1:4)</strong></p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ELISA (50mIU/ml)</strong></p></td><td style="vertical-align:top; width:135.4pt"><p style="text-align:center">97.2%</p><p style="text-align:center">89.4%</p></td><td style="vertical-align:top; width:135.4pt"><p style="text-align:center">99.8%</p><p style="text-align:center">99.2%</p></td></tr></tbody></table><p>ELISA: Enzyme Linked Immuno Sorbent Assay</p><p>IFA: Immunofluorescence Assay</p><p>&nbsp;</p><p>In a large efficacy trial, two years after vaccination with two doses of <strong><em>Priorix-Tetra<sup>TM</sup></em></strong>, seropositivity rates for anti-varicella antibodies were 99.4% (ELISA) and 99.2% (IFA) and respectively 99.1%, 90.5% and 100% for anti-measles, mumps and rubella antibodies (ELISA).</p><p>&nbsp;</p><p style="text-align:justify">In children 9 to 10 months of age vaccinated with 2 doses of <strong><em>Priorix-Tetra<sup>TM</sup></em></strong>, seroconversion rates after a first dose of <strong><em>Priorix-Tetra<sup>TM</sup></em></strong> were comparable for all antigens except measles to those seen in 12-24 months old children in other clinical studies.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">When <strong><em>Priorix-Tetra<sup>TM</sup></em></strong> administered as a second dose of MMR vaccine in children 24 months to 6 years of age, previously primed with an MMR vaccine or with MMR co-administered with a live attenuated varicella vaccine, all children were found seropositive for anti-measles, mumps and rubella antibodies. Seropositivity rates for anti-varicella antibodies were respectively 98.1% (IFA) and 100% in the children previously vaccinated with MMR or with MMR co-administered with a live attenuated varicella vaccine.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">The immunogenicity and safety of <strong><em>Priorix-Tetra<sup>TM</sup></em></strong> administered intramuscularly was evaluated in one comparative study conducted in 328 children who received <strong><em>Priorix-Tetra<sup>TM</sup></em></strong> either by intramuscular or subcutaneous route. The study demonstrated similar immunogenicity and safety profiles for both administration routes.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="height:12.75pt; vertical-align:top; width:83.4pt"><p><strong>Timing</strong></p></td><td colspan="3" style="height:12.75pt; vertical-align:top; width:359.55pt"><p style="text-align:center"><strong>Antibody </strong></p><p style="text-align:center"><strong>Test (cut-off)</strong></p></td></tr><tr><td style="height:12.75pt; vertical-align:top; width:133.6pt"><p style="text-align:center"><strong>Measles</strong></p><p style="text-align:center"><strong>ELISA (150 mIU/ml)</strong></p></td><td style="height:12.75pt; vertical-align:top; width:117.4pt"><p style="text-align:center"><strong>Mumps</strong></p><p style="text-align:center"><strong>ELISA (231 U/ml)</strong></p></td><td style="height:12.75pt; vertical-align:top; width:108.55pt"><p style="text-align:center"><strong>Rubella</strong></p><p style="text-align:center"><strong>ELISA (4 IU/ml)</strong></p></td></tr><tr><td style="vertical-align:top; width:83.4pt"><p><strong>Year 2</strong></p></td><td style="vertical-align:top; width:133.6pt"><p style="text-align:center">99.1%</p></td><td style="vertical-align:top; width:117.4pt"><p style="text-align:center">90.5%</p></td><td style="vertical-align:top; width:108.55pt"><p style="text-align:center">100%</p></td></tr><tr><td style="vertical-align:top; width:83.4pt"><p><strong>Year 6</strong></p></td><td style="vertical-align:top; width:133.6pt"><p style="text-align:center">99.0%</p></td><td style="vertical-align:top; width:117.4pt"><p style="text-align:center">90.5%</p></td><td style="vertical-align:top; width:108.55pt"><p style="text-align:center">99.8%</p></td></tr></tbody></table><p><u>Post-Marketing Observational Safety Surveillance Study</u></p><p>The risk of febrile convulsions following the first dose vaccination of children aged 9 to 30 months with <strong><em>Priorix-Tetra</em></strong><strong><em><sup>TM</sup></em></strong><sup> </sup>compared with a matched cohort who received MMR or simultaneous, but separate MMR and varicella vaccination, was assessed in a retrospective database analysis.</p><p>The study included 82,656 children immunized with MMRV, 149,259 with MMR and 39,203 with separate MMR and varicella vaccines.</p><p style="text-align:justify">The attributable risk of febrile convulsions on cohorts matched for confounding factors in the main risk period of 5 to 12 days following first dose of <strong><em>Priorix-Tetra</em></strong><strong><em><sup>TM</sup></em></strong> was 3.64/10,000 (95% CI: -6.11; 8.30).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No data</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A repeated dose toxicity study in animals did not reveal any local or systemic toxicity of the vaccine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Excipients of the vaccine are: amino acids, lactose, mannitol, sorbitol.</p><p>Solvent is water for injections.</p><p>Neomycin sulphate is present as a residual from the manufacturing process.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The expiry date of the vaccine is indicated on the label and packaging.
After reconstitution: immediate use is recommended. However the stability at + 2°C to 
+ 8°C has been demonstrated for 8 hours after reconstitution.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Store at 2&deg;C &ndash; 8&deg;C (in a refrigerator)</p><p style="text-align:justify">Do not freeze.</p><p style="text-align:justify">Store in the original packaging in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Powder in a vial (Type I glass) with a stopper.</p><p style="text-align:justify">0.5 ml of solvent in an ampoule (Type I glass)</p><p style="text-align:justify">or</p><p style="text-align:justify">0.5 ml of solvent in a pre-filled syringe (Type I glass) with rubber stopper, with or without needles</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">The reconstituted vaccine should be inspected visually for any foreign particulate matter and/or abnormal physical appearance. In the event of either being observed, the vaccine should be discarded.</p><p style="text-align:justify">The colour of the reconstituted vaccine may vary from clear peach to fuchsia pink due to minor variations of its pH. This is normal and does not impair the performance of the vaccine. In the event of other variation being observed, discard the vaccine.</p><p style="text-align:justify">&nbsp;</p><p><u>Instructions for reconstitution of the vaccine with solvent presented in</u><u> ampoules </u></p><p><strong><em>Priorix-Tetra</em></strong><strong><em><sup>TM</sup></em></strong><sup> </sup>is reconstituted by adding the entire contents of the supplied ampoule of solvent to the vial containing the powder. After the addition of the solvent to the powder, the mixture should be well shaken until the powder is completely dissolved in the solvent.</p><p>After reconstitution, the vaccine should be used promptly.</p><p>&nbsp;</p><p>A new needle should be used to administer the vaccine.</p><p>&nbsp;</p><p>Withdraw the entire contents of the vial.</p><p>&nbsp;</p><p><u>Instructions for reconstitution of the vaccine with solvent presented in</u><u> pre-filled syringe </u></p><p><strong><em>Priorix-Tetra</em></strong><strong><em><sup>TM</sup></em></strong><em><sup> </sup></em>must be reconstituted by adding the entire content of the pre-filled syringe of solvent to the vial containing the powder.</p><p>To attach the needle to the syringe, refer to the below drawing. However, the syringe provided with <strong><em>Priorix-Tetra<sup>TM</sup></em></strong><em><sup> </sup></em>might be slightly different than the syringe described in the drawing</p><p><img width="611" height="236" alt="" src="data:image/jpeg;base64,/9j/4AAQSkZJRgABAQEAYABgAAD/4RDyRXhpZgAATU0AKgAAAAgABAE7AAIAAAANAAAISodpAAQAAAABAAAIWJydAAEAAAAaAAAQ0OocAAcAAAgMAAAAPgAAAAAc6gAAAAgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAEZlZGhhIEFsZW56aQAAAAWQAwACAAAAFAAAEKaQBAACAAAAFAAAELqSkQACAAAAAzExAACSkgACAAAAAzExAADqHAAHAAAIDAAACJoAAAAAHOoAAAAIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAyMDIwOjA2OjA4IDExOjA1OjI1ADIwMjA6MDY6MDggMTE6MDU6MjUAAABGAGUAZABoAGEAIABBAGwAZQBuAHoAaQAAAP/hCx9odHRwOi8vbnMuYWRvYmUuY29tL3hhcC8xLjAvADw/eHBhY2tldCBiZWdpbj0n77u/JyBpZD0nVzVNME1wQ2VoaUh6cmVTek5UY3prYzlkJz8+DQo8eDp4bXBtZXRhIHhtbG5zOng9ImFkb2JlOm5zOm1ldGEvIj48cmRmOlJERiB4bWxuczpyZGY9Imh0dHA6Ly93d3cudzMub3JnLzE5OTkvMDIvMjItcmRmLXN5bnRheC1ucyMiPjxyZGY6RGVzY3JpcHRpb24gcmRmOmFib3V0PSJ1dWlkOmZhZjViZGQ1LWJhM2QtMTFkYS1hZDMxLWQzM2Q3NTE4MmYxYiIgeG1sbnM6ZGM9Imh0dHA6Ly9wdXJsLm9yZy9kYy9lbGVtZW50cy8xLjEvIi8+PHJkZjpEZXNjcmlwdGlvbiByZGY6YWJvdXQ9InV1aWQ6ZmFmNWJkZDUtYmEzZC0xMWRhLWFkMzEtZDMzZDc1MTgyZjFiIiB4bWxuczp4bXA9Imh0dHA6Ly9ucy5hZG9iZS5jb20veGFwLzEuMC8iPjx4bXA6Q3JlYXRlRGF0ZT4yMDIwLTA2LTA4VDExOjA1OjI1LjEwNzwveG1wOkNyZWF0ZURhdGU+PC9yZGY6RGVzY3JpcHRpb24+PHJkZjpEZXNjcmlwdGlvbiByZGY6YWJvdXQ9InV1aWQ6ZmFmNWJkZDUtYmEzZC0xMWRhLWFkMzEtZDMzZDc1MTgyZjFiIiB4bWxuczpkYz0iaHR0cDovL3B1cmwub3JnL2RjL2VsZW1lbnRzLzEuMS8iPjxkYzpjcmVhdG9yPjxyZGY6U2VxIHhtbG5zOnJkZj0iaHR0cDovL3d3dy53My5vcmcvMTk5OS8wMi8yMi1yZGYtc3ludGF4LW5zIyI+PHJkZjpsaT5GZWRoYSBBbGVuemk8L3JkZjpsaT48L3JkZjpTZXE+DQoJCQk8L2RjOmNyZWF0b3I+PC9yZGY6RGVzY3JpcHRpb24+PC9yZGY6UkRGPjwveDp4bXBtZXRhPg0KICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICA8P3hwYWNrZXQgZW5kPSd3Jz8+/9sAQwAHBQUGBQQHBgUGCAcHCAoRCwoJCQoVDxAMERgVGhkYFRgXGx4nIRsdJR0XGCIuIiUoKSssKxogLzMvKjInKisq/9sAQwEHCAgKCQoUCwsUKhwYHCoqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioq/8AAEQgA7AJjAwEiAAIRAQMRAf/EAB8AAAEFAQEBAQEBAAAAAAAAAAABAgMEBQYHCAkKC//EALUQAAIBAwMCBAMFBQQEAAABfQECAwAEEQUSITFBBhNRYQcicRQygZGhCCNCscEVUtHwJDNicoIJChYXGBkaJSYnKCkqNDU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6g4SFhoeIiYqSk5SVlpeYmZqio6Slpqeoqaqys7S1tre4ubrCw8TFxsfIycrS09TV1tfY2drh4uPk5ebn6Onq8fLz9PX29/j5+v/EAB8BAAMBAQEBAQEBAQEAAAAAAAABAgMEBQYHCAkKC//EALURAAIBAgQEAwQHBQQEAAECdwABAgMRBAUhMQYSQVEHYXETIjKBCBRCkaGxwQkjM1LwFWJy0QoWJDThJfEXGBkaJicoKSo1Njc4OTpDREVGR0hJSlNUVVZXWFlaY2RlZmdoaWpzdHV2d3h5eoKDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uLj5OXm5+jp6vLz9PX29/j5+v/aAAwDAQACEQMRAD8A+kaKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAK2oX8Ol6fNe3QmMMK7n8iB5nx7IgLH8AawbD4i+F9V8KT+JNL1F73Srdyk0tvaTSNERyd0aoXAAOclcY56c1v6j/yC7r/AK4v/wCgmvCPFfh3Ufh5jxb4Ph8zQ9fsktNcsEOFR5E2rcqOnVufcns52gHvVpcpeWcVzCsqxyqHUTQtE4B9UcBlPsQDUteO+MPHXjFfiTq+heFoX3aPYwXsMANqkV0pZTK07zsGEYUlcxYIJyT0qOLx94y1T4jatBpdu/2PRtTtraeyL2iQfZnBDySPIwlMhJBTZ8vygEHJyAemeIvF2i+FBZtr91JapfTi3gcW0sitIeilkUhSe27GcH0NO0rxXo+ta5qmj6ddPJf6SyrewPbyRmItnbyygMDgkFSQRg9CK8B8YeItX8WeFbfVtW1QhIvHCWMWlCGNUtljB2/MBvL4ySSxHzcAYrT1rxTqHgvxh8Ytc0eJJLy3XS1jMi7lQumzeR3xuz9cZ4oA+g6K4v4e6p4ivW1KDxGszQRmGfTri7ktTcTwSKeXW2YoBuVtpwMj1INdpQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRVbUNSsdJsnvNVvLeytkIDT3MqxopJwMsxAGSQPxpkusaZDq8OlTajaR6jOhkis3nUTSKM5ZUzuI+U8gdj6UAXKKKoSa7pEV8bKXVbJLtZUhNu1wgkEjqWRNuc7mVWIHUgEjpQBfooooAKKKKACiiigAooooAKKKKACiiigAopGZUUs5CqoySTgAVwt/8AF7w7DfSWOiQ6h4iu4ztePSLYzhT7vwv5E0Ad3RXn/wDws3Uv+ie+KP8AwGT/AOKo/wCFm6l/0T3xR/4DJ/8AFUAegUV5/wD8LN1L/onvij/wGT/4qj/hZupf9E98Uf8AgMn/AMVQB6BRXn//AAs3Uv8Aonvij/wGT/4qj/hZupf9E98Uf+Ayf/FUAegUV5//AMLN1L/onvij/wABk/8AiqP+Fm6l/wBE98Uf+Ayf/FUAegUV5/8A8LN1L/onvij/AMBk/wDiqP8AhZupf9E98Uf+Ayf/ABVAHoFFef8A/CzdS/6J74o/8Bk/+Ko/4WbqX/RPfFH/AIDJ/wDFUAegUV5//wALN1L/AKJ74o/8Bk/+Ko/4WbqX/RPfFH/gMn/xVAHoFFef/wDCzdS/6J74o/8AAZP/AIqj/hZupf8ARPfFH/gMn/xVAHoFFef/APCzdS/6J74o/wDAZP8A4qj/AIWbqX/RPfFH/gMn/wAVQB6BRXn/APws3Uv+ie+KP/AZP/iqP+Fm6l/0T3xR/wCAyf8AxVAHoFFef/8ACzdS/wCie+KP/AZP/iqR/inc26+Ze+AvFUMIPzSLZh9vvgN0oA9BornfDHjvw74vVxomoLJcR/6y1lBjmj+qNz+NdFQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBXvrCz1Sxks9TtILy1lGJILiMSI4znlTkHkUy10nTrHSxpllYWtvYBWQWkMKpEFbORsAxg5ORjnJq3RQBnaj4d0XV7y3u9W0ewvrm2OYJrm1SR4uc/KzAleeeKJ/Dui3Osxavc6PYTalCAI72S1Rpkx0w5G4dT371o0UAYl74J8K6ldzXWo+GdHu7icgyzT2ETvIR0LMVyfxqWHwp4etri7uLfQdMimvo2jupEs41a4RvvK5AywPcHOa1qKAKOlaLpWg2rWuh6ZZ6bbu5kaKzt1hRmIALEKAM4AGfYVeoooAKKKKACiiigAooooAKKKOlAHO6jqph8T28JuzbwR4EhJ+U8FjnPttGf9qugWVHj3o6smM7lORXCxS/bNTuLs8gn5T/ALxz/wCg7KLkGC3f7I728khEYaFtvLHGcDg+vPpTA6+LUS0aySWk6RsMqygOCPXA5/SlfV9OiVWmvYYgzbf3jhSD6EHp+NYttrF7aoqERXEajABGxgPqOP0rB8W6supXVrGIHh8mNnPmAdWOOCPYfrQB6FHIkq7onV19VORTq47wxaCxjtpktWYmAyyPBKWyZD8oKcDIAPTPSuqhvbedtsco3/3G+Vh/wE80gJ6KKKAMfxe23wXrA8macvZSxrFBA8zuWUqAEQEnkjoP0rk75fEGkafOPD9tcXEEOmyyaZO8TCSGN3hJhZGRm8yNQxQFGJAVSrMrBvRKKAPIIPEPxF+1aONskkbkZZ7K4UXBM7qyTD7CpQiPysOfs6ZJb5lyFhs7rU59eF3qdtr13LcTaQWln0SaPy2SWdpV+SIDYhf7x7EfM33j7LRQB554K1TxfqOl66PE8s1pcJbqYj9ndWtZir7xG0ltHG6KQu3Bmxjl3BBODouv+LtXXQmGsa8bS/e1FxdroIj2M8MpmA3QECJXFvtkIx+8f5mA+X125toLy1ltbyGOe3mQxyxSoGSRSMFWB4IIOCDWHo8403xNeeHY7e3tbKG1hudOit4hGqRnKOgA4+VlB/7aCgDz7UrnxfqulSNPd+IIBDdWk9/DHpah7OVL6PclsRAftEQj8x8jzCfKjySGZWsQa/44N7fpqkmpW1l9qVZZbPTZJ7i0j3SYaBTaBJA37oEAzkAs3Hb1migDyVLnxHYapdTy6n4kngvHtDc3ltoeGih+ztmSKFoGIPnBVaMh2VWY7f4hv+C7vxLe+JbpPEN7qQit7O3ZIH05YYJJGDbz5hjBLYEbFVf5WdweAFXu6KACiiigAooooAKKKzvEN+dK8M6pqAODaWcs4I/2UJ/pQB5/qrXnxU8XXugWlzLa+FNIkEWpTQMVa/nHWEMP4B3/AP1V6JpWj6doenx2Oj2UNlbRjCxQoFH19z7muY+Eemrpvwt0b+KW7h+2TP3d5TvJP5gfhXaUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQByHjP4e6f4oUX1k39la/b/PaapbDbIjDoGI+8vqDR8PfFl34h0+70/Xolt9f0eX7NqES8KzfwyL/ssOfzrr688u4v7J/aC06a3wqa5pEsdwo/ieEgqx/A4oA9DooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKz9cn+z6PNtOGkAjU+7HH9a0Koavpf9rW8cRnaIK+44XO7ggj8iaAOQs5EitwZcxNKTJiRSnB6de2MU+Q+bfQoOVRTKfr0X+Z/Ku5MaNGEZFZfQjIrDGmaVJe3jzRJbuGABRjFhQPvHGM8k9famIy65XWZjPqMoUO3zLAojXcfcgd8ZP5V3l3oaW9rJcw3zrHGhc+aodcAZ6jB/WuEsbaa4aS4Ay0CGQkSBD5jZC4z1Oc8UAXdH1JFleWyuIS7OcIrmB9q8DKng9M+ldTot9JqF7JZanGZQse9DPGuRzggEcH+fFYM2kyw2yQ3luXSNQuLu33DgdnXj+daeg6Fcf2ZMbcjT/OmDxyZaRgF4G0HGAfm/BjxQM6Y2ZVAttcTQ4yR828f+PZ/Ksy48RNp148F7bO6IcCeNCFbjPTnp6/ypGk8Q6ejNItvqESgk7TsfH+frXInVY2up3ubae1nyXmaLKlcn+LocexGKQHd2mvadeAeVcoGP8LHH69D+FaAYMoKkEHkEd684Elrdp5iT284PO512N9cjBB/2iDU8b3dmyfZp7mAycooPmK/vkYLD6An3oA9BorjrfxRqECuZkhuo422uyttZT6EHBU+x/Ota28V2MrrHcrLayMpYLIh5A6n3Hv096ANuuZ8Vf8AEu1fQdeXhba7+xXLf9MLjCfpKID9Aa6CC9trpEe2uI5VkG5Cjg7h6j1rmfiXLfReA9SFjpL6rE9u6XEMEuyeNSv+sjGCGZTzt4PHByMEA6yivPvg54x1Tx74Uu/EGrosPm3hht4E+6kaRoCfcly5P4DtXoNABRRRQAUUUUAFFFFABWB48/5J14j/AOwXc/8Aopq36wPHn/JOvEf/AGC7n/0U1AEPw4/5Jj4b/wCwbB/6AK6WvH/Bdv4rvPA+iLZPrMduLKIIftNpbx7doxj927ke5wa3j4Z8WyAFrqUnPIfX5h/6BCKAPQqK87Hg7WXXF9o+j357PeatdzMPxdTU8PhPWYSTZaR4d018YEkE9wWH/fIQ/rQB3tFcva6H4rEQS68WRqB/zw05cj/gTs2fxFTSaJ4iT5rTxXIXBzturGJ0Pt8oU/rQB0VFc5pfiC/i1RdI8UWcdpeSZ+zXVuxNvd46hSeVcDnYfwJwa6OgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvP8AxF/yXTwd/wBeN9/6Ctd9JIkMTSSuscaAszMcBR6k15hd69Y678cvCkmltJNBFZ3oFx5TLHL8o+4xGHAx1GR70Aeo0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABSMoZcMAR6EUtFAGbf6Ha3tlNboXtfNGGaA7c8916HPTkVmaV4ZuNNmMUk1vc2jyiV90RDkqPlHUjGea6WigCr/Ztuv+oDW5/6YuUH5Dj9KPJvIv8AVXSyD+7Mn9Vx/I1aooAydUfUn02WKKxWWRgB8kvBGeeuD0zXKy3bW/y31rcW2P8Anou4D6H+H8cV6BSMoYYYAj0IoA86Nrpt7u2CJj1byztI9yOp+tRf2S8HFneSQg9I25U/h0/MGu3u/DelXnMtmisOjR/KR9MdPrWZN4PaPJ0/UZowf4JPmB+v/wCrPvQBzbPqcP8Ar4I7tF4JU4YD6/4Cok1G0GIpVmsy38DKSh/4CM/ngVuyaJrduoPlW92A2B5b7Co9cHp+tULqXyPMTULKZFHQyRZWT6//AF8UAV0ginzJatHL3LQvhvqcZU/iAauQarqtjjy7t3QHG2ddwP0YZx+IyfUVnnTtLu5F8l/LYDLPGxBjP0PI/LHvSfZNVgUm1vFucdIrgZLr/vc8fj+FAG3o+v22k27wx6QlvC0rzSfYgCu9zuYlR0JJJ9Peuhs/EWl3uPKu0VsZ2v8AKR+fb36VxkbedNGl3atE5489PmjU+x+8v406bT/M3ZwzKcqrjJb39QffcDQB6ICCAQcg9CKK85iW9sGJtbqWCMLkMHLIx9MH+eR9a0bXxZqdvgX8MUq4JZvuMvoD/CSfbgdzQB2tFc9b+NNOcILqOe1Zlyd6ZUf8CHBHuOPet23uIbu3jntpFlikUMjochge9AElFFFABWB48/5J14j/AOwXc/8Aopq36wPHn/JOvEf/AGC7n/0U1AEPw4/5Jj4b/wCwbB/6AK6Wua+HH/JMfDf/AGDYP/QBXS0AFFFFABRRRQBXv7C31Oze1vI98b++Cp7MCOQR1BHIrnINeu/DV5Hpvixi1rIwjtNZxiOT0SbtG/bP3W9jxXV1Hc20F5bSW93DHPBKpWSORQysD1BB6igCSiuVNnqXhAb9KWbVNFXlrAktPaj/AKYk/fUf3DyP4T2rf0zU7PWNPjvdNuEuLeT7rr6jqCOoIPBB5FAFmV/Lidz0VSahsbtb2381OmSKi1qbyNCvZf7kDt+lYngC9+2+H5HJyVnYfoKAOoooooAKKKKACiiigAooooAKKKKACoLy8ttPspbu+mSC3hUtJI5wFFZ2t+JrPRZIrbZLeajcD/R7C1XdLL746Ko7s2APWqllod7qd1FqXixo3ljYPb6dC26C2PZiT/rHH948DsB1oApWdle+Mrkahr8D22iqQ1lpcgw0/pLOP1WPoOpyemd4gUJ8cvBqqAqixvQABwPlWvQa8/8AEX/JdPB3/Xjff+grQB6BRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRWd4g1b+wfDWpav9ne6+w2slx5EZw0mxS20fXFcb4X8d6hq2nabq82paBqOjXCs+oXdkHg/svELSbJQ7t3wC7bMY+78wIAPQ6Kx4vGHhqaC3mh8Q6VJFdSNFbyJexlZnXGVU7vmIyMgetVrjxx4bbTWnsfE2hM8kUrW7yahH5bsgySSG+6vG7HQUAdDRXM6Z4y0uHRtPPiXxH4dj1K4tftD/AGS/UQyqAS0kW87jH8rc+x9K0p/E+gWujw6tda5psOmzkLDeyXcawyE5wFcnaeh6HsaANSisaPxh4Zl0mXVIvEWkvp0MgikvFvozCjnGFL7sA8jjPcVrQzRXNvHPbyJLDKoeOSNgyupGQQR1BHegB9FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFIQGGCAR70tFAGbdeHtKvMedZxgjoUG0r9MdKyZ/BoXJ0+/lj5zslAdc/5/H3rqKKAOIn0fXLQ5MMd2oH3omw2PTnJ/n9apNemBvKureW3Ofuuh2/kM/oTXolNkjSVCkqK6nqrDINAHBRXkUuHilDE8BlYBj7ZHyn6dqkIRl3YXGeG5AH/Al5B9zXSXfhjSbxmZ7YRuwwXjO0//AF/oaz38G+U6PY6hKhXgrKNwI7c9R9M49qAMV7ONy2EYE/Mdq7vxIXB+netzwtEIG2xjajozcfxHK/MfU89fes8+HtdSQRj7LLGG3GQtg7fy5b8hXT6ZYfY4cyACRgBgdFAycfmST9fQCgC9RRRQAVgePP8AknXiP/sF3P8A6Kat+sDx5/yTrxH/ANgu5/8ARTUAQ/Dj/kmPhv8A7BsH/oArpa5r4cf8kx8N/wDYNg/9AFTXfib7H4gu7A2N1cx29vDIWtIGlYM5kyCB7IMfU0Ab9Fc7/wAJnbHPlaRrsjD+EaXKv6sAKjHiXW7zH9m+Eb5QTjfqE8Vuq+5AZmx+FAHTVinxDHe6s+m6GFvJoHAu5gf3Nt/slh1fH8I59cVSn8Paxrts8fiLWGt4pFINppOYl/4FIfnb8NoPpVHT/EFl4M8jQvENlDo0O7Za30Eeyzn9Of8Alm57q3foTQB2tFIrK6BkYMrDIIOQRS0AFcprek3eiX0viPwvCXmY7tR05Thb1B1ZR0EwHQ/xdD2I6uigDzf4gfEG2svDJjjsp5rTV7Q/ZL6MjyyWXoe4I9K534U+OhGToUGnXF7dXE5kDREBY1wASxPQDFdkuiafd6hrfgzV4BJp92v9oWS/3FckSBT2KyfMPTzBV7wJ4A03wJpb29m7XV1MxM13KoDuM8Lx0A9PxoA6qiiigAooooAKKKaxIGRQA6imJIG470+gArntS1e9v7+XR/DJjFzHgXd9Iu6Ozz2x/HJjkL0HU9gbniLU5dO00LYhXv7uQW9mjdDI38R9lALH2U1NoukQaHpMNjbZYJkySt96Vycs7HuSck0AQ6J4dsdCSVrYPNd3B3XN5O2+advVm/kBgDsBWrRRQAV51r0sjfH3wpG8LIiWN4UkzkOCo/Igj+Vei15/4i/5Lp4O/wCvG+/9BWgD0CiiigAooooAKKKKACiiigAooooAKKKKAM/Xzqg8P3p8PiNtTEJ+yiUgIZO27Pb1rzOx8DDT/ibZeKNL8Pv4Qt7eKc65IbyH7HeJ5eAI0Rj8u4b9zrEMLuK7unrlMlijnheGeNZIpFKujrlWB4IIPUUAeefDnw/Jo99rMdjcwX3hi1uzc6DHburBBPGsjqpzt2rvIQ55EjZPNYXgnwHqGlfDHxHBqnhRY9fuJr17Qs1s8r+dGUXbIHIXhiDlhxnrnn1uw0+y0qxjstLs4LK0iyI4LaJY40ycnCqABySfxqxQB4LZ+CfFUEnw0e58J3U6+GrS5S+QXNocSOu2PbmbBIKhs9sjvkDGt9F1rwT4Q+H8OpaHqq+ItGvL+SG3sreLUQY3ILOYI5lZ1+dBuDrtOc9Vz9J1n6toGj6/DHFruk2OpxxNujS8tkmCHpkBgcGgDwjRfC19f+E/B7eCY9eB8KapPHqVpeQwWl6JJVV2kSObdCNofKqxPD9c817L4C0BfC/giw0iOO8ijtw+yK9mjlmjVpGYKzRgJkBui5A6AsBk7On6bY6RYR2OlWdvY2kWfLt7aJY40ySThVAAyST9TVmgAooooAKKKKACisXWdbks5ks9PiE95IdqrjPPXH5cnsBSWt3rFlcW8euC1ljuW2LLbKV8p+oVgScg4xuGOe3NAG3RRRQAUUUUAFFFNllSGJpJWCogyxPYUAOorLttZaZWllspYrfzNiy7ge+Mkdhng9cHPpWpQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWB48/5J14j/AOwXc/8Aopq36wPHn/JOvEf/AGC7n/0U1AGN4U1y20L4R+G5p1eaaTToEtrWIZluJPLGEQdz79AOTxW54W0q70+xnu9YZW1XUZftF3sOVjOAFjU/3UUBffk96w/hZoNlZ+BdD1ILJPe3GnQ5uJ3LsilQdiZ+6o9Bj3zXcUAFFFc94ovLvztN0vTbh7ae+nw00e3cka8tjORnHPToDQB0NQ3dnbX9pJa30EdxbyrteKVAysPQg1T0xp4by7sbi4e4EOx4pJMb9rA8EgAHlWrSoA5O08DvoJI8Iaxc6Xbk5+wzD7TbL/uqx3J/wFgPapoE8WzXslrcatpMQjIYtFYSb2Q9CN0uOxHQ9K6as3WIrhFiv7BDJcWpJMQ6zRn7yfXgEe4HrQBctYZILZY57h7mQfelcAFvwAAFTVBZXtvqNlFd2cglhlXcjD/PB7Y7VPQBz3iqxmH2LXbBGe80h2l8tRzNCwxLH9SACP8AaVa27O7g1Cyhu7OVZredBJHIp4ZSMg1NXM+D1/s+51vQ1/1Wn3xe3GOFimUShR7BmcfQUAdNRRRQAUUUUAFFFFAGfcSG2ueOnUVfVgyhh0IyKy9c/dxxS++01Vu9aOneDb3UEw0trE/lqf4n/gH4kgUAVdLY6/42vtTbmy0jdYWfo0xwZ3H0+VM+z11NZvh/SU0Pw/Z6cnLQxjzH/vyHl2PuWJP41pUANd9kbPtZtoJwoyT9KwW8c+HIneO61NLWVDhoblGicf8AAWAJ/CugrJvpW1LUP7LtmwkYDXkqn7qnpGPdu/ov1FAFKLxS+ryiLw1p9xcqeTe3MLw26D1BYBnPsox7iuX1OxNp8c/CLyzyXNxLZXvmSueuFGAF6KBk8D8cnmvSlUKoVQAAMAAdK4DxF/yXTwd/1433/oK0AegUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABUV1OLa1kmIzsUkD1PYVLWR4nuGt9FdkBLZJH/AVLf+y0AUNDQCG91y4O9zvSJiP4VPzN/wJgfwCjtWlLZ6jLZorXEUrbo3ZZY8HcrBiNy8Y4/u/jWdJpE0NrYW1reOA6JGYzymETO7A9wM5z1q79o1m0/19tHcqMfMh5/MDJ/75/GgC59tmj/4+bOVR/ejw4+vHP6VJDf2tw2yKZS+MmMnaw+qnkVSTxBbbtt1HLbPzw6/4Vb32OorsPk3G05KMAxU+4PSgC1RVP8As1Y/+PWeeA9gH3D8mzRjUIjwYLlffMbY+vIJ/AUAOv7s2cAZQpZmwN5wqjGST7AAmsm7uptRVLYSxAGRchQyyHOcEow4AIJzk/dpmr3xlkSKS2kRwREImIJd5D90EHH3A2fQMDTdKuPteq3F9dS7o4ASHxhQB8o2+q/6zk8nINAGtqEMaaWtoi4SRkhCjsCQP0GT+FX6xJ9Zt5L6xV0mt9s7MxuIWQbfLcZyRgDJHfvW0jrIoZGDKeQQcg0ALRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFYHjz/knXiP8A7Bdz/wCimrfrA8ef8k68R/8AYLuf/RTUAQ/Dj/kmPhv/ALBsH/oArfur21sYfOvrmG2iHV5pAi/mawPhx/yTHw3/ANg2D/0AVl+IoodY8ZWtnfhTaQOS6yEBWCRiQjnruZ4s+yY7mgDp9SvUl8N3V3p1yrqYGaKeFww6dQRxXI6PcRz+MtPQJDI6I7vLtcujbXATezMW4OT05IqrHBb2IlhtryQRahawXRiWf5fN8wLL8o4+ZSvHqDWP4dSaVp7oS+Q/9khg5OXjklUnr04ab+nagDvLfxFpL+Krlor1ZEktEQsqtsVo3fPOMEnzP/Ha1v7d0z/n8T8jWfDo0NvBHDD4iv0jjUIiieLCgDAH3Kf/AGWv/Qy6h/3/AIv/AIigC7/bumf8/ifkaP7d0z/n8T8jVL+y1/6GXUP+/wDF/wDEUf2Wv/Qy6h/3/i/+IoAzru5j029l1Hw5dwMZm33OnysUjnbu6Nj5H/Ru+DzU9l8QdBuCI76d9Kn6GLUE8r8n+434Matf2Wv/AEMuof8Af+L/AOIpr6RFKhSTxFfOjDBVpoiD+GygC/P4g0e2tDdT6rZRwKNxla4Xbj65rmfDHibR7vUta1Z76GH7XNGI4ZG2usKptR2Xqu87mGexFeS69ounQ+Kr8JbwyGBZmjlMag7hc43fKAM446VJplrD/bd85Ulo44WUlicEouadgPf4tZ06eZIo7yIyOcIpbBY+gz1qtN4r8O287w3GvaZFLGxV43vI1ZSOoIJ4NWNQsm1DR2t4pFilKq0UjLuCOMFWxxnBAr5w1Kee38ZGWe8lhcXk8cwgmTaN00vC5Q8bsdc96QH0Va+JdCvrhYLLWtOuJm+7HFdo7H8Ac1p18vxylZJgbu4Y211KVaWaN9qsu8HG0Hr1weOoHFfSOk6i9/AwuIhDcRFRIgbcpyoYMDxkEH+Y7UAX6K8/udQmsvi5dPEc7rJYijE7SMBs4/z1q8L+K71a8e80+CdgIwC7Hjg9OKANnxFe2cemSxyXcCSoQQjSANn6fSuV1G5J8H3zcmO2urW4mAGcRLMjOfwVSfwrndbWzHiWbzbOFYWlz5YxgZgPcjrXb6VfaLaX3kbjF9sBixNIHVzjO3kdxmmB1qsrqGQhlYZBByCKUnAyeBXnHiWwfwtZQN4Z8RX2nwzTeX9mVftcUI2sfkj2syjjGAcDPSubW+lmbOsavc6v/wBM7zTr3yvxjQBT+INID02bXJNUuGsfDRWZlbbPf4zDb+oB6O/+yOB3I6HU0/T4NMtBBb7jyWeRzl5GPVmPcmvPLfx3eWkKQ25tEhRdqRpot4iqPQACrsfjy+aMFrixBPY6fdgj8NtAHoFef+Iv+S6eDv8Arxvv/QVpf+E8vQcCSwf6Wd2P/ZKxF1i51f43eFWukjUx2d5t8uGWPOVH/PRRnp2zQB61RRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFYni1WOgybV3feBA90ZR+pFbdRzwR3Nu8M6B43GGU9xQBTEb3EVpeWc8eFh+XeuVIbBzwR6V5x4r+PWj+G5/7OtrKTVdVkl8mGK1f9yWzgbpCOM+ihj9K7SfRrLRdKml1DWLxNItY2klhlkURhRydzBdxHtnn3rFTwbH4yWHXPEts0FwLm3uNNtXUZsYIpVkVCOzybfn9Mhf4MkA7E3tjcAxTPHk/KY5l29e2GqGbQbGXBWMxFTkeWeB9AcgfgK0HjSRcSIrj0YZqr/ZkCf8erSWp7eS+AP+AnK/pQBT/s3UrYf6HqBcAcJNk/qc0NqWpWak3lh5irn54j1A57Z/XbVzy9Qi+5NFOueki7Tj0yOP0qtqV5MNLuUns5kd4iqmM71LEYAyORz3IAoA524mlnmecZEgVUQHtLNyx4/uphfbJrWsNPjltrezIPlSL9omGcHZ0jU4xjPX6qaypF+0yjqVury5cYxxgrED/3yTW4+lpqN/c3XnSRSIfJjZeCAAO/XGSTwRQBeNg6/wDHvdzKP7kn7xcfjz+tVGsZY2Lm0iZjli9nIYXY/To34mgWusWp/cXSXCZ+7KOcfX/Emk/tm5tl/wCJjYSRgDLOnQfj90f99Z9qAD7VLAQpu5IzkKFvIeCe/wAy4Bq1HfzbN723mx8nzLWQSD8uD+ABoh1ixuPlE4Un+GQFc/n1p7afZTHzUjVWIAEkLFGx9VwaAFTUrR22mYRv02yDYfyNWqovY3AXCXQmUZIS5jDjPbkYP86q/ZJbcYS1kh7BrGbge+xvl/QmgDYorj9W8WXOi3UIPl3Fu8qxMZ42hdCeueOgBUk471dtPG2mXH2wyh447NlWWdcSRHcSAVK8kZBGcCgDo6KrWupWV6qm0uoZdw3LtcEkeuKs0AFFFFABRRWbr3iHSvDGlvqOu3sdnaocb36sfQAck+woA0qKx/DPivRvF+lnUPD94t1ArlH+UqyN6FTyK2KACiiigArA8ef8k68R/wDYLuf/AEU1b9YHjz/knXiP/sF3P/opqAIfhx/yTHw3/wBg2D/0AVj+ILS0Pji2TV4Ip7a4kKqJV+VTJGFT/wAfhx7F19as/CbV7bVPhro8UG5ZrK0ignicYZGCDBx6MMMD3BrpNX0LTddtxBq1otxGOgJII/EEHsPyFAHmqxeHxqKNZ2Pl3FjbQQuy2kgZZ3kG8E7eCFAJz2YVU0Mwz2N5aX9utzFJoy+Yu3csrRqA67e/MLDH1Fel3um2uk+Fbu302ARRpG0m0ZYsRySSeWJx1OTXMaFYxx+KrK4jCmORHR/3kbgttkOVKsTtPXkdSfWgBy6B8MnUMvhnTirDII0ZuR/37pf+Ee+Gf/Qsaf8A+CZv/jdbNnonka9LawajqS2kFqhEJuSVUszYC9xtCY/GtX+yF/5/b7/wIagDkf8AhHvhn/0LGn/+CZv/AI3R/wAI98M/+hY0/wD8Ezf/ABuuu/shf+f2+/8AAhqiubK2srWS4u9Tu4YY13PJJdEKo9zQBy3/AAj3wz/6FjT/APwTN/8AG6D4e+GYGT4Y04D1OjN/8bq59i1jX2B0y9v9I07P/H1O5a4nH+xG3CD/AGmyf9kda0V8D6GyD7fDNqcmMGW/uHmY/wDfRwPwAoA8V1ZLC2129h0yKO2sxDMtvCkflqo+09AuBj6Yp2lyxnWNQAkXLRQgDcOcIua9Qn8F+CYvFFtp48OwyXV1BJMxUtsijUqMlc4GWYAYHrVC9+HvhzSfGekDTbBba31Hzop4I2OAyoXV1z908EHHBzz0p3A727vV0/SXu3jeURRg+XHjc57AZ4yTxXz1q+q67HNqbrqFpZi0keZYDKztFsunfHEeNwOT1/HtXv66Lb+ZG00tzOImDqks7FQw5Bx0OOvNYsvw50KW+nuv9LR5yxdUuCF+Zix4+rGkB4ze63rEfiOV5dZtTJfQiXzYnZiWEbR9DGuSVbb6DOa9+0azuII5Li+2CecINiHIjVVwFzgZPUk47+1ZMXw68PpfQ3csVxcSQAiMS3DFQDjIwMZHA4PFdTQB51fWklz8W7iOFd7i0WXGQMLtC5/M1qWuj3rapfAJGCPLzuf/AGfYGuisG0rUJW1bTfs88kgMBuogCWCsQV3egYHipLjS7G6mMtxaxSSEAFmXkigDyfxVpiN4hmt9SSF40xK+8blAWFjk8dsV0ukeBPD9yLXUobO1NpLGXUW9t5fnIy9G4BKkHp34rR8WeGNAHh7UbybTITIlu5DcjnaVHQ+9UfhZ4iGo+H/7GuZM3mlqsa5PMkHRH/ADafce9MBPE3gXR5bW3OleHYy0c26QW0aRuV2sOCwweSOK4+HRNGkvxZTaLfWVyxwiXzQQeYf9ksmG+gzXtlQ3Vpb31s9vewR3EMgw0cqhlb8DSA8zHw4jz82gzEf9fcA/9p0h+GcGfl8PtjtnUl/+N12BivPCx325mv8ARv4oCS81mPVD1dB3U5YdsjiuggniuYEmt5FlikUMjochgehBoA8tb4ZIfu6AAPfUgD+kdUdP0OXQvjR4WgkgkgR7S8ZUe9Nx/AM4yo29q9jrz/xF/wAl08Hf9eN9/wCgrQB6BRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFc34l1G6uryHw1oczQ6heJ5lxdJ1sbbOGk/325VB65PIQ0AVm/4rPxF5Y+bQNHn+f8Au3t2h6e8cRHPrIMfwHPW1W07T7XSdNt7DT4VgtbaMRxRr0UD+f171ZoAKKKKACs7WZxFbxhugbzXx12xjf8AzC1o1XurRboKd7RyJnY6YyMjB4PBHsaAOcismTWLS0PIjHm7lbIJchm5/wB6N/wIq5LMNOvp/tEl9bCafckyRmWJsgADGDt/IfWpNKiDapL+7hUWwZQY49m7LYBxnqNjf99VekH2nVUjPMdsokI9XOQv5AE/iD2oAihvLl0zBLaXwHBMb7GJ78cj9am/tFEOLmGa3/2nTK/XcMgD64qWeytrnmeFHbGN2PmA+vWqOova6Jp0+oXWqNYWluu+WSdwY0Ueu7oPoc0AWDa6dqC7wkEwbnchHPvkVVbQFjbdY3U1ueONxI49wQT+Jx7VFasuqWFvqUNtb3sF1FHPFPDmF3VhlTg+xB5NSed9n6XVza4zxdx70+pb0/4EKAD/AIndqOsV4oB64DH05GP5fjThrwhbbf2stuc4DEcdPfGfoM1Yju7oqGEMVzGeklvL29cH+hNRXuqRfYZUKvFM67USaMjJbgDPTqfWgDzjxXqC3euRuCdkUbXDZGCM8jI/3fLFc55f+jIh/wBZM5zj2+Xj8TVvUrkT3V5cKCVeXZGO+xeePwwPwqL/AFVyM/MLaPJ/2iBk/iWYflVAdL4It21TxfO9wxngtbQxEyfNwSFVcnkfcY8V6E8QsLq28mV1imkKNG7kqPkZsjPT7vbjk1zPwwsTDot3evy9xOUDEdVQbc/i24/jXReI136DcKo/fMAkB5ysjHap456t+VSBj2/jZnfdLZxtAVaQOk4VlQHGSH2j34JFa0fibTDhbqZrFyM7LxDF7dTwfwNeN+NtROmWeo26QQt5lv5BKL5bFR8g+XhsZ8zrnNUjrskF5qNrBc3cFuLKNBbyN5iuSWBBDYKrjt+tAHu+s61aaFol1qt6zG1tY/MlMS7yF9cDr614Hba3Y/GP4328OpXIGgWAZrOzkyPtRH+z6seT/sjFdWsRvPhzdPkwy31+9uTGpQuNpUjbk4BOBjoO1c14EsE+F8S3N1Aja3dxsZVuYyPKjzwinIIJ7nn6UDOn8BWcXhf48eLfD+noIdPuLaK7ihQYVDgHgdgN5Fev1434Ju7jXPjxquvSW/kW1zpkccXzhgWVY9ygj0OfSvZKBBRRRQAVgePP+SdeI/8AsF3P/opq36wPHn/JOvEf/YLuf/RTUAch4esrjTPAXhfxVo8RkuLfSbeK/tkHN3bBATj1dMll9eV716VbXEN5axXNtIssMyB43U8MpGQR+Fc18Plkf4V+Hlhk8pzpkG19u7B2Dt3ptlNqvhdZLe60lrzTjIzxy6Z8xhDckGEncBnJwpbGcUAdXXLeJ4BpuraVrsFuzLbSmK48iIu2x+CdqjJA5/HFamm+J9F1aUw2GowPOv3rdm2Sr9UbDD8RWrQBl6VKb2/vb5EdYJBHHCzoVLhQSTggHGXI/CtSsbU/F2h6VcfZbm/R7voLS3BmmJ/65oC36VT/ALS8S6vxpelx6Rbt0utTO6THqIUP/oTD6UAbt5ew2MHmTk8naiKMs7f3VHc1mwaZPqd1Hf66ijym3W1ju3JCezt2Z/0Xt6mCy8M3sN99sv8AxJqF5PjGPLhjRR6ABMgfjXQ0AFFFFAFCLS4o9fudVLu800EduFbG2NVLNx9S3P0FYthL/wAJF43k1GE7tO0aN7WCQdJrhyPNI9QgUJn1LelMuP7Q1zUdU0rTbk2lotyEvbxW/eAeVH+7i9GI6semeAT06LTbaystMgttLSNLSFAkSxHKgDjr3oAtUUUUAFeY/G74g/8ACH+FTp2nS7dW1NWjiKnmGPo0n17D3+lenV4F8XPhHqd9HrfjO4143s0MfmpZi22hIV/hDbj91cnpzz60Ac98A/iD/YGvHw3qk2NP1KTMDOeIZzx+TdPrivp6vi34b+C18eeKjpP9pnTXWBp0lEe8kqRwBkeuc+1fYmjWl5YaLaWmpXov7qGMJJc+Xs80jjcRk4Prz1oGzA+J18LLwDe56zMkQ/Fh/QGuL+H2lXbeGbjxDpcZfUbS6JhQHH2iJVHmRf8AAs8ejKppvx58QJDHpmixv87E3UoHYDKr/Nvyrv8A4f6S2jeBNMtpV2zNEJpR/tP8x/LOPwoEbGmara6taxXNk++KWFZVJGCA2RgjsQVII7EVcrldMli0r4hanpcjrGNRt0vbOPoG2lhMB77mDEf7ZNdVQAVitbSaFcSXFkrSWEzF5rVRkwserxj0PUr+I5yDtVDc2lveRhLqFJlByA65xQBJFKk8SywuHRxlWU5BFcD4i/5Lp4O/68b7/wBBWty78ImHEvhjU7jRZ1yRGh823fP96Fjj8V2n3rjZJtdf44eFIfEdpaRSxWd6I7izlLRzgqOdrDKEehz160AerUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRWTfeKNI03V4tMvbox3UpjVR5LsgaRtkas4XarM3CgkE4OKANaiio4p0llmjUSBoWCsXjZQSVDfKSMMMEcjIzkdQRQBJRRRQBmeINbj0HSWujC9zO7LDbWsf37iZuEjHpk9T0ABJ4BqDwzocukWc0+oyrc6tfv59/cKOGfGAi56Igwqj0GTySTel1Szh1i30yV2F3cRPNCnlMVZUKhjuxtBG9eM55q5QAUUUUAFFFFABRRRQBjxrNp2rXchtZZLeYAq8WG+bJJG3r1Y89OKvWMMiRyS3A2zTvvZc529gv4DFWqKACvLPiz4Hj8farpWgvq1/HJceZP5KOvkW0Ua/NKUAy7F2jQbj0ZsYwa9TrlvCH/E4vNS8VSfMuouILEntaREhCP99i8me4dfSgDR8Iafc6T4I0PTdQAF1ZafBbzhTkb0jVWwfTINbFFFAFaTTrWRy5hCOTkvGSjH6kdao6jo91dWZhttSkiPJXzUEgzggE9DxnPXqBWvRQB5nP8ADu9hmsUjbfAhJuZY33HOQQyocY6Yxk1zd1peo2No813B5ck04iEcgKOxySDgjABPHX/GvcKRlV1w4DD0IzTuBneHdO/snw5YWJ+9DCofBzl8Zb9SawvEusSu1qlvHbbFaS5XzrnyzII+AR7EnI55wK6NtJs2ztiMYOcrE7Rq2fUKQDWRr/hiTVZQ9vJAE8tYjBKh2lAclQQeAfoaQHjfjJtURJ/7Us7hVO0gzJvU5ZVBz6ZJI57msi8vIV1LVJjtWJVgLruxuAUnG1vUkV6prHhK7eAbbWa2lV43E9qfNUkMDyuRkcDgjHtXNWHhybU/GU6X6WsqXtwheQRNC3lQgbzswBhj1P8A9amBvRaaLPTfDGgPhDDb+fO2/wAvY7fMcnBAwxH1xisvxrNeSao9tcSmaMKIl89A2T977y57fSteLWbO88Ralqs91cxW4UpDLANy7Vx1HcegwevPauMnuTc30s9vcQzSAmYEKUYMcjoP4sE9qEB1/wAN7YNrizJCsIWOWQorA7QxUdR16V6lXG/DvTfs9jcXZBwxEMZPPC/eOf8AeOP+A12VDAKKKKQBWB48/wCSdeI/+wXc/wDopq36wPHn/JOvEf8A2C7n/wBFNQBD8OP+SY+G/wDsGwf+gCulrmvhx/yTHw3/ANg2D/0AV0tAGfqmgaTrcYTV9NtrwL90zRBiv0PUfhWba+B9LsZlaxuNUt4lOfIj1OcRn8N/6V0VFAFPT9I0/SlcabZQWvmMWkMUYUuT3Y9Sfc1coooAKKKKACsnxLq8mjaK01pGs17M629nCx4kmc4UH2HU+wNaN1dQWVrLc3kyQQRKXkkkbCqB1JNc1pKz+KdZt/EF3A9vp1oG/syCVcPKWGDcMO2VyFB5wST1GADjvHNzr3hfwhLovh+C8nuJw9xqmtCIqNz8uVI6E9P9kACuf+C+ua/ozHTpLK81DQnk2+ZGhf7I55yP9k55H4+tezeKYPtPhPVIf+elrIv/AI6a5z4U2f2PwxcLjG66Y9P9laAO4ooooAKZPDHc28kE6B4pUKOp6MCMEU+igD5B1Oy1P4MfFqOeGJpIraUy2xbhbm3bIK59cEg+hFe3r+0D4GOj/azdXQuNmfsRtn8zdj7ucbfxziu08U+ENE8ZaX9h8QWS3EanMbg7XiPqrDkV5p/wzR4Z+2iT+19U+z7smHKZx6btuaBnD+DoNR+MPxXm1fUIWXToJVmuB1VEX/Vwg9ycflk19PDjpWX4e8OaV4W0iPTNCs0tbZOcLyXPdmPUk+prUoEcj4/0i5uLKx13SUZtT0K4F3EqdZYuk0XvuTPHqBXUWd5BqFjBeWciywTxiSN16MpGQamrlJXPgi6lnYM3hydzI+0Z/s+Rj8zY/wCeRPJ/ukk9DwAdXRTIpY54UlgkWSN1DI6HIYHoQR1FPoAK8/8AEP8AyXTwd/1433/oK16BXn/iH/kung7/AK8b7/0FaAPQKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArhfE2j6tceLor3SdMuRIzWy/bILmIQSIkhZluYpG5C7so8amQHOCv8XdUUAeaan4Z16HR7y2spNdvXs9RjSyeDWJUmktnnSeUu0kqh9qM0Kkljhfc1Q1bQvFR1a9gsbHxSdPW7na2kh11Rvh+xxIikvc7+Z0ZxnBG48jcwPrVFAHkTaZ40vdcnuvL8QWUzWhjtne7Bt47o2gVTIq3W3YJc5AgbLc7yp40oNM8T2/wl8QQXj60NS3PJYoshFzHhUKiN1up2YbwThpOclSNuAfS6KAPI77w94tvIblLOw1uDzLXUV0+W51WMz2LvDD5QeVZi3M0UjDaXADqDhchYdU0vxrqN/qTwaR4rtIJ3u5bdI9chQLvgj8pDtusqFmR2wuAAQM7Sy17FRQB5G2meMr7Xb++SLxBZS3FrMlmst1m3jnMQA3qt3twNrhcQqNzKfMbCub/AIP0LxNF4l099fXX/scFtMd01/siWQyho1eMXkzSYBl5YtkMoP3F2+m0UAFFFFABRRRQAUUUUAc342uZn0uDRLCRo73W5vscbofmijIJmkHptjDYP94qO9b9rbQ2VnDa2saxQQRrHHGo4RQMAD6AVz2lQS6r411LWrqJ0gsV/s2wWRSMjIaeUA/3nCpn0iz3rpqACiiigAooooAKKKKACiiigArm/HT2y+G3Se6ureedhDbLZRxPcTSN0jjEisMnHJxwASSACRraxrFpoWmSX1+zCNSFVI13PK5OFRFHLMxwAB1NZeh6Pdz6gfEHiNVGpyIUt7VW3Jp8R/gU9C5wN79yMD5QMgHmPwr+E2o6Pq/ib/hJbyZ3/c2tvIrBxsKLM6gsvIBZFyAuSh4HSotR0F4fixpvhfQ5o7uUqbu+naHAs48YAGD1PXB7kV6R4qm8c2l2T4QtdNv7e4j27byQxtav/e4++p6465pvgHwQfCltdXmp3X9o67qcnm396R95uyr6KKAOnsLKLTrCG0txiOFAo9/erFFFABRRRQAVgePP+SdeI/8AsF3P/opq36wPHn/JOvEf/YLuf/RTUAQ/Dj/kmPhv/sGwf+gCulrmvhx/yTHw3/2DYP8A0AV0tABRRRQAUVnatr+maHGh1K6WN5DiKFQXklPoqLlmP0FZQ1DxPrX/ACDdPi0S1bpcaj+8mI9RCpwP+BN+FAHSkhVJYgAckntWBeeM9Njme10kS61fLx9m08eZtP8Atv8AcT/gRFRr4Ks7r5/EV5ea5JnO28kxCD7QphPzBrftrWCzt1gtII4IUGFjiQKo+gFAHOweH77W7qO+8YPE6RuJLfSYDughYdGcn/WuPcBR2HeunoooAgvY/OsJ4/78bD9KzvDFl9g0kxYxmUt+g/wrYpAoUYUYFAC0UUUAFFFFABRRRQAUUUUAFIwDKVYAgjBB70tFAHKHwvf6DO0/gu6jggYlpNIusm2Y9zGRzEfplf8AZq0vi6Cz2p4ktZtFlPG+f5oCfaZfl/762n2roaR0WRCjqGVhgqRkEUAJHIk0ayQusiMMqynII9Qa4HxD/wAl08Hf9eN9/wCgrW3L4PjspGuPCt5Jok5O4wxjfayH/ahPA+q7T71yNxd6rcfHDwpFrmnpaXENlegSQS74ZwVHzJ/EOnIYce/WgD1OiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAry/xo9hb/EW1upZ7WW7D2SR2lwxiueJi260cZ8zkr5kOPmG0ll4z6hRQB5tqvjLxLo+i3M+oXmiWlxp+oR2Nw9zZSpDMZbhRG6Ez/KBA6yMMtgk8/KaydR+I17o+t6nYQ6t4SivIr2aK5mkgaMy+VYwyiQr5+SQ2+Ign+EDIKkH1TTdMttJtPs9n5xUsXZ57iSeRie7PIzM3YDJ4AAHAAq3QB5M3xT1W41yePS59DuoIrE3cdijo1xcH7IJhHGftAdmZjxiErt53E5FWJNeuvG3wZ8Sz38Gn3kkAkSJrV4ZI5CiJIrFYppxGysem8kbQ3GQB3UXhfTYdabVU+2m4aQyFH1C4aDcRjcIS/lg/ReOta9AHkeofFq6037I0ur6FPG+oiITQwFYb21zCJJopXuAqiMyOh2+aSYy20ANtn0j4ha9qM2kbNa8M3f9oPebbe1tnMkotmxiM/aDlpFBI4+XcPv7fm9VooA8e0Pxv/wk/iLwtPrj6XFeR6tLHbtDPBvKPZS7kKpPKVIcqDlgTlPlB4r2GiigAooooAKKKKACqup6naaPps1/qUywW0C7nc8+wAA5JJwABySQBVqsa40FtQ8SRajqdwJ7azw1jZhcJHLjmV+fnfsvQKM9zkAFLR9Mu9X1OPxD4ihMMqA/2dp74P2JCMF27GZh1P8ACDtH8RbpqKKACiiigAooooAKKKKACsDx5/yTrxH/ANgu5/8ARTVv1gePP+SdeI/+wXc/+imoAh+HH/JMfDf/AGDYP/QBXSEhVJYgAdSe1ec+CNd1K6+HegWHhWwW4mj0+FJr66yltAwQZHrIw9F49SK2YPAUd7L9p8X6pda/OefJlbyrVPZYFOCP97caANG48X6Ws7W+nGXVrpTgwaenmlT6Mw+Rf+BMKqyQeK9b4luIfDtoeq2+Li6Yf75GxPwDfWuitraCzt0gtIY4IUGFjiQKqj2AqWgDJ0bwxpehu81nA0l3KP3t5cOZZ5f9525/Dp7VrUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFef+If+S6eDv+vG+/8AQVr0CvP/ABD/AMl08Hf9eN9/6CtAHoFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAUNdvLzT/D9/d6ZaG8vILd5IbcAkyOASFwOT9Byelc34e8eW9zCkesXtvNLPdy21rNY2c6pIY4RI6yIQxt5RiT91I27CcZrqdT0+LVtMnsblpEinTY7ROUYD2Ycg+4rmp/Bsp2QSTyaqLq8jur7UL6dYp08sKEWNIYlRgVBQ8pwx5bOKAJW+IGi3BMNndXUEyXFvBIbnR7sLG0rxhEbKLtZxIoGSMFgSCARTrb4jeGLu0muLa9uJEhCbgun3G9i0nlhVTy9ztv+UqoJU8ECi98DRXr6kza3qkX9oahbai4jEH7uSAoYwuYj8uYo8g5J2Dnls4GrfDC5XRng0nWby/laIQNDqMttHG8Zn85slbVwSWyMMjKQSCO9AHS2vj3w9ePaJDc3IN24SPzbC4j2sXMah9yDy9zqyrv27ipC5Iq1e+K9H0/WF0u5uJftbKSEjtZZFzsZ9m5VK+YVRiEzuIHAORXMaX8L7Vm0bUNaMI1PTFRFENrZyp5ccrPHGGa2XYF3H5okiPPOSoNb9/4UN3qV7dWmuarpi38Xl3MNk8QWRthQShmjZ0cLtwVZR8i8dcgFWT4k+GIVUzXN7GzeZ+6fS7oSDy9pcFDHuBUOrEEZ2nd05rqI5EmiWSJ1eN1DK6nIYHoQe4rzWP4VXWm6tZw6NrN1DpTC5a9m328c+6VI1IRFttmG8pdxyrZJIOc59IggjtreOCBdkUSBEUdgBgCgCSiiigAooooAKKKKACsvxPYtqfhLV7FM7rqxmhXHXLIR/WtSigDj/hPfx6h8KtAeLgxWi28i91eP5CD75FdhXlYuT8I/GF2L1GHg/XLkzpcqMrp1y33lYDojdc9vzr1GCeK5gSa3kSWKRQyOjAqwPcEdaAH0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXnupyf2h+0DodvAN39l6RcTzkfw+YQig/lmui8X+M9K8G6X9q1OQvPJ8ttZxcy3L9lVevXv0FZHw68N6lZLqPiPxQoXXtckEs8YORbRAYjhH0HX3+lAHb0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAEN3Z29/Zy2t9BHcW8y7ZIpVDKw9CDXAt8KpdImeTwH4p1Lw7GxLfYwBc2wPtG/T869EooA4NfDXxGVQD4/tWwOp0WPJ/wDHqX/hG/iL/wBD7af+CVP/AIqu7ooA4T/hG/iL/wBD7af+CVP/AIqj/hG/iL/0Ptp/4JU/+Kru6KAOE/4Rv4i/9D7af+CVP/iqP+Eb+Iv/AEPtp/4JU/8Aiq7uigDhP+Eb+Iv/AEPtp/4JU/8AiqP+Eb+Iv/Q+2n/glT/4qu7ooA4T/hG/iL/0Ptp/4JU/+Ko/4Rv4i/8AQ+2n/glT/wCKru6KAOE/4Rv4i/8AQ+2n/glT/wCKo/4Rv4i/9D7af+CVP/iq7uigDhP+Eb+Iv/Q+2n/glT/4qj/hG/iL/wBD7af+CVP/AIqu7ooA4T/hG/iL/wBD7af+CVP/AIqj/hG/iL/0Ptp/4JU/+Kru6KAOE/4Rv4i/9D7af+CVP/iqP+Eb+Iv/AEPtp/4JU/8Aiq7uigDhP+Eb+Iv/AEPtp/4JU/8AiqP+Eb+Iv/Q+2n/glT/4qu7ooA4T/hG/iL/0Ptp/4JU/+KqKXwj8Qboqlx8RRDF/H9l0iNHI9iScV6BRQByHhv4a6L4f1L+1rh7nWNZI51HUZfNkH+72X8K6+iigAooooAKKKKACiiigAooooAKKKKAP/9k=" /></p><p style="margin-left:17.85pt; text-indent:-17.85pt">1.&nbsp;&nbsp; Holding the syringe <strong><u>barrel</u></strong> in one hand (avoid holding the syringe plunger), unscrew the syringe cap by twisting it anticlockwise.</p><p style="margin-left:17.85pt; text-indent:-17.85pt">2.&nbsp;&nbsp; To attach the needle to the syringe, twist the needle clockwise into the syringe until you feel it lock. (see picture)</p><p style="margin-left:.25in; margin-right:0in; text-indent:-.25in"><!--[if !supportLists]-->3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->Remove the needle protector, which on occasion can be a little stiff.</p><p>Add the solvent to the powder. After the addition of the solvent to the powder, the mixture should be well shaken until the powder is completely dissolved in the solvent.</p><p>After reconstitution, the vaccine should be used promptly.</p><p style="text-align:justify">A new needle should be used to administer the vaccine.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Withdraw the entire contents of the vial.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Any unused product or waste material should be disposed of in accordance with local requirements.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Not all presentations are available in every country.</p><p style="text-align:justify"><em>Priorix-Tetra is a trade mark of the GSK group of companies.</em></p><p><strong>&atilde;2016 GSK group of companies</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufacturer:
GlaxoSmithKline Biologicals s.a.
89, rue de l’Institut - 1330 Rixensart
Belgium
Tel: (32) 2 656 81 11     Fax: (32) 2 656 80 00

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Version number: GDS012/IPI10 - Date of issue: 12/10/2015
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>